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Introduction
Diabetes Mellitus is a chronic progressive disease characterized by hyperglycemia and the 
inability of the body to maintain a favorable glucose metabolism (1). Worldwide over 400 
million people – and in The Netherlands over 1.1 million people – live with diabetes, and 
around 90% of these people have type 2 diabetes mellitus (T2DM) (1-3). The global prevalence 
of diabetes is projected to increase with approximately 50% to over 600 million in 2045, and 
the Dutch prevalence is expected to increase a similar percentage (1, 4). This epidemic is 
largely attributable to unhealthy energy balance-related behaviors such as a lack of physical 
activity (PA) and unhealthy dietary patterns, a global overweight and obesity epidemic, and 
unmodifiable risk factors such as an increasing age and a family history of diabetes (1, 5, 6). 
T2DM is characterized by resistance to the blood glucose lowering effect of the hormone 
insulin in combination with β-cell dysfunction. β-cells are located in the pancreas gland and 
are responsible for the production, storage, and release of the insulin hormone when the 
blood glucose levels rise. Insulin transports glucose from the bloodstream into body cells 
such as muscle or fat cells where it is stored or converted into energy, which is necessary to 
the execution of day-to-day tasks (1). An inadequate insulin production and the inability of 
the body to optimally respond to insulin play a key part in the pathogenesis of T2DM and 
generally underlie the disrupted glucose metabolism. In T2DM, both the liver and muscles, 
two organs that play an essential role in glucose homeostasis, are insulin resistant which 
is characterized by increased glucose production by the liver and poorer glucose uptake 
by muscles resulting in elevated blood glucose levels, i.e. hyperglycemia (1). The most 
important indicator for long-term glycemic control is the level of glycosylated hemoglobin 
(HbA1c) which is an estimate of the average blood glucose levels over the past two to three 
months. An HbA1c-level of ≤53 mmol/mol (≤7%) is associated with a small risk of diabetic 
complications while this risk progressively increases with higher HbA1c-levels. Values above 
53 mmol/mol (7%) are therefore frequently referred to as poor glycemic control but higher 
values are accepted in daily practice when the benefits of treatment are very limited or the 
risks of treatment are deemed too high (1). 
Consequences of poor glycemic control in type 2 diabetes mellitus
Prolonged hyperglycemia is associated with considerable comorbidity and complications 
including foot ulcers, neuropathy, nephropathy, and retinopathy (1, 7). In addition, T2DM is 
one of the main causes of cardiovascular diseases (CVD) such as stroke, myocardial infarction, 
and peripheral arterial disease. In fact, people with diabetes are 2-3 times more likely to 
suffer from a CVD, compared to those who are not affected. Further, poor glycemic control is 
associated with an increased risk of oral health problems, enhanced rates of cancer, physical 
and cognitive decline, and depression (1, 8-10). Worldwide, in 2017, 4 million deaths were 
attributable to diabetes and its complications and total global healthcare expenditures 
were estimated at 727 billion United States Dollars (1). In the Netherlands, in 2017, almost 
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3.000 deaths were accounted for by diabetes and its complications, and in 2015, national 
expenditures were estimated at 1.6 billion euros (11, 12). Next to the human and economic 
burden, diabetes can also leave its mark on society, reflected by drained healthcare budgets, 
frequent hospitalizations of patients, loss of productivity, and impact families of the individual 
affected by diabetes, e.g. through reduced spending limits for families or demanding informal 
caregiving (1). However, if adequate diabetes management is achieved, disease related 
complications can be delayed or even prevented, especially when diabetes is early diagnosed. 
Hence, despite the progressive nature of T2DM, patients who adhere to treatment strategies 
can live long and high-quality lives (1).
Management of type 2 diabetes mellitus
A number of core treatment behaviors can be identified for those who are affected by the 
disease. Primarily, management should aim to improve healthy lifestyles, i.e. improving 
dietary patterns, to increase the level of physical activity, to maintain a healthy body weight, 
and should address smoking cessation (1). As insulin secretory capacities of the pancreas 
progressively decrease over time, or in the event of failing attempts to alter unfavorable 
lifestyles or to markedly reduce body weight, eventually many patients will require medical 
interventions. Oral hypoglycemic agents (OHAs) are generally considered primary medical 
interventions, with metformin being the most employed initial oral treatment globally and in 
the Netherlands (1, 13). Ultimately, patients may require a combination of oral medications, 
whether or not combined with insulin injections or other injectable drugs (1, 14, 15). Most 
patients also need additional drugs to lower their blood pressure and cholesterol levels in order 
to reduce the elevated cardiovascular risk. The aim of the multifaceted treatment as described 
here is to achieve a favorable glucose metabolism, minimize CVD risk factors, improve the 
quality of life of those affected, and increase patients’ life expectancy accordingly. The burden 
of this treatment can be quite high for an individual with T2DM but the management of 
diabetes can only be of optimal impact if patients adequately adhere to the agreed treatment 
behaviors. 
Adherence to treatment behaviors
Patient adherence to core treatment behaviors poses a serious challenge. Despite the clinical 
benefits related to adherence to core treatment behaviors, i.e. achieving glycemic control, 
minimizing the risk of CVD, and living long and high-quality lives, patients’ adherence is 
regularly suboptimal in practice (16). Treatment non-adherence not only affects the person 
with T2DM, but it is also associated with societal and political consequences, such as increased 
hospitalizations and healthcare expenditures (7, 17-22). The majority of patients does not 
consistently adhere to healthy lifestyle changes (23-25). Only a quarter to half of the adult 
population with T2DM achieves the recommended level of PA (26, 27). With regard to daily 
dietary recommendations, targets for protein, saturated fat, unsaturated fat, and fiber intake 
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are achieved by less than 50% of the patients, respectively (26). A recent qualitative in-depth 
exploration of patients’ eating pattern revealed that savory and sweet unhealthy snack intake 
emerged as major issue in their diet and accounted for a substantial amount of caloric intake. 
Health professionals also identified that unhealthy snack intake was highly prevalent in patients’ 
diet (28). As a decreased caloric intake has been proposed as a means to improve the dietary 
pattern of patients with T2DM, targeting unhealthy snack intake could certainly contribute to 
this (1). Furthermore, across studies on adherence to oral hypoglycemic agents and insulin 
therapy, the adherence prevalence ranged from 39-93%. Most of these reported a prevalence 
of adherence <80%, which is a commonly used threshold for unfavorable adherence levels 
(29, 30). Treatment non-adherence is generally not restricted to one treatment behavior, as 
less than 5% of the patients diagnosed with T2DM adheres to all treatment recommendations 
(i.e. smoking cessation, sufficient physical activity, sufficient fruit and vegetables consumption, 
moderate alcohol use, and maintaining a healthy Body Mass Index), and over 80% could make 
two or more behavior changes to improve treatment (25). 
In sum, for most patients with T2DM it appears that non-adherence co-occurs across different 
treatment behaviors, contributing to poor glycemic control. Therefore, a multi-behavior 
approach covering healthy lifestyle and medical behaviors in targeting treatment non-
adherence is relevant. In order to understand adherence behavior and to identify targets 
for intervention, it is of primary importance to identify determinants of those behaviors, as 
described below. 
Understanding adherence to healthy lifestyle and medical 
behaviors
In order to develop new and effective strategies that help to improve adherence to healthy 
lifestyle and medical behaviors, it is essential to explore and understand what determines 
patient adherence to these behaviors. Once knowledge about relevant determinants is 
established, programs can be developed accordingly by addressing these factors, and 
thereby increasing the likelihood that intended improvements in adherence concerning 
healthy lifestyle and medical behaviors are achieved (31). A multitude of factors interact 
simultaneously in the process of (non)-adherence including social and economic factors, 
the healthcare system, characteristics of the disease and therapy, and patient-related factors 
(32, 33). Although all these factors provide entries for targeting treatment non-adherence, 
most are difficult to change, and while if changed, they may only be of indirect impact on 
adherence through perceptions of the patient (33). As patients are considered largely self-
responsible for their level of adherence, and individual factors account for the large majority of 
the variance observed in glycemic control, patient-related factors seem to be the most viable 
and changeable intervention domain (33, 34).
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Health behavior theories and models can guide the process of exploring and understanding 
individuals’ engagement in health behaviors. Various theories and models are available, such 
as the Social Cognitive Theory (35), the Trans Theoretical Model (36), the Health Belief Model 
(37), and the successive Theories of Reasoned Action and Planned Behavior (38, 39). Most of 
those described behavior change as a deliberate or rational process and mainly incorporated 
personal-related beliefs. Existing models and theories have been able to explain variance 
in diabetes-related health behaviors to some extent (40, 41), but have also been subject to 
substantial criticism (42). The criticism largely focusses amongst others on the predictive 
validity of the models, its reductionism, and the importance of addressing different phases of 
behavior change (43). It is acknowledged that the vast majority of explained variance is not 
accounted for by constructs included in such theories, that the quantity of constructs may be 
insufficiently elaborated to explain behavior that is assumed to be volitional, and that various 
phases of behavior change can be distinguished (42, 44). For example, the Theory of Planned 
Behavior assumes that that motivational factors, i.e. attitudes, subjective norms and perceived 
behavioral control, are predictive for someone’s intention to perform a health behavior, and 
that the intention is predictive for actual behavior (39). However, the theory less explicitly 
dedicates attention to the determinants preceding the formation of motivation. Research 
has, for instance, shown that factors such as knowledge and risk perceptions may play an 
important role as factors determining motivational factors such as attitudes and self-efficacy 
(45). Additionally, only a limited amount of the variance of behavior is explained by intention, 
and therefore the role of developing and enacting action plans should be addressed in order 
to understand and change behavior (46-50).
A way to proceed may be to integrate available theories and models, e.g. by maintaining their 
strengths and eliminating or refining their pitfalls. An example of such an integrative model 
is the integrated model for explaining motivational and behavioral change, shortly called the 
I-Change Model (43). The I-Change Model (figure 1) integrates various well-known socio-
cognitive theories, e.g. the Social Cognitive Theory (35), the Trans Theoretical Model (36), the 
Health Belief Model (37), and the Theories of Reasoned Action and Planned Behavior (38, 39). 
The I-Change Model has been successfully applied to map salient beliefs of health behavior 
(change) and to develop change programs on a wide range of health-related behaviors (51, 
52). The I-Change Model is applied in this dissertation as theoretical framework to explore and 
understand (non)-adherence and to guide the process of improving non-adherence to core 
T2DM treatment behaviors.
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Figure 1 The I-Change Model as applied in this dissertation, adapted from (de Vries, 2017)
Theoretical Framework: The I-Change Model
The core of the I-Change Model distinguishes between a pre-motivational, motivational, and 
post-motivational phase, which are moderated by information factors, i.e. personal, message, 
channel and source factors, and preceding factors, i.e. biological, psychological, behavioral, 
and environmental factors. The model posits that an individual first needs to be aware of 
the necessity of a change in behavior in order to create a sufficient level of motivation to 
cognitively process new information regarding the pursued behavior change. Awareness 
can be obtained by acquiring sufficient knowledge of the topic (e.g. what defines treatment 
adherence), by recognizing the possibility and severity of consequences due to treatment 
non-adherence (e.g. feelings of susceptibility and severity of the negative consequences of 
hyperglycemia due to medication non-adherence), and cognizance (e.g. whether the patient 
can adequately estimate if they are currently adherent or not). The model postulates that such 
pre-motivational factors play a more distal role, i.e. an indirect relation to behavior is assumed 
through factors in the motivational phase. This means that patients first need to become 
aware of the necessity of behavior change, in order to form motivation (45). Motivational 
factors in the model include factors also acknowledged by other social cognitive theories 
such as attitudes, social influences and self-efficacy. Attitudes entail a weighing of positive 
and negative rational and emotional beliefs towards the pursued behavior (e.g. pros and 
cons of engaging in physical activity). Social influences include perceptions of social support, 
norms and modeling behavior of relevant others (53), and self-efficacy entails one’s perceived 
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ability to successfully enact behavior under tempting circumstances (e.g. being physically 
active when it rains) (54, 55). Together, these motivational factors determine the intention a 
person has to change a certain behavior. 
Once a high intention to change behavior is present, individuals can facilitate behavior change 
by making preparatory and coping plans and applying these plans in practice, as research 
shows that a high intention does not automatically warrants change (56, 57). For instance, an 
individual could prepare engaging in physical activity by planning where, when, and how they 
will be active. By anticipating challenging situations where the intended behavior change is 
likely to be difficult to adhere to (e.g. when having a busy day or when being ill) and making a 
plan to deal with the situation (e.g. instead of eating in the cafeteria, the patient intends to eat 
while having a walk instead), individuals can increase the likelihood of successfully carrying 
out the intended behavior, despite these personal challenges (47). 
Improving patient treatment adherence
Once it is defined which treatment behaviors of a patient could be improved and relevant 
information on the determinants of those behaviors is obtained, programs can be initiated 
accordingly (58, 59). In the planning phase of the design of a program that aims to improve 
patient adherence, it is of importance to explore the various avenues how such a program 
could be delivered. For instance, it is not only relevant to show effectiveness, but also that 
as many people of the target population as possible can be reached in order to maximize 
program impact (60). 
Consultations between health professionals and patients seem to provide a viable platform 
to address the issue of non-adherence and to discuss how to improve adherence. In the 
Netherlands, healthcare reaches most patients affected by T2DM as they generally visit their 
health professional every three to six months for a consultation of approximately 20-30 
minutes. During these sessions, many standard topics should ideally be discussed, according 
to established protocols, such as the patient’s well-being, glycemic control, complaints and 
complications, as well as therapy adherence (13).
Practice nurses and diabetes nurses, who are the primary contact point of care of T2DM 
patients in the Netherlands, seem to be in an ideal position to address the issue of treatment 
non-adherence and to align strategies on how to improve adherence (14, 61). Despite 
acknowledging the importance of treatment adherence, scarce and busy consultations often 
impede health professionals from discussing this complex topic (14, 62). Moreover, research 
suggests that health professionals lack knowledge, motivation, and confidence to address 
(non)-adherence and to promote healthy lifestyles during these consultations (63, 64). As 
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patients still require support to self-manage their illness and related treatment behaviors, 
alternative program delivery strategies need to be explored. 
Multiple patient-focused programs are available that aim to tackle the issue of treatment 
non-adherence in patients with T2DM. These programs are heterogeneous regarding their 
intervention strategy, design, setting, population, and outcomes. The vast majority of these 
programs targets solely improvements in adherence to medical behaviors, while it is well-
known that in order to achieve glycemic control, also adherence to healthy lifestyle behaviors 
is needed (33, 65-67). As a consequence, most programs either show small or no effects (33, 
68). Moreover, as non-adherence frequently co-occurs across distinct core T2DM treatment 
behaviors, a program that targets a combination of both healthy lifestyle and medical behaviors 
through a multi-behavior approach, might therefore be more likely to be effective (25). Next 
to such a multi-behavior approach, other factors may enhance the success of programs that 
target improvements in adherence, such as the delivery of the program through the Internet.
Delivery of behavior change interventions through the Internet
The Internet has widely and successfully been applied for health services and health 
promotion activities such as the management of T2DM; such activities delivered through the 
Internet are often referred to as eHealth (65, 69-72). eHealth applications have shown to be 
(cost)-effective, easy in use, and can temper pressure on the healthcare system, for instance 
by outsourcing activities or tasks of health professionals to the Internet (73-78). In addition, 
unlike face-to-face interventions such as regular consultations with a healthcare professional, 
advantages of eHealth programs include their broad reach, i.e. their potential to reach large 
audiences of people, the ongoing support of the self-management process outside the 
clinical setting through its constant availability, and they may free health professionals to shift 
their focus to other priorities (71, 79). 
The success of eHealth programs, also in line with factors determining the effectiveness 
of programs in general, depends on the application of a solid theoretical framework, the 
possibility to identify behaviors at risk, the application of goal-setting and possibilities for 
self-monitoring, the incorporation of interactive, tailored, and visual supported content, and 
focusing and aligning on distinct behavior change phases, i.e. awareness, motivation, and 
self-regulation (65, 70, 71, 79, 80). Despite acknowledging a wide variety of success factors 
for eHealth programs, a review in 2014 on eHealth programs supporting T2DM management 
(71) concluded that only one of the nine included studies reported significant improvements 
in dietary behavior and PA; no effects were observed for medical behavior adherence (79). 
Generally, existing eHealth programs related to the management of T2DM often include 
little interactive content and tailored strategies, are mainly text-based, do not employ a 
theoretical foundation and technology, and focus on separate behaviors that play a role in the 
management of T2DM instead of combining behaviors (65, 70, 71, 80). In sum, eHealth does 
provide a viable option to improve treatment behavior adherence in patients with T2DM. So 
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far, however, success factors have not been adequately applied which may explain the poor 
results of existing programs. Hence, eHealth initiatives targeted at T2DM treatment adherence 
can be significantly improved by building on a theoretical framework, including interactive 
and visual supported content, applying a multi-behavior approach, and incorporating risk 
identification, goal-setting, and adherence monitoring facilities. Moreover, programs could 
be improved by the application of computer-tailoring technology; a strategy that can yield 
highly personalized advice to a patient and relevant information aligned to the person’s 
behavior change phase (81). 
Computer-tailoring technology
Patients with T2DM generally show non-adherence in multiple behaviors, but the specific 
behaviors most suitable for improvement may differ among individuals (25). For instance, an 
individual may be more willing or confident to improve a particular behavior, compared to 
another. This emphasizes the need for programs that are aligned to the particular profile of an 
individual and a generic approach will usually not fit all when multiple behaviors are targeted 
(82). The strategy of adapting a program to the characteristics and needs of the user by asking 
questions and using the responses to generate tailored computer driven advices is referred to 
as computer-tailoring (81, 82). Compared to generic programs, computer-tailored programs 
are more likely to be perceived as personally relevant and to stimulate greater cognitive 
activity in users (83). Computer-tailored content is based on unique answers given on a web-
based assessment. Such an assessment consists for example of questions on adherence 
levels of the person regarding behavior (e.g. levels of adherence to mediation or physical 
activity guideline targets), demographic characteristics (e.g. gender, age, education level, and 
comorbidity), and socio-cognitive variables (e.g. knowledge, attitudes, and intention towards 
behavior change). The answers to such questions are processed in a computer system 
that links individual or combined answers to pre-formulated health messages. Tailoring 
algorithms link the individual’s responses provided to a questionnaire to appropriate advice 
messages and thus result in the delivery of highly tailored and relevant web-based advice. 
Consequently, individualized content is presented which in a way mimics the counseling 
process of healthcare professionals counselling their patients (81). 
The development and evaluation of ‘My Diabetes Profile’
The aim of the project described in this dissertation was to develop and evaluate a web-
based computer-tailored program for patients with T2DM in order to improve adherence to 
healthy lifestyle and medical behaviors, i.e. improving PA levels, decreasing caloric intake from 
unhealthy snacks, and increasing adherence to OHAs and insulin therapy (14, 15). This project 
consisted of several phases. 
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First, explorative studies were conducted in order to identify which treatment behaviors were 
subject to improvement in patients with T2DM and which specific determinants within those 
treatment behaviors were associated with (non)-adherence. Exploring salient beliefs, which 
are the cognitive representation of determinants, is essential to understand what determines 
those behaviors. Moreover, this information is important to know which specific feedback 
messages were needed for this population and in order to construct programs that are likely to 
be successful in behavior change (31, 38, 84). In fact, at the level of beliefs, salient information 
should be obtained about the considerations that lead people to engage or not engage in a 
given health behavior (84, 85). Besides the conduct of explorative studies, relevant information 
was gathered through studying recent Internet programs that examined the effect of 
computer-tailoring technology on improving adherence to multiple behaviors. The outcome 
of the explorative studies, which consisted of both qualitative and quantitative research, is 
presented in chapters 2 and 3.
Second, an advisory committee was formed prior to the development of the program, in order 
to discuss its content, tailoring strategy, and to align the program with the needs and wishes 
of the target group. The committee included both delegates from the target population, 
i.e. patients with T2DM, as well as local experts in the field of healthcare, computer-tailoring 
technology and health behavior change.
Third, we developed ‘My Diabetes Profile’, a program that integrates the factors which 
were identified to determine success of eHealth programs aimed at improving treatment 
adherence and which was theoretically grounded in the I-Change Model (43). The program 
consists of several subsequent sessions, i.e. a health risk appraisal session, an awareness and 
motivation session, and a goal-setting, monitoring and action planning session. Throughout 
these sessions, individuals receive personally relevant information on risk behaviors and 
relevant content tailored to various phases of behavior change which are addressed in the 
I-Change Model. In addition, the tailored content is offered through video-, visual- and brief 
text-tailored advice. Furthermore, the program focuses on multiple behaviors involved in the 
management of T2DM in a sequential matter. Specific elements of the program, for example 
the videos, navigation tools, and its usability were pragmatically tested in our target group. 
Conducting such usability evaluations are a pivotal step in the development of programs in 
order to make pre-trial improvements, and to assess patients’ satisfaction with the program 
(86). Improvements were made based upon these usability evaluations, that is, instructions 
were included on how to answer certain questions, important text words and fragments were 
highlighted to raise awareness and cognitive processing, and clear directions were included 
on how to navigate in the program.
Fourth, we developed a protocol for a randomized controlled clinical trial (RCT) to determine 
the effectiveness of the My Diabetes Profile in patients with T2DM. In an RCT, which is generally 
considered the golden standard in conducting effectiveness research (87), participants are 
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randomly allocated to an intervention or control arm and compared in terms of a selected 
outcome measure, e.g. adherence to treatment behavior (88). Assessments were conducted 
at baseline, i.e. just before the six-month program access period, and directly after the access 
period. Outcomes compared between both trial arms comprised of overall adherence 
behavior change, i.e. a composite score of changes in adherence to separate core treatment 
behaviors, and - as a secondary outcome - a score for the change in each separate adherence 
behavior. An extensive description of the program, including its development and content, 
as well as a protocol for conducting the effectiveness trial is described in chapter 4 of this 
dissertation. 
Fifth, a multi-center RCT was performed, in both general practice and outpatient clinics. 
For a period of six months, patients with T2DM were recruited by their practice nurse or 
diabetes nurse, and randomly allocated to either the intervention arm (receiving program 
access) or the control arm (receiving no program access, waiting list) for six months. When 
conducting an RCT in order to examine the effectiveness of a program, large sample sizes 
are often required to warrant sufficient study power. In our trial, as well as in many other 
trials, patient recruitment was based on the efforts of health professionals, given their direct 
contact and trustful relationship with their patients (89, 90). Recruiting the required sample 
size for randomized controlled trails can be a challenge, but is essential to successful conduct 
of clinical trials (91). Many trials do not reach their required number of patients, which can 
jeopardize generalizability of observed results, reduce study efficiency due to extended 
recruitment periods, and lead to premature discontinuation of trials (90, 92-94). Moreover, 
the dissemination of possible effective treatments to a broad population may be delayed 
(95). Researchers have been called to thoroughly evaluate their recruitment procedure 
applied in trials, as current research highlights the paucity of conclusive evidence regarding 
factors influencing recruitment success (91, 96). In our trial, nurses across the Netherlands 
were approached in order to recruit at least eight patients with T2DM to our trial. Once all 
patients were included in the trial, this recruitment process was evaluated by exploring factors 
influencing nurses’ recruitment and the results of this evaluation are presented in chapter 5. 
The results of the RCT are described and discussed in chapter 6 of this dissertation. 
Aim and outline of dissertation
The main aim of this dissertation was to develop and subsequently provide insight in the 
effectiveness of the eHealth program, My Diabetes Profile, which aimed to improve adherence 
of patients with T2DM to core treatment behaviors, i.e. improving physical activity levels, oral 
hypoglycemic agent adherence, insulin therapy adherence, and decreasing caloric intake from 
unhealthy snacks. This dissertation is divided into two parts which subsequently contribute to 
its overall aim, and is concluded with a general discussion (Chapter 7).
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Part I: Formative research, program development and trial protocol
Chapter 2: Exploring beliefs on diabetes treatment adherence among Dutch type 2 diabetes 
patients and healthcare providers.
Chapter 3: Psychological predictors of adherence to oral hypoglycemic agents: An application 
of the ProMAS questionnaire.
Chapter 4: A web-based program to improve treatment adherence in patients with type 2 
diabetes: Development and study protocol.
Part II: Recruitment and effectiveness evaluation
Chapter 5: Exploring factors influencing recruitment success of nurses recruiting diabetes 
patients for a randomized controlled trial.
Chapter 6: The effectiveness of a web-based computer-tailored program to improve treatment 
adherence in patients with type 2 diabetes: A randomized controlled trial. 
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PART 1
Formative research, program 
development and trial protocol

This chapter has been published as:
Vluggen S, Hoving C, Schaper NC, de Vries H. Exploring beliefs on diabetes 
treatment adherence among Dutch type 2 diabetes patients and healthcare 
providers.
Patient education and counseling. 2018; 101(1):92-8.
Chapter 2
Exploring beliefs on diabetes 
treatment adherence among Dutch 
type 2 diabetes patients  
and healthcare providers
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Abstract
Objective: Despite well-known beneficial effects, adherence to core elements 
of diabetes treatment is suboptimal. This study, conducted in the Netherlands, 
aimed to explore if and how treatment adherence success factors are applied 
in diabetes consultations, and to explore salient personal beliefs about 
type 2 diabetes treatment including both healthy lifestyle adaptations and 
pharmacotherapy.
Methods: A qualitative study using semi-structured interviews among nine 
Dutch healthcare providers predominantly involved in diabetes management 
and 19 Dutch type 2 diabetes patients. Data was systematically analyzed 
through deductive coding analysis using Nvivo.
Results: Most patients visited their consultations unprepared. Patients did not or 
vaguely experience goal-setting in consultations, whereas healthcare providers 
indicated to set treatment goals. Shared-decision making was applied, however 
patients were rather passive collaborators as mostly healthcare providers 
were in charge of making treatment decisions. Despite suboptimal treatment 
adherence, many advantages and few disadvantages of treatment strategies 
were reported. Adherence self-efficacy was lower in situations outside daily 
routine.
Conclusion: Treatment adherence success factors are not optimally applied, 
and in particular treatment adherence self-efficacy could be improved.
Practice implications: The application of treatment adherence success factors 
in consultations could be improved, and personal beliefs should be addressed 
to improve treatment adherence and optimize counselling.
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Introduction
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by 
hyperglycaemia and the body’s inability to retain an optimal glucose metabolism (97, 98). 
Worldwide nearly 400 million people live with T2DM, with expectations of almost 600 million 
people being affected by 2035 (98). This rise is largely attributable to unhealthy energy 
balance-related behaviours such as physical inactivity and unhealthy dietary patterns (97-
99). Core T2DM treatment elements, which target an optimal glucose metabolism, consist of 
adaptations towards healthy lifestyles, i.e. increasing physical activity (PA) and improving dietary 
patterns, and pharmacotherapy, i.e. taking glucose lowering pills and/or injecting insulin 
(100). Despite the well-known long-term benefits of adequate glycaemic control on reducing 
microvascular complications and death from any cause (16), patients’ treatment adherence is 
suboptimal (101-103). Several studies show that the majority of T2DM patients does not meet 
recommended levels of PA and does not adhere to dietary guidelines (23, 24). Moreover, King 
et al. (25) showed that over 95% of diabetes patients failed to adhere to all five healthy lifestyle 
recommendations studied. Adherence prevalences on diabetes pharmacotherapy vary across 
studies from 38.5 to 93.1%, far most of them reporting prevalences <80% (30). Poor adherence 
not only impedes beneficial treatment effects, but is also associated with disease worsening, 
cardiovascular risks, a reduced quality of life, more hospitalizations, increased healthcare costs, 
and premature mortality (7, 18-22, 104).  
Treatment adherence implies collaboration between a healthcare provider (HCP) and a 
patient in the formulation and agreement of treatment strategies. This collaborative care 
strategy can be applied in consultations, which should serve as a setting where patients 
are informed, educated, facilitated, motivated, and taught skills to optimally self-manage 
T2DM in daily life (105). Determinants of patient treatment adherence have been identified 
at both HCP and patient level. At the HCP level, knowledge insufficiencies, lack of time and 
motivation, and difficulties in involving patients in decision-making have been identified as 
adherence barriers (63). Patients on the other hand often lack knowledge and motivation to 
change lifestyles, and discipline to persist adapted lifestyles (14, 63, 64). Moreover, French et 
al. (84) demonstrate that personal beliefs about treatment play an important role in treatment 
adherence, especially regarding the core elements of T2DM treatment. To ensure treatment 
success and adequate glycaemic control, active patient engagement, applying goal setting 
principles, tailoring treatment strategies to patients’ needs, beliefs and abilities, involving 
patients in decision-making, and effective ongoing self-management beyond consultations 
is required (15, 64, 104, 106). Because the basis for treatment strategies originates from 
consultations between HCPs and patients, and as still many patients suboptimally adhere to 
their treatment, it is evident to profoundly explore if and how treatment adherence success 
factors are applied in consultations. Moreover, it is important to explore salient personal 
beliefs about core treatment elements as they play an important role in treatment adherence. 
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A better understanding of these factors can offer handles to optimize treatment adherence 
and improve T2DM counselling (84).  
The aim of this study was to: (1) explore if and how treatment adherence success factors 
are applied in consultations between HCPs and T2DM patients, and (2) explore salient 
personal beliefs about T2DM treatment, including both healthy lifestyle adaptations and 
pharmacotherapy among HCPs and T2DM patients. 
Methods
Procedure
We conducted a qualitative study using semi-structured individual interviews among HCPs 
predominantly involved in T2DM management and T2DM patients. The study was approved 
by the ethics committee of the MUMC+ (15-4-094). 
HCPs and patients were recruited from July up to November 2015 in the southern region 
of the Netherlands. Purposefully efforts were made to recruit a heterogeneous sample in 
terms of age, gender, education level, and healthcare setting. A priori, we aimed to conduct 
25 interviews among fifteen T2DM patients and ten HCPs: our initial analysis sample (107). 
This number was chosen because both perspectives needed to yield sufficient representative 
results. We aimed to include more patients, as the absolute number of patients is much 
larger than the actual number of HCPs. Moreover, we thought that HCPs would carry many 
experiences of consultations with patients, whereas patients would only have their own 
experience. After these 25 initial interviews, two additional patient interviews and one 
additional professional interview were conducted to confirm saturation and content validity 
for both interviewed groups (107). No new themes emerged from these additional interviews, 
hence data saturation was reached.  The inclusion criterion for HCPs was: having treated T2DM 
patients in the Netherlands at least once in the last three months. Further we included general 
practitioners, practice nurses, internists, diabetes nurses, and dieticians. In the Netherlands, 
these professionals are predominantly involved in T2DM management and in shaping 
treatment strategies, hence these HCPs were included (14). HCPs were recruited through 
e-mail, including a non-committal study description and a participation request. In case of 
participation agreement, an interview date was picked, and HCPs provided written informed 
consent. HCPs were interviewed by the first author at the HCPs’ workplace. Afterwards, they 
received a symbolic diabetes-related reward. Five general practices and one hospital were 
approached to recruit patients. Eligible patients were identified by the HCP and inclusion 
criteria were: T2DM diagnosis for at least one year, 40-70 years old, receiving treatment in the 
Netherlands, and using at least one form of glucose lowering medication. Patients not able 
to speak and understand the Dutch language and patients unable to use a computer were 
excluded. Eligible patients were approached by their HCP to explain study details, including a 
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non-committal information letter with a study description, and a participation request. In case 
of willingness to participate, s/he could contact the researcher, an interview date was picked, 
and patients provided written informed consent. Patients were interviewed at the research 
institute by the first author and rewarded with a €25,- gift card. 
Measurement
All interviews were structured using an interview route. Various experts involved in T2DM 
management and T2DM patients provided feedback on the interview route and adaptations 
were made resulting in a final version consisting of four topics: consultations between HCPs 
and patients, salient personal beliefs about T2DM treatment, diabetes literacy, and eHealth. 
Diabetes literacy and eHealth are not further elaborated in this manuscript. Interviews started 
with identifying demographic characteristics. The I-Change Model (figure 1) (108) was used 
to theoretically inform this study. The model distinguishes an awareness, motivation, and 
action phase in explaining and changing behaviour, which are influenced by preceding and 
information factors. It incorporates various socio-cognitive theories (36, 37, 109) and has been 
used frequently to identify beliefs involved in health-related behaviour (110). Consultations 
between HCPs and patients focussed on treatment adherence success factors such as goal-
setting, shared-decision making (SDM), and self-management (education). These factors 
fall under ‘information factors’ in the I-Change Model (108). Moreover, the I-Change Model 
incorporates several determinants of treatment adherence which have been identified earlier 
like knowledge, attitudes, self-efficacy, and action planning (14, 63, 64). These determinants 
were operationalized (table 1) to identify underlying salient personal beliefs of core treatment 
elements. The identification of these beliefs focussed mainly on determinants in the awareness 
and motivation phase. 
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Figure 1 The I-Change Model
Table 1 Interview questions: operationalization I-Change Model concepts
I-Change Model Concept Operationalization
Information Factors
Perceived Cues
Cognizance
Knowledge
What is the course and content of a consultation meeting?
Do patients prepare their consultation, and how?
Are treatment strategies and goals formulated, and how?
What is the role of the patient and HCP in a consultation, and (how) is 
shared-decision making applied?
What is a direct trigger for you to be physically active?
Do you (think) you adhere to your medication regimen?
What is the effect/mode of action of your medication?
Which are (un)healthy foods?
Risk Perceptions
Attitudes
   
Social Influences
Self-efficacy
Intention
Action Planning
Coping Planning
What could happen if you don’t use your medication, and how severe 
would you find this?
What could be consequences of being physically inactive, and how 
severe would you find this?
What are advantages for you of a healthy diet?
What are disadvantages for you of being physically active?
Who supports you to use your medication?
Are there people who think you should eat healthy?
In which situations is it more difficult for you to be physically active?
Are you planning on improving your medication adherence?
Which plans do you have to increase your physical activity?
Which coping plans do you have to eat healthier when facing a 
difficult situation?
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Analysis
Interviews were audio recorded, transcribed verbatim, anonymized, and analysed using 
Nvivo 10 (111). Deductive coding analysis (112) was performed by two researchers; the first 
author and a research assistant. For HCPs and patients separately, a pre-defined coding tree 
was independently applied to a single random transcript by both researchers. Interview 
passages were assigned codes, and the creation of additional codes and inconsistencies were 
discussed and agreed upon. The same process was then repeated on three other random 
transcripts. This resulted in a final coding tree which was then applied to analyse four random 
HCPs transcripts and four patients’ transcripts by both researchers (112). Subsequently, the 
intercoder reliability and Cohen’s Kappa were assessed using the coding comparison query. 
For both HCPs and patients, this resulted in a percent agreement of 0.99, reflecting a high 
degree to which interview passages were assigned to the same codes by both researchers. 
The Cohen’s Kappa showed to be 0.67 for the HCPs group and 0.79 for the patients group, 
reflecting a good strength of intercoder agreement (112, 113). 
Results 
Sample characteristics 
Thirty-one participants agreed on study participation: nine HCPs and 22 patients. Three 
patients were excluded because they did not meet the inclusion criteria. Five interviews were 
conducted in two parts because of time constraints of participants. HCP interviews were 
conducted with general practitioners (GP, N=2), practice nurses (PN, N=2), internists (INT, 
N=1), diabetes nurses (DN, N=2), and dieticians (DIET, N=2). Interviews with HCPs lasted on 
average 61 minutes, ranging from 50-75 minutes. Interviews with patients lasted on average 
82 minutes, ranging from 59-107 minutes. Patients had on average a suboptimal HbA1c-level 
of 63 mmol/mol, and were on average obese (BMI = 35.4 kg/m2). Sample characteristics are 
shown in table 2. 
Table 2 Sample characteristics interviewees
N (%) Mean (SD)
T2DM Patient Characteristics 
Gender 
Male 10 (52.6)
Female 9 (47.4)
Education level
High 6 (31.6)
Low 13 (68.4)
continue
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Table 2 Sample characteristics interviewees
N (%) Mean (SD)
Marital Status
Single 4 (21.1)
In a relationship 15 (78.9)
Pharmacotherapy
Glucose lowering pills 6 (31.6)
Insulin 3 (15.8)
Combined 10 (52.6)
Age 57.3 (7.1)
HbA
1c 
 (mmol/mol)a/b 63a (18.1)
BMI (kg/m2)b 35.4 (6.7)
T2DM Duration (years) 12.7 (8.6)
Interview Duration (min.) 82 (17.3)
HCPs’ Characteristics
Gender
Male 3 (33.3)
Female 6 (66.7)
Work Setting
Primary Healthcare 5 (55.6)
Secondary Healthcare 4 (44.4)
Age 47.3 (11.4)
Interview Duration (min.) 60.6 (7.8)
BMI body mass index, HbA
1c 
glycosylated haemoglobin, SD standard deviation, 
a This equals an HbA
1c 
of 7.9%
b Target values for HbA
1c 
and BMI are < 53 mmol/mol and < 25  kg/m2 respectively. 
Diabetes consultations
Course and content
Most patients indicated to visit their practice nurse or diabetes nurse quarterly, their general 
practitioner or internist once a year, and a dietician if appropriate. All HCPs reported that the 
course and content of those consultations was highly protocolled, meaning that several topics 
like discussing blood tests results, lifestyle and medication (adherence), and complication 
management would recur every consultation. Moreover, if applicable, time was devoted to 
issues raised by patients like questions and personal demands of care. Little time was spent 
on self-management education [Quote #1]. Most HCPs and patients reported that patients 
did not prepare their consultations. Patients who did so, reported activities such as recording 
blood glucose levels and writing down questions. HCPs stated that they would welcome a 
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more active participation and disease engagement of their patients, as many were passively 
oriented. Few HCPs actually tried to stimulate their patients to actively participate [Quote #2]. 
Goal Setting
Most patients indicated that no goals were set regarding treatment strategies. Patients 
reported that if goals were set, they were often vague and perceived as advice rather than 
goals [Quote #3]. In contrast to patients’ perceptions, most HCPs reported that they often 
formulated goals during consultations, especially concerning lifestyle changes, improving 
glycemic control and treatment adherence, and stabilizing disease worsening. Most HCPs 
indicated to tailor goals to patients’ needs and abilities by proposing small steps and realistic 
goals [Quote #4]. Some HCPs reported that treatment goals were often not reached due to a 
lack of motivation in patients. According to some HCPs, patients sometimes aimed for higher, 
unachievable goals [Quote #5]. 
Shared-Decision Making
A small majority of HCPs and patients indicated that the course and content of consultations, 
as well as the formulation of treatment strategies and goals, were determined by the HCP 
and patient in conjunction. This manifested itself either in patients who passively agreed on 
subjects and treatment strategies proposed by their HCP, justified by ‘the HCP knows best’, or 
through a few patients who came up with treatment ideas themselves. HCPs perceived that 
older patients were more dependent on the HCP’s approach and younger patients were seen 
as more active collaborators through bringing up treatment ideas themselves and searching 
information on the Internet [Quotes #6 and #7]. Many HCPs indicated that treatment 
adherence was the patient’ own responsibility. Contrary to the overall passive engagement in 
the formulation of treatment strategies, all patients felt they were responsible for treatment 
adherence. 
Adherence to treatment elements
Many patients stated to be physically active and only few stated to be fully inactive. Often 
mentioned activities which contributed to PA were: walking (the dog/upstairs), cycling, 
shopping, household activities, and visiting a physiotherapist or gym. However, according to 
almost all HCPs, adherence to PA guidelines was poor [Quote #8]. According to most HCPs, 
adherence to healthy diets was poor. Issues identified focused on irregularity of meals, portion 
size and snacking in between and/or after regular meals. In general, patients indicated to 
maintain a healthy diet. However, when asking for detailed diet description, emphatically 
intense savory and sugary snacking behavior in between or after regular meals could be 
identified in most patients [Quotes #9 and #10]. Near all HCPs reported that adherence to 
pharmacotherapy in patients was suboptimal. Both intentional (purposely skipping or altering 
regimes) and unintentional (forgetting) non-adherence underlie this statement. Half of the 
patients indicated to always adhere to their diabetes pharmacotherapy. Regarding adherence 
to glucose lowering pills and insulin, similar types of non-adherence emerged like forgetting, 
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skipping, stopping, stacking medication, adapting dosages, and using medication at varying 
times [Quotes #11 and #12]. 
Awareness beliefs
HCPs believed that patients’ knowledge levels regarding health benefits of PA were sufficient. 
Almost all patients believed that regular PA should be part of a healthy lifestyle. When 
discussing risks of PA non-adherence, patients stated risk of weight gain, loss of fitness, 
becoming less mobile, getting hyperglycemia, and developing cardiovascular diseases [Quote 
#13].  Regarding a healthy diet, HCPs indicated that patients were aware of the fact that they 
should eat less and healthier, but that they were less aware of the products which did and 
did not contain carbohydrates. Furthermore, HCPs encountered patients who believed that 
treatment involved a no-sugar diet. In contrast to HCPs perceptions, most patients stated 
to be aware of what carbohydrates are, and which products contained them. Patients 
believed that an unhealthy diet could result in hyperglycemia, cardiovascular diseases, weight 
gain and an increase of pharmacotherapy. Most HCPs stated that the majority of patients 
had insufficient knowledge regarding their pharmacotherapy. This manifested itself in not 
knowing which pills were glucose lowering pills, or being unfamiliar with their mode of 
action. HCPs indicated to make patients aware of the susceptibility of getting complications 
as a result of pharmacotherapy non-adherence [Quote #14]. Most patients could not or only 
vaguely explain the mode of action of their medication. Almost all patients stated that non-
adherence would result in hyperglycemia, and almost half of them associated non-adherence 
with long-term consequences like myocardial infarction, blindness, kidney problems and 
atherosclerosis. Some patients only using glucose lowering pills expressed the fear of non-
adherence resulting in an increase of pharmacotherapy [Quote #15]. 
Motivational beliefs
Near all HCPs and patients identified advantages of regular PA. In patients’ perspective, 
frequently reported advantages were: feeling fitter, feeling more comfortable and energized, 
enjoying PA, and PA being good for their weight and glucose. Lowering their insulin use, 
decreasing the change of complications, and enjoying the social component of PA, were 
less frequently mentioned advantages. Near all patients and HCPs stated PA has no major 
disadvantages [Quote#16]. Almost all patients identified advantages of a healthy diet. Having 
favorable blood glucose levels, feeling better, losing weight, and potentially decreasing their 
pharmacotherapy were most frequently mentioned advantages. Near all patients stated that 
a healthy diet doesn’t involve disadvantages. Regarding adherence to pharmacotherapy, 
almost all patients reported its blood glucose lowering function as an advantage. Feeling 
healthier and believing pharmacotherapy controls T2DM, were other frequently mentioned 
advantageous beliefs. Most HCPs and patients indicated side effects, (fear of ) hypoglycemia, 
feeling hungry, injection sites, weight gain, antipathy against introducing chemicals into their 
body, and social undesirability as disadvantages of pharmacotherapy adherence [Quote #17].
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Both HCPs and patients identified situations in which patients were perceived to have 
lower self-efficacy to adhere to their treatment strategies. Regarding PA adherence, lacking 
motivation, being busy, and feeling tired were most often mentioned situations. Less often 
mentioned situations were: if the weather is bad, when feeling ill or having to be physically 
active alone [Quote #18]. Adherence to healthy diets is believed to be more difficult when: 
feeling tempted to eat unhealthy, feeling stresses, emotional or bored, having a party, and in 
weekends or evenings. These situations seem to provoke unhealthy snacking [Quote #19]. 
Situations identified which might impede pharmacotherapy adherence were: being stressed, 
having a party, going out for diner, going on vacation, feeling ill, having an unstructured day/
life, or in the evening. A single time, patients identified situations like: not feeling burdened by 
T2DM and their partner not alerting them as difficult situations [Quotes #20 and #21].
Table 3 Interviewee quotes
Quote number Respondent Quote
#1 DN1 “If you don’t plan it well concerning self-management, the 
consultation, there is a disproportion… there are maybe 10 
minutes to talk about self-management… that is too short” 
#2 INT1 “Some do [prepare], the majority doesn’t. I think it accounts for 
most of our patients... they just sit down and wait and see what 
happens”
#3 T2DM3 “They said: well, your sugar [level] should be better”
#4 DN1 “Always small goals, very small steps, and also [to] approach it 
positively. You feel that works for people. If they would just not 
gain weight; that is also ok” 
#5 PN1 “If I notice that they want to set too high goals of which I know 
they will never succeed in… than I will definitely say to them: well 
very good that you thought about it, but maybe we should take 
smaller steps” 
#6 DN1 “You are a kind of team that tries to help each other; the patient 
helps you by giving information about their situation, and you try 
to help the patient to gain control over their diabetes” 
#7 DIET2 “You often see in elderly, they say: “tell me what to do, what I 
should inject, what I should eat…” following [advice] is not self-
management”
#8 GP1 “They know they should be physically active for 30-45 minutes 
daily, they know it, but they don’t do it” 
#9 DN2 “A cookie is a habit rather than exception, and the food is not 
limited to three meals daily” 
#10 T2DM11 “When it is 3 or 4 PM, I want to eat two cookies along with my 
coffee, or some licorices, and in the evening… Once I start eating 
a couple of sweets, than those taste buds… they keep asking for 
sugar” 
Continue
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Table 3 Interviewee quotes
Quote number Respondent Quote
#11 DN2 “I think at least 30% doesn’t always take that what they think 
they should do, definitely [there] are people who forget a pill, 
[and there] are always people who purposely don’t take their 
medication”
#12 T2DM8 “In particular with insulin, kind of cheating we call it, by injecting 
a little more or a little less. Sometimes it works well, sometimes it 
goes awfully wrong” 
#13 T2DM7 “I think I will gain some weight… by expending more energy by 
being physically active, I can use less insulin, which makes me 
lose weight” 
#14 INT1 “You try to motivate them by pointing at the complications… 
that’s the hardest part of diabetes, you don’t give medication 
because people suffer from complaints, unless they have 
hyperglycemia, but the approach is to invest in the future, to 
prevent a heart attack, blindness and dialysis”
#15 T2DM3 “I get tired and off course a lot can happen to your blood vessels, 
[and] your eyes”
#16 T2DM3 “I think [you] become more physically fit, and your sugar [level] 
gets better… and my weight will decrease”
#17 T2DM7 “I had abdominal pains, or [I was] nauseous of those pills, because 
I had to take a lot of them” [T2DM7]
#18 GP1 “It can have various causes, that they don’t understand it, or 
because they have no money, or they don’t have time, or because 
it’s really busy at home, or because they feel ashamed, many 
different causes, or because they just don’t feel like it”
#19 DN2 “In between meals, and in the evening it happens even more, 
because mostly they had dinner and it’s 7:30 PM, and then of 
course the closet opens and people sit in front of the television… 
instead of doing some PA or walking, [they] snack, sometimes till 
late in the evening”
#20 T2DM4 “Everything involving distraction creates the chance to forget 
your pill” 
#21 DIET2 “If you have a normal day, you’ll take your pills. But if a day is 
really hectic… or they go out for dinner… then those pills are 
forgotten”
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Discussion and conclusion
Discussion
The first aim of this study was to explore if and how treatment adherence success factors are 
applied in consultations between HCPs and patients. In our population, diabetes consultations 
usually took place quarterly, were highly protocolled, and included discussing treatment 
adherence. This is in line with current Dutch guidelines (14). In line with HCPs’ perceptions, 
most patients indicated not to prepare their consultations. Although HCPs pleaded for a more 
active contribution by their patients, few actually stimulated their patients to do so. HCPs and 
patients believed that decision making regarding consultation content and the formulation 
of treatment strategies was overall taking place in conjunction. However, a tendency towards 
reliance on HCPs’ guidance was reported by HCPs as many patients, especially older patients, 
seemed to passively agree on HCPs’ treatment suggestions. It is known that HCPs experience 
difficulties in involving patients in decision making (63). Previous research showed that 
patients should be active collaborators in care, that HCPs should enable patients to make 
informed decisions, and that treatment decisions should preferably be made in conjunction 
(104, 114). Moreover, SDM should be at the center of diabetes consultations according to 
Dutch guidelines (14). Applying SDM principles not only has the potential to improve quality 
of life, it has also been shown to improve physiological markers such as HbA1c-levels (115). 
Although both HCPs and patients indicated that patients should be primarily responsible for 
treatment adherence, our results suggest that the HCP is the main initiator and responsible for 
making treatment decisions. This can have considerable unfavourable consequences for the 
execution of those strategies (115).  
Contrary to perspectives of HCPs, most patients perceived that during consultations, no or not 
concrete enough treatment goals were set in order to manage their diabetes. Such perspective 
discrepancies between HCPs and patients might lead to not reaching treatment goals. As 
a consequence, nurses sometimes feel powerless if their patients do no reach treatment 
goals (63). Earlier, the importance of applying goal setting principles in achieving behaviour 
change has been emphasised (116), and this approach has been shown to result in significant 
improvements in HbA1c-levels (117). Although according to HCPs goal setting was applied, 
active patient engagement, clarity about goal setting, and adequate self-management 
education on how to achieve those goals, seemed to be lacking. HCPs perceived that patients 
sometimes aimed for higher, unachievable goals. As a reaction, they indicated to tailor 
strategies to patients’ abilities and proposed taking small steps in behaviour change. Despite 
these efforts of HCPs, it is known that many HCPs aren’t trained to aid patients in setting 
achievable goals, and that they might lack knowledge in facilitating patients to set small goals 
or to make action plans (116). In addition, HCPs might be willing to set goals for their patients 
themselves. While most HCPs and patients indicated to make treatment plans in conjunction, 
it seemed that especially older patients could be characterised as rather passive collaborators. 
Contrary to younger and more active patients, older patients should not only feel responsible 
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for the execution of treatment strategies, but should also be actively involved in setting them. 
This leads to increased motivation and self-efficacy, and has positive consequences on its 
execution (106, 115, 118). This is in particular of interest because HCPs reported that one 
reason for not reaching treatment goals in patients was a lack of motivation.   
The second aim was to explore salient personal beliefs about T2DM treatment, including both 
healthy lifestyle adaptations and pharmacotherapy. First, this study indicated that adherence 
to the core diabetes treatment elements was suboptimal. HCPs emphasized that adherence 
was poor regarding all treatment elements, contrary to some patients who stated to adhere 
to one or more treatment elements. Both HCPs and patients felt that knowledge regarding 
PA was sufficient, however regarding knowledge of healthy diets, their perspectives differed: 
HCPs thought that this inadequate while patients thought that this was adequate. Regarding 
pharmacotherapy, both groups reported that patients’ knowledge was insufficient. Many 
patients were aware of the susceptibility of getting complications as a result of non-adherence 
to core treatment elements, although most of these were short-term consequences. It is 
notable that despite the reported poor adherence, many advantageous beliefs were reported 
of adherence to all treatment elements. Contrary to PA and healthy diets, pharmacotherapy 
adherence also yielded many disadvantages. Larkin et al. (119) reported that in particular 
non-adherent patients were more likely to be worried about pharmacological side effects. 
Disadvantages like these are frequently reported regarding taking oral medication (120), 
should be thoroughly discussed in consultations, and patients should be made aware that 
the advantages of adherence outweigh the disadvantages (106). Last, self-efficacy to adhere 
to treatment strategies seemed to be lower in certain difficult situations, which tend to occur 
when daily routine is compromised, like having an unstructured day/life. Similar difficult 
situations were reported for PA, healthy diets and pharmacotherapy. Low self-efficacy has 
been related to reduced adherence levels earlier (121), and should therefore be enhanced, 
especially in these situations out of daily routine.
This study shows some strengths and limitations. First, HCPs and patients were interviewed, 
allowing comparison of both perspectives. Second, a theoretical framework (The I-Change 
Model) was used which incorporates factors that are known to determine behaviors involved in 
diabetes treatment. These factors were operationalized to contribute to a better understanding 
of the underlying salient beliefs. Last, our data was analyzed systematically using a deductive 
coding approach with a pre-defined coding tree. Our analysis showed satisfying intercoder 
reliability and agreement levels. This study also has some limitations. First, participants were 
recruited from one geographical region. Recruitment of HCPs proved to be more difficult than 
expected as just one internist was recruited. Despite efforts to create sample heterogeneity, 
future studies should aim for nation-wide recruitment to increase generalizability. Second, 
some interviews were split in two parts because of patients’ time restraints. Future interviews 
should possibly be more concise and set time limits. Third, post-motivational determinants 
like action planning and coping planning should also receive attention in terms of identifying 
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salient personal beliefs regarding these determinants. Last, the qualitative design of the study 
yielded in-depth findings, but observational research designs are required to objectively 
assess our findings.
Conclusion
Our T2DM patient sample shows insufficient metabolic control and both perspectives of 
HCPs and patients add up to the conclusion that both lifestyle and medication adherence is 
suboptimal. Most patients visited their consultations unprepared, justified by perspectives of 
both interviewed groups. Patients did not or only vaguely experience that treatment goals 
were set, whereas HCPs indicated to actually provide them. Although both groups believed 
that SDM is applied, it seemed a rather passive collaboration, with the HCP mostly in charge 
of making treatment decisions. However, contrary to older patients, younger patients could 
actually be characterised as more active collaborators. A lack of motivation and inactive 
involvement of patients might justify poor treatment adherence. Also the inability of HCPs 
to involve patients in decision making, the potential incapacity of HCPs to set achievable 
goals for their patients, and the misconception between HCPs and patients about if goals 
are actually set, could contribute to poor treatment adherence.  Regarding personal beliefs, 
awareness factors seemed to be sufficient. However, perspectives regarding healthy nutrition 
knowledge of patients, differed between HCPs and patients, and pharmacotherapy knowledge 
and awareness of long-term consequences could be improved. Despite reporting many 
advantages of treatment adherence, and – excluding pharmacotherapy –  few disadvantages, 
treatment adherence was still suboptimal. As indicated by HCPs and patients, self-efficacy 
seemed to be lower in situations outside daily routine, and should be enhanced to improve 
treatment adherence.
Practice Implications
A fruitful collaboration between HCPs and T2DM patients should build on input and active 
engagement from both parties. Shared-agreement and clarity about goals, taking small steps 
in behaviour change, and tailoring goals to patients’ needs and abilities are considered key 
factors in facilitating treatment adherence. HCPs should make patients aware that they should 
also be responsible for active preparation, engagement and collaboration in the formation of 
treatment strategies. Self-management education, accompanied by use of salient personal 
beliefs about T2DM treatment, should be cornerstone of consultations. These can enhance 
the necessary motivation for improving treatment adherence, support adequate self-
management, and facilitate persisted behaviour change outside consultation time.
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Abstract
Objectives: This study aimed to identify psychological predictors of oral 
hypoglycaemic agent (OHA) adherence and to compare adherence rates 
between a novel and well-known instrument, i.e. the ProMAS and MARS-5. 
Design and main outcome measures: A longitudinal study design was 
applied with surveys at baseline and six-months follow-up. At baseline, OHA 
adherence using the ProMAS and MARS-5, socio-cognitive determinants, 
and demographics were assessed. At follow-up, the ProMAS was applied as 
outcome measure, on which socio-cognitive determinants and demographics 
were regressed using linear regression analysis. 
Results: The baseline and follow-up sample included 304 and 231 participants 
respectively. When applying cut-off points of ≥15 for the ProMAS and ≥23 for 
the MARS-5, 47.7% and 89.5% adhered to their OHAs. Consistent predictors of 
better adherence comprised a low education, lower severity perceptions, and 
higher self-efficacy and intention. After correcting for baseline adherence, a low 
education and higher self-efficacy remained significant adherence predictors. 
Conclusions: Compared to the MARS-5, ProMAS data was less skewed, similar 
to objectively collected data, and yielded insights in a broader spectrum of 
(non)-adherence behaviours. Results stress the need for adherence improving 
interventions which particularly should target higher educated patients and 
patients with low self-efficacy, low intention and high severity perceptions. 
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Introduction
The long-term beneficial effects of intensive glycemic control in type 2 diabetes patients 
on disease progression, cardiovascular risks, and early mortality are well known (16). Initial 
treatment strategies comprise healthy lifestyle recommendations (30), i.e. improving dietary 
patterns, regular physical activity, smoking cessation, moderate alcohol consumption, and 
a healthy Body Mass Index (BMI) (25). Only 3.5% of the 40-75 year old patients achieves 
adherence to all these recommendations which often makes the initiation of pharmaceutical 
interventions inevitable (25). Depending on the necessity of treatment intensity, oral 
hypoglycaemic agents (OHAs) are usually considered primary pharmaceutical strategies. As 
insulin secretory capacities of the pancreas progressively decrease, eventually many patients 
will require more than one drug, whether or not combined with insulin therapy.
Despite the pivotal role of OHAs in pursuing glycemic control, adherence rates are suboptimal 
(30). Suboptimal adherence not only attenuates beneficial treatment outcomes (16), but is 
also associated with reduced quality of life, increased healthcare costs and hospitalizations, 
and early mortality (18). Adherence rates range widely across studies between 38.5-93.1% 
which is probably largely attributable to the variety of objective and subjective measurement 
instruments used (30). Subjective measurement instruments, i.e. self-report questionnaires, 
are most often employed, given their low costs, usability, potential to test large sample 
sizes, and the wide range of adherence behaviours that can be assessed (122-124). The 
Medication Adherence Report Scale (MARS-5) (125) and the Morisky Medication adherence 
Scale (MMAS) (126) are frequently used self-report instruments that have been developed 
for adherence research involving chronic illnesses (122, 127). These validated questionnaires 
have demonstrated sufficient internal reliability (125), but faced criticism regarding their often 
highly skewed adherence distributions and limited range of adherence behaviours assessed 
(128, 129). Therefore, new instruments are needed that assess adherence behaviour more 
accurately. 
The Probabilistic Medication Adherence Scale (ProMAS) (124) has recently been developed 
in response to flaws in existing self-report instruments and could potentially solve these 
measurement issues. The ProMAS assesses eighteen adherence behaviours with varying item 
difficulty, selected from extensive literature review and patient interviews (124). Hitherto, 
research showed that the ProMAS, when compared to the MARS-5, yields less skewed 
adherence distributions, shows a better match with data collected by objective methods (33), 
and provides in depth insights in which adherence behaviours are improvable (124). However, 
additional research is needed to confirm findings, particularly to assess the applicability of the 
ProMAS for specific disease states such as type 2 diabetes.
As OHA adherence can vary markedly between individuals, not only new instruments that 
measure adherence more accurately are needed, but preferably these instruments should 
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also identify factors which predict adherence. This in order to develop effective adherence 
improving interventions. Reviews conclude that adherence is a complex process in which 
various domains of adherence determinants interact, i.e. social and economic factors, 
healthcare system factors, therapy-related factors, condition-related factors, and patient-
related factors (33). Although all domains may provide relevant intervention targets to 
improve adherence, most of these domains are difficult to change and might only influence 
adherence indirectly through perceptions of the patient (33). Hence, patient-related factors, 
including socio-cognitive determinants such as a person’s awareness, motivation, intention 
and self-regulation (43), seem to be the most viable domain to intervene in. Nonetheless, 
only few studies have applied socio-cognitive theoretical models to explain OHA adherence 
behaviour (130, 131) and only one was quantitative in nature. This cross-sectional study 
showed negative associations of perceived general barriers and perceived side-effect barriers, 
and a positive association of self-efficacy with medication adherence as measured with the 
MMAS (130). To the best of our knowledge, studies have not yet applied longitudinal designs, 
allowing the identification of factors with predictive value for OHA adherence, and have not 
yet applied promising adherence assessing instruments such as the ProMAS. Therefore, the 
aim of the current study was twofold. 
The first aim was to compare OHA adherence between the ProMAS and MARS-5. The second 
aim was to identify socio-cognitive predictors of OHA adherence using the ProMAS as 
outcome. 
Materials and methods
A longitudinal study design was applied in type 2 diabetes patients with surveys at baseline 
and six-months follow-up. The study was approved by the Medical Ethical Committees of the 
Maastricht University Medical Center (15-4-181) and Zuyderland Hospital (15-N-209).
Participants and procedure
The current study is part of a larger project which also aims to identify socio-cognitive 
predictors of adherence to insulin therapy. Two hospitals with outpatient clinics and 55 
general practices in the southern part of the Netherlands were approached to aid in recruiting 
participants. All hospitals and six practices indicated their willingness to participate. Patients 
were eligible if diagnosed with type 2 diabetes, aged 40-70 years old, and used at least one 
type of blood glucose lowering medication, i.e. either OHAs and/or insulin therapy. Patients 
not able to speak, understand or write the Dutch language were excluded. A total of 1674 
potential participants were invited by the research team to participate via postal mail by 
an information letter (personalised with a signature from their own physician), an informed 
consent form and the baseline questionnaire. In case participants completed and returned 
the baseline questionnaire, they were sent the follow-up questionnaire six months afterwards. 
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For the purpose of the current study, we aimed to retain 182 participants at follow-up to 
ensure enough study power, taking into account an α of 0.05 and a study power of 0.8 (132). 
Questionnaires
The baseline questionnaire consisted of 130 questions and the follow-up questionnaire 
consisted of 78 questions on adherence to OHAs, socio-cognitive determinants, and 
demographics. 
Adherence to OHAs
Adherence to OHAs was assessed by the ProMAS (124) and MARS-5 (127). The ProMAS was 
assessed at baseline and follow-up, the MARS-5 at baseline. Both instruments assess adherence 
without a time frame over which adherence is assessed. This implies that adherence is assessed 
from medication initiation onwards which in most diabetes patients can add up to several 
decades. This might not only lead to a questionable relevance of results, but also to results 
which are subject to recall-bias due to a not recent enough recall time-frame (122). Moreover, 
in the Netherlands, most patients visit their physician quarterly for a diabetes check-up in which 
guidelines recommend that therapy adherence should be one of the main discussion topics 
(14). Based on these arguments, adding a three-month time-frame over which adherence 
behaviours were assessed to each item of the ProMAS and MARS-5, was considered tenable, 
e.g. ‘it has happened at least once in the last three months that I forgot to take (one of ) my 
oral hypoglycaemic agents’. The eighteen items of the ProMAS can be scored on a binary 
answering scale (1=yes, true or 0=no, not true) and assess various adherence behaviours, e.g. 
forgetting medication, taking less or more medication, and changing medication dosages. 
A higher sum score represents better adherence (range 0-18). The outcome can be applied 
either as continuous or dichotomised measure in which a score of ≥15 is considered high 
adherence (124).  
The MARS-5 consists of five items which can be scored on a 5-point scale (1=always – 5=never) 
and assesses adherence behaviours, e.g. forgetting, stopping, and skipping medication (127). 
Its sum score ranges from 5-25, with higher scores representing better adherence, and is 
most often dichotomised to distinguish between non-adherence and adherence. Although 
no golden standard exists, a cut-off point at ≥23 is widely applied and considered high 
adherence (133). 
Socio-cognitive determinants
Socio-cognitive determinants were derived from the I-Change Model (ICM) (43), which is a 
theoretical framework integrating various well-known socio-cognitive theories (36, 37, 109). 
The ICM (figure 1) has been applied frequently to map salient beliefs of health behaviour 
(change), including medication adherence (134). The model assumes that behaviour can 
partly be explained by socio-cognitive determinants and that behaviour change is a phased 
process. The ICM distinguishes between three phases; an awareness, motivation and action 
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phase, influenced by information and preceding factors. Awareness determinants are 
believed to have a distal indirect influence on behaviour and include a person’s knowledge, 
risk perceptions, i.e. how susceptible someone feels to get a certain illness and how severe 
this illness is valued, and salient cues to action, i.e. prompts which trigger engagement 
in health behaviour. Subsequently, these awareness determinants influence distinct 
motivational determinants such as attitudes towards performing health behaviour (pros and 
cons), perceptions of social influences (support, modeling and norms), and self-efficacy, i.e. 
a person’s perception of their own competence to successfully execute a health behaviour 
in difficult situations. A person’s intention to change health behaviour is influenced by these 
motivational determinants. However, a high intention towards behaviour change does not 
consistently warrant successful behaviour change (56). Action phase determinants facilitate 
this process by the formation of preparatory plans and coping plans, which are assumed to 
increase the likelihood of successful translation of expressed intentions into the pursued 
behaviour. Distinct determinants were assessed through several salient beliefs, derived from 
earlier research (28), and combined into scales. 
Figure 1 The I-Change Model as applied in this study
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Knowledge was assessed by ten items, e.g. shaking and sweating are signs of a too high blood 
glucose level, which could be scored on a binary answering scale (1=true or 0=false). An 
overall sum score was calculated ranging from 0-10, with higher scores representing more 
knowledge. 
Risk perceptions were assessed with eight items each for perceived susceptibility (α=0.83), e.g. 
susceptibility of developing visual conditions in the future (1=very unlikely – 5=very likely) and 
perceived severity (α=0.88), e.g. severity of having a heart attack in the future is (1=not serious 
at all – 5=very serious). 
Cues to action (α=0.94) were measured by eleven items, e.g. when I read information about 
OHAs, I am prompted to use my OHAs as prescribed (1=totally disagree – 5=totally agree). 
Attitudes were measured using six items each for perceived pros (α=0.87), e.g. when I use my 
OHAs as prescribed, I (1=do not feel healthier – 4=feel much healthier), and perceived cons 
(α=0.70), e.g. when I use my OHAs as prescribed, I (1=suffer a lot of side effects – 4=do not 
suffer side effects).  
Perceived social influences were assessed with eleven items including support (4 items, α=0.80), 
e.g. my partner supports me to use my OHAs as prescribed, modeling (3 items, α=0.78), e.g. 
my family members use their medicines as prescribed, and norms (4 items, α=0.82), e.g. my 
physician thinks I should use my OHAs as prescribed (1=totally disagree – 5=totally agree). 
Self-efficacy was measured with eleven items, representing eleven salient out of routine 
situation in which self-efficacy to be adherent might be reduced (α=0.89), e.g. how difficult 
or easy is it for you to use your OHAs as prescribed when being on vacation (1=very difficult 
– 5=very easy). 
Intention was assessed with two items (α=0.90), i.e. I plan/I want to use my OHAs as prescribed 
(1=totally disagree – 5=totally agree). 
Preparatory plans (α=0.77), e.g. I plan to put my OHAs in a fixed place, and coping plans 
(α=0.98), e.g. I have a plan to use my OHAs in a difficult situation such as being on vacation, 
were assessed with seven and eleven items respectively (1=totally disagree – 5=totally agree). 
Demographics and dossier data
Demographic characteristics included gender (1=male, 2=female), age, education level 
(1=low, 2=medium, 3=high), relationship status (1=alone, 2=together with partner), 
nationality, length, weight, consultation content and a description of prescribed medication. 
From the participants’ electronic patient dossier data were extracted on systolic and diastolic 
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blood pressure, as well as the laboratory values of HbA
1c
-level, creatinine clearance, and LDL-
cholesterol. Body Mass Index (BMI) was calculated as weight/length2.
Statistical analyses
Analyses were performed using SPSS 24.0, applying a significance level of 0.05. Missing data 
was imputed applying principles of Downey and colleague (135). Participants missing over 
20% of the total data or participants missing data on outcome measure(s) were excluded from 
the analysis. 
Descriptive statistics and frequencies were applied to describe sample characteristics. 
A logistic regression was performed regarding demographic variables, i.e. gender, age, 
education level and relationship status, to identify potential selective attrition between 
baseline and follow-up. 
To answer the first aim, descriptive statistics and frequencies were applied to map both 
overall adherence scores of the baseline ProMAS and MARS-5 as well as scores on individual 
questionnaire items. Overall adherence scores were compared by applying dichotomised 
outcome measures. Subsequently, bivariate analyses between demographics, socio-cognitive 
determinants, and follow-up adherence (ProMAS) were performed using Pearson’s correlations. 
Additionally, a correlational analysis was performed between the continuous baseline outcome 
of the ProMAS and MARS-5. To answer the second aim, multiple linear regression analysis 
was performed by regressing demographics, socio-cognitive determinants and the baseline 
ProMAS sum score on the continuous ProMAS follow-up adherence sum score. The selection 
of variables to include in the multiple regression analysis was based on the assumption of 
the theoretical framework that was applied in the study (136). The model assumes that socio-
cognitive variables (e.g. knowledge and self-efficacy), patient background variables (e.g. age, 
gender, and education level), and clinical outcomes (e.g. HbA
1c
-level) may either directly or 
indirectly influence adherence behaviour (43). Independent predictor variables were entered 
hierarchically in the analysis according to the assumptions of the ICM: 1) demographics and 
dossier data, 2) awareness determinants, 3) motivational determinants and intention, 4) action 
determinants, and 5) baseline behaviour. Baseline behaviour was added in the last regression 
model to examine its impact on socio-cognitive predictors entered in previous models.
Results
Participants
The flow of participants throughout the study is shown figure 2. Five hundred participants 
returned the baseline questionnaire (29.9% response rate). Of the 362 participants included 
in the baseline sample, 260 returned the follow-up questionnaire (72% response rate). After 
exclusion of participants missing over 20% of the data or with missing data on the outcome 
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measure(s) (135), data of 304 participants remained for the analysis of the first study aim, 
and data of 231 participants for the second study aim. As described in table 1, two third of 
population was male, the mean age was 60.8 years and the majority of participants lived 
together with a partner. Education level was fairly equally distributed. Participants had a 
relative long average disease duration of over 12 years. The majority of participants was obese 
with inadequate blood glucose control as reflected by the elevated mean HbA
1c
-level, while 
the mean LDL-cholesterol was well within target range for many participants (14). Two thirds 
used one class of OHA medication; nearly 90% used metformin. Near half of the participants 
applied insulin therapy alongside their OHAs. The attrition analysis revealed that participants 
with a low education level were more likely to drop-out during follow-up (OR=1.85, p=.02). 
Table 1 Sample characteristics
N (%) Mean (SD)
Age 60.8 (6.8)
Gender
Male 209 (67)
Female 103 (33)
Education level
Low 96 (30.8)
Middle 110 (35.3)
High 98 (31.4)
Relationship status
Together with partner 237 (76)
Alone 74 (23.7)
Diabetes pharmacotherapy
OHA(s) only 176 (56.4)
OHA(s) and insulin therapy 136 (43.6)
Number of different OHAs in use
One 212 (67.9)
Two 67 (21.5)
Three 14 (4.5)
OHA medication type
Metformin 273 (87.5)
Glimepiride 41 (13.1)
Gliclazide 25 (8.0)
Continue
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Table 1 Sample characteristics
N (%) Mean (SD)
Treatment sector
Primary care 73 (23.4)
Secondary care 239 (76.6)
ProMAS Baseline Score 13.6 (3.6)
MARS-5 Basline Score 24.1 (1.4)
ProMAS Follow-up Score 13.8 (3.4)
Diabetes duration (years) 12.3 (7.7)
HbA
1c
-level (mmol/mol)a 61 (12.7)
BMI (kg/m2) 31.9 (5.2) 
Creatinin Clearance (ml/min)b 88.1 (24.2)
LDL-Cholesterol (mmol/l) 2.1 (0.7)
Blood pressure (mmHg)
Systolic 133.6 (14.1)
Diastolic 76.8 (10.1)
OHA oral hypoglycaemic agent(s), BMI body mass index, HbA
1c
 glycosylated haemoglobin, SD standard deviation
a This equals an HbA
1c
-level of 7.7%
b Estimation of glomerular filtration rate
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Figure 2 Flow of participants throughout study  
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Overall ProMAS and MARS-5 adherence scores
The average baseline adherence score was 13.6 (range 2-18, SD = 3.6) for the ProMAS and 24.1 
(range 16-25, SD = 1.4) for the MARS-5. With a cut-off point of ≥15, 47.7% of the respondents 
adhered to their OHAs regarding the ProMAS, while 89.5% of the respondents achieved OHA 
adherence regarding the MARS-5 when using a cut-off point of ≥23. 
Adherence assessment scores
Scoring percentages to items assessed in the ProMAS and MARS-5 are shown in table 2. 
Regarding the ProMAS, items two and six were reported as non-adherent by more than half 
of the participants, and both comprise adherence behaviours concerning medication timing. 
Items one, five and ten were reported as non-adherent by over 40% of the participants, and 
comprise adherence behaviours such as forgetting medication, being positive about having 
taken all the required medication, and having taken medication at a different moment 
than prescribed (e.g. with breakfast or in the evening). Items which comprised adherence 
behaviours such as (temporarily) stopping medication, changing medication dosages, filling 
prescriptions, initiating medication taking, and taking more medication than prescribed, were 
reported as non-adherent by less than five percent of participants.
In the MARS-5 questionnaire, slightly more than 50% of the participants reported to have 
never forgotten to take their OHAs, while nearly all others indicated that this occurred rarely 
or sometimes. Over 95% of the participants indicated to have never altered the dose of their 
OHAs, stopped taking their OHAs, or decided to skip one of their OHAs intakes. 
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Bivariate analyses
Correlations of demographics and socio-cognitions with follow-up adherence 
As shown in table 3, older participants, as well as participants perceiving more pros, having 
a higher self-efficacy and higher intention to adhere, showed higher levels of adherence. 
Moreover, participants who made a higher number of preparatory plans and coping plans for 
difficult situations, showed better adherence. Significant negative correlations with adherence 
indicated that participants with a high education level had lower adherence scores compared 
to low educated participants, and that participants with a lower HbA
1c
-level and lower risk 
perceptions showed better adherence. Participants perceiving more cues to action and more 
cons significantly showed lower levels of adherence. 
Correlations of outcome measures 
A moderate to large correlation was observed between the ProMAS and the MARS-5 (r=.67; 
p=.00), representing a substantial positive association between both measures (137). 
Predictors of OHA adherence
Results of the regression analysis are displayed in table 4. Results of model one demonstrate 
that higher age and a low education level predicted better adherence. In model two, 
participants with a high score on cues to action and severity perceptions were less adherent. 
Participants with a low education maintained showing better adherence. In model three, 
education level and severity perceptions remained significant, while cues to action became 
insignificant. Living together, a high self-efficacy and intention were other predictors of 
better adherence. In the fourth model, the significance of relationship status disappeared, 
while the other factors remained significant. In the fifth model, the significance of severity 
perceptions and intention disappeared, and a low education level, high self-efficacy and 
baseline adherence predicted better adherence at follow-up. The fifth model explained 48% 
of the total variance in OHA adherence. 
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Table 4 Predictors of OHA adherence at six-months follow-up
Model 1 
β
Model 2 
β
Model 3 
β
Model 4 
β
Model 5 
β
Gendera .11 .14 .11 .14 .04
Age .20** .14 12 .10 .08
Medium educationb -.09 -.11 -.13 -.15 -.08
High educationb -.23** -.28** -.23* -.23* -.17*
Relationship statusc -.13 -.13 -.14* -.13 -.07
HbA
1c
-level -.13 -.11 -.04 -.04 -.01
Knowledge .01 .04 .04 .03
Susceptibility -.10 -.02 -.02 -.07
Severity -.20** -.22** -.21** -.12
Cues to action -.15* -.07 -.11 -.09
Attitude: pros .10 .08 .06
Attitude: cons -.01 -.02 .01
Social support -.08 -.09 -.11
Social modeling .09 .07 .06
Social norm -.09 -.10 -.01
Self-efficacy .26** .25** .16*
Intention .22** .19* .10
Preparatory plans .07 .02
Coping plans .11 .09
Baseline OHA adherence .45**
R2 .12 .20 .32 .34 .48
*P<.05
**P<.01
a Gender: 1=male, 2=female. 
b Reference category: low education, low education=1, medium education=2, high education=3
c Relationship status: 1=together, 2=alone
Discussion
Our first aim was to compare OHA adherence between the ProMAS and MARS-5. Overall 
adherence differed markedly between these questionnaires, with a difference around 40% in 
adherence percentages, which is in line with earlier publications (30, 124). 
Patients are generally considered to be adherent if the adherence percentage to prescribed 
medication matches or exceeds 80% (138). This implies a submaximal, but acceptable 
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adherence percentage, which leaves room for improvements in patients’ adherence. Applying 
this acceptable principle, the ProMAS adherence percentage of 47.7% virtually matches the 
adherence percentage as collected by objective methods, in contrast to the adherence 
percentage of 89.5 as observed in the MARS-5 (33). As shown in our study and previous 
application of the ProMAS, when dichotomized, the percentage of patients being adherent is 
about 50%. These data match data gathered from objective measures, assessing medication 
adherence of chronic ill patients, or more specific patients applying OHAs such as those 
assessed by our study. Although we did not use an objective measure ourselves, data on OHA 
adherence through objective measures is widely available. These data also show that around 
50% of the patients adhered to their OHAs (139-141). 
In addition, the ProMAS covers a broader spectrum of adherence behaviours compared to the 
MARS-5. For instance, additionally to forgetfulness which has been reported earlier as the most 
common reason for non-adherence (142), the ProMAS also identified incorrect medication 
timing as a major issue in non-adherence. By contrast, the skewed adherence distribution 
of the MARS-5 only slightly discriminates between adherent and non-adherent patients. 
Therefore, current results confirm earlier work in which the ProMAS and MARS-5 are compared 
and underline the promising character of this novel adherence instrument to assess OHA 
adherence in type 2 diabetes patients (124). 
We observed a moderate to large correlation (r=.67) between the ProMAS and MARS-5. This 
implies that there is a fairly substantial linear coherence between the measures. However, by 
squaring the correlation, which results in an R2 value, a more interpretable inference can be 
made about their cohesion. This results in an R2 of .45, which represents a shared variability 
of 45% by the ProMAS and MARS-5 score. To put this value into perspective, still 55% of the 
variability is left to be accounted for by other variables. This shows that shared variance 
between the ProMAS and MARS-5 is rather moderate.
Our second study aim was to identify socio-cognitive predictors of OHA adherence using the 
ProMAS as outcome. In the fourth multivariate model, a low education level, lower severity 
perceptions, and higher self-efficacy and intention predicted better OHA adherence. A low 
education level and higher self-efficacy remained significant predictors even after adjusting 
for baseline behaviour. 
While DiMatteo (143) and Kirkman and colleagues (144) associated higher levels of education 
with medication adherence, a recent study by Chew and colleagues (145) indicated that 
higher education was associated with poor diabetes medication adherence. Another review 
by Jin and colleagues (146) reported inconsistent findings. Contradictory findings might be 
due to variations in study designs and populations, outcome measures applied and analysis 
methods (144, 145, 147). However, a potential explanation for the identification of a low 
education level as predictor of OHA adherence in the current study, is that patients with 
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a low education might believe more in their physicians’ treatment suggestions (146). As a 
result, lower educated patients might be more prompted to follow physicians’ prescriptions 
compared to higher educated patients.
Unexpectedly, severity perceptions were significantly inversely related to medication 
adherence in both bivariate and multivariate analyses; current socio-cognitive models 
assume that higher levels of perceived threat should result in higher levels of medication 
adherence (37, 43). One potential explanation could be that our analyses were confounded 
by depression, which was not measured in our study. Depression was in earlier studies 
associated with higher severity perceptions (130) and with lower self-efficacy and medication 
adherence (30). According to the Protection Motivation Theory, it is assumed that adverse 
actions will be preserved if there is a high threat perception but low perceived self-efficacy 
(148). Clearly further research is needed to explore the inverse relation of severity perceptions 
and medication adherence.
Self-efficacy has been reported extensively in earlier studies as a factor associated with 
adherence to diabetes medication (28, 130, 142). Particularly, lower self-efficacy to adhere to 
medication tends to occur in out-of-routine situations, e.g. being on vacation, out for dinner, 
busy or ill (28, 142, 149). Associating medication taking with everyday activities has been 
found to aid in OHA adherence, while a change in daily routine would make adherence more 
difficult (142, 150). Achieving medication adherence in routinely situations, might increase 
self-efficacy beliefs through mastery expectations. On the contrary, it might be more difficult 
to achieve medication adherence in out-of-routine situations because no association can be 
made with everyday activities, given the irregularity of the situation (54). Repeated success, 
i.e. adherence to medication in situations when routine is disrupted, might increase self-
efficacy and in turn medication adherence and should in that regard be facilitated by linking 
adherence to daily activities (54, 142).
Strengths and limitations
This study is subject to some strengths and limitations. To our knowledge this is the first 
study that applied a longitudinal study design in assessing socio-cognitive predictors of 
OHA adherence and to use the ProMAS to assess adherence. Moreover, this study added a 
time-frame of three months over which adherence is assessed, which might have decreased 
recall-bias and provided a more accurate adherence assessment. Limitations include the 
social desirability issues of self-report adherence measures (129). Despite the considerable 
advantages of assessing adherence through self-report instruments, a combination of 
subjective and objective measures is preferred (129) and should, when feasible, be included 
in future studies assessing adherence. By including both self-report and objective measures, 
one is able to make mutual performance comparisons. An advantage of applying both 
measures simultaneously in one study is that results will be obtained from the exact same 
study population contrary to comparing results across studies and study populations. 
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Our approach to predicting OHA adherence assumed that adherence is a rational process, 
partly explained by socio-cognitions. Although a large part of the variance in adherence 
behaviour was explained by these socio-cognitions, a substantial contribution to non-
adherence behaviour was made by forgetfulness, which is considered unintentional, i.e. non-
rational behaviour (151). Hence, future studies should examine a combination of rational 
processes and processes underlying unintentional non-adherence, to contribute to a potential 
holistic understanding of OHA adherence. 
Conclusion and recommendations
Results primarily indicate that OHA adherence is suboptimal, independent of measurement 
instrument and cut-off point applied. Our results confirm earlier research on the wide variety 
of OHA adherence percentages, which largely depends on methodology and cut-off points 
applied. Consensus on the best method to assess adherence is lacking and no golden standard 
exists in dichotomizing adherence scores which may hamper interpretability of divergent 
results. However, when applying sub-maximal cut-off points, which is generally acceptable, 
the ProMAS yielded results similar to objectively collected data. Moreover, when compared 
to the MARS-5, the ProMAS yielded less skewed data towards adherence and insights in a 
broader spectrum of (non)-adherence behaviours. Hence, the ProMAS seems better equipped 
to deal with flaws present in existing self-report instruments. Adding a relevant time-frame 
might decrease recall bias and provide more accurate estimates of adherence. 
Suboptimal adherence stresses the need for effective adherence improving interventions. 
Decreasing forgetfulness and medication taking timing issues might increase adherence rates. 
Interventions should particularly target higher-educated patients and patients with low self-
efficacy in out-of-routine situations as these characteristics predict lower adherence levels. 
Our result regarding severity perceptions requires further inspection to examine potential 
explanations suggested in this paper.
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Abstract
Background: Many patients with type 2 diabetes mellitus (T2DM) sub-
optimally adhere to core treatment recommendations, such as healthy 
diets, sufficient physical activity and pharmacological support. This paper 
describes the development of the web-based computer-tailored program My 
Diabetes Profile (MDP), incorporating identified success factors of web-based 
interventions, and the protocol for testing the effectiveness of this program in a 
randomised multi-center trial.
Methods: Formative research - including the input of a program committee, 
qualitative and quantitative studies with patients and health professionals and 
a literature search - yielded input for the development of the MDP program. 
MDP provides video and text tailored advice, based on determinants and 
salient beliefs derived from the I-Change Model, on decreasing unhealthy snack 
intake, increasing physical activity, and improving adherence to both oral blood 
glucose lowering drugs and self-administered insulin therapy. Patients with 
T2DM recruited by practice nurses and diabetes nurses across the Netherlands 
fill in online questionnaires at baseline and six-months follow-up. Participants 
are randomized on patient level to the intervention group (access to the MDP 
program) or control group (receiving care as usual). 
Discussion: The formative research using co-creation principles proved 
essential in the development of the MDP program and involved various 
disciplines in T2DM management including target group representatives. Co-
creation revealed clearly that patients needed short and attractive messages. 
Consequently, a mix of video and short text messages were chosen for the 
ultimate program format. Pilot testing was useful to further shape the program 
to needs of patients and professionals.
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Introduction 
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by hyperglycemia and 
the body’s inability to maintain a normal glucose metabolism (152). Worldwide over 400 million 
people live with diabetes, with expectations of almost 650 million people being affected by 
2040 (152). Core T2DM treatment recommendations concern lifestyle modifications such as 
improving dietary patterns and increasing physical activity (PA) as well as pharmacological 
support such as oral blood glucose lowering drugs and/or (self-administered) insulin therapy 
(14, 15). Unfortunately, patients’ adherence to each of these separate recommendations 
is suboptimal (23-25, 30, 102). The majority does not consistently meet dietary or PA 
recommendations (23-25), and most studies on adherence to pharmacological support, report 
adherence prevalences below 80% (range 38.5-93.1%) (30). Suboptimal adherence not only 
attenuates positive treatment effects (16), but is also associated with disease worsening, an 
increase in cardiovascular events, quality of life reduction, increased healthcare expenditures 
and hospitalizations, as well as early mortality (7, 17-22). Clearly, new avenues need to be 
sought to improve treatment adherence in patients with T2DM. 
Patients’ (non)-adherence to specific treatment recommendations can partly be explained 
by socio-cognitive determinants, such as a person’s knowledge, attitudes, self-efficacy and 
intention (43). Salient personal beliefs about a certain treatment recommendation, underlying 
these socio-cognitive determinants, are considered important in predicting treatment 
adherence (84, 109). For instance, patients often lack knowledge and motivation to modify 
lifestyles, as well as clear goals and coping plans to persist in these changes (14, 63, 64). 
Therefore, these determinants need to be addressed in interventions that aim to improve 
treatment adherence (84).     
The Internet offers novel opportunities to improve treatment adherence in chronic diseases 
such as T2DM (70). E-Health interventions have shown to be (cost)-effective, easy in use, have 
fewer availability restrictions than regular medical consultations, and can temper pressure 
on healthcare systems (73-78, 86, 153). Moreover, these interventions can apply computer-
tailoring technology; a methodology to provide patients with personalised advice based 
on unique answers given during an online assessment (81). Yet, a recent general review on 
Internet interventions supporting diabetes management (71) concluded that only one of 
the nine included studies reported significant improvements in dietary patterns and PA, with 
small to modest effect sizes of .19 and .32 respectively (79). Furthermore, none of the studies 
focussing on improving medication adherence yielded significant results. However, existing 
web-based support programs often include little interactive content, are mainly text-based, 
make little use of theoretical substantiation, and focus on separate behaviors which play a role 
in the management of T2DM instead of combining behaviors (71, 80). As success factors of 
web-based interventions include using a theoretical framework, providing interactive tailored 
information, applying goal setting principles, using tracking tools, identifying risk behaviors, 
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making use of visual support and focussing on various phases of health behavior change (i.e. 
awareness, motivation and action planning) (70, 71, 79, 80), web-based diabetes treatment 
adherence interventions effects might be significantly improved by incorporating these 
factors. 
First, this paper describes the development of the new web-based computer-tailored 
program (My Diabetes Profile), aiming to improve patients’ adherence to core T2DM treatment 
recommendations, by incorporating previously identified intervention success factors. 
Subsequently, it describes the protocol for the assessment of its effectiveness in a randomized 
multi-center trial. 
Methods and design
My Diabetes Profile program
As preparation for the development of the My Diabetes Profile (MDP) program, formative 
research was conducted. Firstly, both qualitative (28) and quantitative studies were conducted 
to identify the scope of treatment (non)-adherence and to elicit salient personal beliefs involved 
in treatment recommendation adherence (109). Findings indicate that patients’ adherence 
to treatment recommendations was suboptimal and therefore subject to improvement. 
Moreover, many patients incorrectly perceived themselves as adherent to distinct treatment 
recommendations. With regard to non-adherence to dietary recommendations, patients were 
most likely to engage in unhealthy snack intake (28). Secondly, knowledge was accumulated 
from previously developed computer-tailored programs targeting improvements in treatment 
recommendation adherence (52, 154, 155). Thirdly, a program committee was formed to foster 
co-creation, following the principles of Havelock’s linkage approach (156). The committee met 
three times during the 18-months program development phase and included members from 
various disciplines involved in T2DM management: practice nurses (PNs), diabetes nurses 
(DNs), a dietician, an internist, a general practitioner, health scientists, an e-Health expert, and 
patients with T2DM. Based on the input of the formative research and co-creation, the MDP 
program was developed.  
The content of the MDP program is theoretically grounded in the I-Change Model (ICM) (43). 
The ICM integrates different well-known socio-cognitive theories (36, 37, 109) and is used often 
to identify salient beliefs of health behavior (change) and develop interventions accordingly 
(110). The ICM differentiates between three phases; an awareness phase, a motivation phase 
and an action planning phase, which are influenced by preceding factors and information 
factors (see figure 1). The model assumes that behavior change is a result of becoming aware of 
the necessity of behavior change by activating risk perceptions and increasing knowledge of 
the behavior and its consequences. Moreover, a person’s cognizance level indicates if a person 
is (in)correctly aware of carrying out the recommended behavior. For instance, a person could 
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perceive to be sufficiently physically active, while in fact recommended levels sufficient PA 
are not met. Contrary, a person could correctly perceive that s/he is not sufficiently physically 
active, which indicates awareness of the discrepancy between what is recommended and 
actual behavior. In sum, first one needs to be aware of the necessity of behavior change. 
Subsequently, if sufficient awareness of behavior change is present, a weighing of the pros 
and cons of the desired behavior, perceptions of social influences, and the level of one’s own 
belief to successfully carry out the desired behavior in certain difficult situations (self-efficacy), 
determines the motivation a person has to change a behavior. The strength of the intention to 
change a behavior a person has, is determined by motivational factors and awareness factors. 
The ICM assumes that people who express a low intention towards behavior change, can 
increase their intention to change by increasing their motivation and awareness of a specific 
health behavior. Contrary, people who express a high intention towards behavior change 
have a higher likelihood of successful translation of this intention into practice, by making 
and enacting action and coping plans. In this phase, again self-efficacy plays a major role in 
carrying out action plans. It is well known that expressing a high intention towards behavior 
change, does not necessarily guarantee successful behavior change (56). Hence, the action 
phase facilitates the translation of intention into actual action. 
Figure 1 The I-Change Model 
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Program content
The MDP program starts with a baseline assessment consisting of demographic questions, 
questions on comorbidity, patient’s perceived adherence (cognizance) to separate treatment 
recommendations, and an objective treatment recommendation adherence assessment 
regarding PA, unhealthy snack intake, medication adherence (adherence to oral blood 
glucose lowering drugs and/or self-administered insulin therapy), and smoking. The objective 
treatment recommendation adherence assessment will serve as outcome measure and is 
described in more detail in section 2.3.2.
The program lasts a total of six months, and consists of two practically identical blocks of 
three months. In each block of three months, participants can select a single treatment 
recommendation to improve. For instance, it might be that a participant selects unhealthy 
snack intake to improve in the first three months, and physical activity in the second three 
months. However, participants are able to select the same behavior again in the second three 
months if they believe this particular recommendation needs further improvement relative to 
others. In turn, every three-month block consists of three sessions; 1) health risk appraisal, 2) 
awareness and motivation, and 3) goal setting and action planning, which guide the behavior 
change process. All sessions last on average 20-30 minutes and can be continued any time 
where someone left off.
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Figure 2 Schematic overview of program course
Session 1: health risk appraisal 
In the first session, participants receive a tailored health risk appraisal based on the answers 
given to the baseline assessment. The health risk appraisal provides information on whether 
their perceived adherence to treatment recommendations matches with objective guideline 
targets. For those behaviors that the participant is not yet adherent to, their intention to 
change that behavior is assessed. As the last parts of session one, participants are prompted 
to self-select a single behavior that can be improved and which will be their focus for the 
coming three months while working with the program. The approach of selecting a single 
improvable behavior at a time was chosen because on the one hand patients are more 
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successful in achieving behavior change in one treatment element, when compared to two 
(116). On the other hand, improving behaviors sequentially rather than simultaneously, might 
work better if patients are permitted to self-select a behavior to work on first and which 
aligns best with their willingness to change (157). Although smoking status is assessed and 
followed-up with tailored advice in the health risk appraisal, it is not considered a core T2DM 
treatment recommendation (14, 15). Hence, participants are not able to select this behavior 
within the MDP program. Instead, all smokers receive a brief advice to quit and are directed 
to their general practitioner for further information and support. In case participants meet 
all recommendations they are recommended to select PA, as current Dutch guidelines state 
that any physical activity beyond the weekly recommended 150 minutes is desirable (158). 
A participant who has selected a behavior for which s/he has a low intention to change (i.e. 
not motivated to change, or motivated to change but not within the next three months) 
is directed to session two (i.e. awareness and motivation). This session particularly aims to 
increase this motivation or raise awareness for the need to make improvements, with the 
ultimate goal to achieve a high intention to change. Therefore, session two is designed for 
participants to keep on working with the program procedure, even while they express a low 
intention to change an improvable behavior. If a behavior is selected for which the participant 
has a high intention to change (i.e. motivated to change within three months), the participant 
is directed to session three (i.e. Goal Setting and Action Planning). This strategy was chosen to 
optimally tailor the intervention to the behavior change state of the participant as assumed 
by the I-Change Model (43).
Session 2: awareness and motivation
The second session consists of two sub-sessions and is specifically designed for participants 
who chose to work on a behavior for which they have a low intention to change.  
The goal of sub-session 2a is to increase a participant’s motivation to change behavior by 
providing tailored advice on the motivational determinants ‘attitudes’ (i.e. pros and cons) and 
‘perceived social influences’ (i.e. social support, social modeling and social norm). First, salient 
beliefs with regard to motivational determinants are assessed on a 5-point Likert scale (totally 
disagree – totally agree), after which tailored feedback is provided. Session 2a ends with 
again an assessment of the intention to change the behavior. If a participant now has a high 
intention to change the behavior, the participant will be directed to session 3. If a participant 
still holds a low intention to change, s/he continues to session 2b. 
The goal of sub-session 2b is to increase a participant’s awareness to change behavior by 
providing tailored advice on the awareness determinants ‘knowledge’ and ‘risk perception’. 
Salient beliefs with regard to risk perception are assessed on a 5-point Likert scale; knowledge 
items are answered on a dichotomous scale (true, false). Session 2b ends with a final 
assessment of the intention to change the behavior. If a participant now has a high intention, 
the participant is directed to session 3. If a participant again has a low intention to change 
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the behavior, the program advises to wait for the second block of three months. Participants 
are then able to select a different behavior to work on or to use the time in between to 
contemplate changing the initial selected behavior.    
The approach to start with increasing motivation and if necessary raising awareness was 
chosen to keep the program as proximate to behavior as possible according to the ICM.  At 
the same time, the aim was to offer only the most relevant feedback and content to patients, 
in order to keep the total time to use the program low and feedback tailored to the individual 
user’s needs.
Session 3: goal setting and action planning
In the third session, participants are primarily prompted to set specific goals for their selected 
behavior. For instance, participants who wish to increase their level of PA can select how many 
more minutes/week they want to be physically active. The program facilitates goal setting by 
providing several pre-formulated options varying in difficulty, but also provides an option to 
construct their own goal. Participants are encouraged to set small, realistic and achievable 
goals (116). Next, participants select pre-formulated action plans or construct their own. For 
instance, if a person wants to become more physically active, the program facilitates goal 
achievement likelihood by formulating specific plans on how to become more physically 
active, e.g. taking the stairs more often or cycling to work. Subsequently, self-efficacy is assessed, 
i.e. participants are asked to identify pre-formulated or individual situations in which they 
might find it difficult to carry out the intended goal, e.g. being physically active when it rains. 
Self-efficacy is assessed on a 5-point Likert scale (very difficult – very easy). This is followed by 
tailored advice on why particularly these situations are considered difficult and how to deal 
with them. Last, participants are prompted to formulate specific pre-formulated or individual 
coping plans for their difficult situations. Session 3 ends by providing patients with an overview 
of the advice they received and the goals and plans they made. Participants can now revisit 
their advice at any time, as well as the general program modules in the main menu. 
Forms of computer-tailoring
The MDP program offers two forms of tailored advice, video and text tailoring, throughout 
all sessions. First, participants receive segment-tailored information messages via video, to 
generate attention and to help process information (80). Tailoring based on segmentation 
entails that participants who score high, medium or low on a specific determinant receive 
different video content. For instance, a participant that scores high on pros of PA (i.e. seeing 
many advantages to being physically active) receives a video that reinforces the advantages 
a participant sees and provides additional advantages. Contrary, a video for participants who 
score low on pros of PA (i.e. perceiving few advantages to being physically active) includes 
arguments to persuade participants of the most salient advantages of PA. All videos are 
animated video’s created with Go Animate software (159). Animated videos were preferred by 
the program committee over real life videos because they were perceived as more exciting 
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and potentially less confronting to patients with T2DM. After a video, participants receive a 
brief text advice, which generally consists of five to ten text lines with more in-depth tailored 
information. For instance, the health risk appraisal text on PA provides accurate numbers of 
minutes a participant is physically active. Keywords in the text messages are either underlined 
or highlighted by color or font to generate additional attention (160). 
Ipsative advice
The health risk appraisal (session 1) at three-month follow-up (i.e. the start of the second 
three-month block) uses both the answers given to the baseline assessment and the answers 
given to the halfway assessment to provide ipsative advice (161). Ipsative advice can be 
offered in interventions with multiple feedback sessions in time and can provide insights 
in the direction and extend of changes over time in relevant behaviors (161). The advice is 
displayed in tailored text messages, which provide the participant information on whether s/
he significantly improved, deteriorated or did not change a certain treatment element. 
General modules
In addition to tailored behavioral modules, the MDP program also includes three general 
modules; My Care, My Values and My Profile. These general modules were incorporated 
to make the program a more complete self-management tool, to facilitate consultation 
preparation, and to stimulate program revisits. My Care facilitates participants in preparing 
their consultations and stimulates participants to proactively formulate questions, provide a 
brief health update, and to learn how to be an active collaborator in consultations. My Values 
gives participants the opportunity to enter and visually keep track of their blood glucose 
levels, blood pressure, weight, and body mass index. My Profile provides a clear overview of 
the participant’s most recent entered values, their medication, and their next appointment 
with their healthcare professional. Figure 3 displays the main menu of the MDP program. 
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Figure 3 Main menu of the My Diabetes Profile program 
Health report 
In order to facilitate discussion of respondents’ health goals during regular medical 
consultations, the healthcare professional will have access to the patients’ individual health 
report summary. The health report visually displays the behavior the respondent has selected 
to improve, the goals s/he has set, and the information from the My Care and My Values 
modules. 
Usability testing
To identify potential program bugs, to assess participants’ satisfaction with the program, and 
to make pre-trial improvements, usability tests were conducted with healthcare professionals 
(n=5) and T2DM patients (n=17). Recruitment occurred pragmatically in one outpatient 
clinic, where healthcare professionals and patients were deliberately recruited, taking into 
account profession, age, gender, education level, medication use, to strive for heterogeneity. 
Healthcare professionals were provided with login-data and program instructions, and were 
asked to visit the program website. Patients were provided with login-data and program 
instructions and were asked to use the program. While reading the instructions and visiting 
the program, healthcare professionals and patients were instructed to express their thoughts 
and opinions using the thinking aloud method (162).  Usability tests were conducted at the 
research department in the presence of a researcher and were audio recorded. Expressed 
thoughts and opinions were used as input to improve the program. Healthcare professionals 
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and patients reported that they were very satisfied with the program and its usability. Only 
minor changes had to be made, which included instructions on how to navigate in the 
program, on how to answer questions on PA adherence, and on how to thoughtfully read 
questions and information.  
Prompts to promote program use
The My Diabetes Profile program includes periodic email prompts to persuade participants 
to (re-)log in and to enhance usage. Periodic prompts are considered promising in enhancing 
effectiveness (163) and short timing prompts (two weeks after their first visit) seem to be 
most effective in encouraging computer-tailored program revisits (164). The prompts used 
in our program are tailored to the participants’ gender and last name. Participants receive a 
maximum of two email reminders, within two weeks after their most recent visit, to prompt 
completion of a yet uncompleted session, or when new sessions or assessments become 
available.  
Study design effectiveness trial
A multi-center randomized trial with a waiting list control group design will be used to assess 
the effectiveness of the developed MDP program in patients with T2DM. After recruitment, 
registration and informed consent procedure, all participants will be randomly assigned to 
either an intervention group or control group. Group allocation takes place on patient level 
by means of computer randomization which allocates 50% of the participants to either group. 
Respondents of both groups are then prompted to fill in an identical baseline assessment 
(T0). Intervention group participants then gain access to the MDP program for six months. 
Control group participants are made aware that they will not receive access to the program 
at this stage, but are eligible for delayed access, after completion of the effectiveness trial 
(waiting list control group). 
Six months after baseline completion, all participants are prompted to fill in the follow-up 
assessment (T1). Afterwards, control group participants will receive instructions on how 
to request program access. The study is approved by the Medical Ethics Committee of the 
Maastricht University Medical Center (16-4-171). The study is registered in the Dutch Trial 
Register (NTR6840).
Recruitment of T2DM participants
In the Netherlands, T2DM patients are predominantly treated by practice nurses (PNs) and 
diabetes nurses (DNs) in the general practice and hospital outpatient setting respectively, who 
are in turn supervised by physicians (14). Most T2DM patients visit their PN or DN quarterly, 
and in case of no direct risk factors of health complaints every semester (14), hence these 
healthcare professionals are in an ideal position to recruit patients for our trial. Trial inclusion 
criteria are: 1) T2DM diagnosis for at least one year, 2) 40-70 years old, 3) using at least one form 
of diabetes pharmacological support, and 4) having no walking disability. Exclusion criteria 
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are: 1) not speaking or understanding the Dutch language, 2) having no access to the Internet, 
and 3) insulin pump therapy. People on insulin pump therapy will be excluded because of 
the distinct adherence nature of insulin pump therapy compared to self-administered insulin 
therapy. Given this recruitment strategy, patients are nested in the general practice and 
hospital outpatient settings. 
PNs and DNs across the Netherlands will be approached through email (with an invitation 
and brochure that explained study details), telephone calls, letters to their work address 
and social media platforms. PNs and DNs can register for the study by contacting the 
research team directly, or by registering via the project website. PNs and DNs are asked to 
recruit T2DM patients during regularly occurring medical consultations, through telephone 
calls or through email for a period of six-months. Prior to the start of the effectiveness trial, 
participating healthcare professionals are provided with detailed information about the 
study and the MDP program. A recruitment checklist can be used during consultations to 
facilitate recruitment and graphically depicts the study’s inclusion criteria. The checklist also 
includes the healthcare professional’s unique username and password, and instructions on 
how to register a participant. Following registration by their PN or DN, patients immediately 
receive an email from the research team including login instructions and an invitation to fill 
in the online baseline assessment. After logging into the system, patients are provided with 
extended study information and an online informed consent form. After signing for informed 
consent, participants are directed to the baseline assessment. 
Power calculation and data collection
Primary outcome measure and power calculation
To assess the effectiveness of this multiple behavior intervention program as a whole, 
changes in adherence to PA, unhealthy snack intake, oral blood glucose lowering drugs 
and self-administered insulin therapy will be standardized and summed into a composite 
lifestyle index score as primary endpoint. As proposed by Prochaska and colleagues (165), an 
option to create standardized change scores is to subtract baseline scores for each behavior 
separately from follow-up scores and subsequently divide this by the standard deviation of 
the difference of the specific behavior. This way, effect sizes can be calculated for all behavior 
separately. Subsequently, to create the index score, separate effect sizes for all behaviors were 
summed. The effect size for unhealthy snack intake was reverse coded since the intervention 
aimed to decrease this behavior. To assess significant change between the intervention and 
control condition, a two-tailed T-test was applied with an α of 5%. 
Our power calculation is based on the primary outcome measure and aims for a near medium 
MDP program effect size of 0.4. Assuming an intraclass correlation coefficient of 0.02, an α of 
5%, and power of 0.80, 116 patients per group are required at the end of the trial (232 in total). 
Considering an attrition percentage of 50%, our aim is to include a minimum of 464 patients 
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at baseline. We expect that each PN/DN can recruit eight patients, hence we aim to recruit a 
minimum of 58 healthcare professionals.
Data collection
The data obtained from the first entry into the program, as described earlier in section 2.1.1 
(Program Content), will be used as baseline assessment. These measurements will be repeated 
at a six-months follow-up assessment except for the comorbidity questions. Socio-cognitive 
determinants are assessed with four to six items on a five point Likert scale (totally disagree – 
totally agree). We use the following instruments to measure our primary outcomes. 
Physical activity
The level of PA is assessed using the validated Short Questionnaire to Assess Health-
Enhancing Physical Activity (SQUASH) (166). The SQUASH assesses physical activities in the 
area of commuting, leisure time and sports, household, and work and/or school. Activities 
can be reported in average hours and minutes per day, and the frequency of weekdays 
these activities are carried out. A total number of weekly minutes of physical activity will be 
calculated based on the SQUASH.
Unhealthy snack intake
A food frequency questionnaire (FFQ) developed for this trial is used in which participants 
are asked to recall their last week’s unhealthy snack intake. The FFQ lists unhealthy snacks 
identified by earlier research supplemented with unhealthy snacks which are commonly 
consumed in the Netherlands (167, 168). All listed unhealthy snacks account for a specific 
amount of caloric intake which will be summed to create a total number of weekly calories 
consumed from unhealthy snacks. 
Oral blood glucose lowering drugs adherence
Oral drug adherence will be measured with the ProMAS questionnaire (124), a self-report 
instrument which has been recently developed in response to flaws in existing and frequently 
used self-report adherence measures such as the MARS-5 and Morisky Medication Adherence 
Scale (124, 169). It consists of eighteen items that assess a variability of adherence behaviors, e.g. 
forgetting, stopping, changing dosages, or taking medication too late (range 0-18). A higher 
score indicates a better adherence. In close collaboration with the developers, we translated 
the original English ProMAS questionnaire to Dutch which fits the use in this intervention 
study. To be able to compare changes over time, we further added a time period to every 
single items to assess adherence of the past three months. Based on the eighteen items, a 
sum score will be calculated as outcome for adherence to oral blood glucose lowering drugs. 
Insulin therapy adherence
Adherence to insulin therapy is measured with a self-administered questionnaire, adapted 
from the ProMAS questionnaire (124). Non-relevant items were removed, resulting in a 
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measure with nine times. Items were considered not relevant if they did not distinguish 
between adherence and non-adherence for insulin therapy (e.g. the item ‘I sometimes take 
fewer medicines than prescribed by my doctor’ was removed as patients using insulin should 
adjust their dosage in case of hypoglycemia or illness). In line with the assessment of oral 
blood glucose lowering drugs adherence, a time period was added to every single item to 
assess adherence of the past three months. Based on the nine items, a sum score will be 
calculated as outcome for adherence to insulin therapy, ranging from 0-9 where higher scores 
indicate better adherence. 
Data analysis
Complete case analyses will be conducted for participants who completed both the baseline 
and follow-up assessment. Sensitivity analyses will be carried out for those who did not 
complete the follow-up assessment, i.e. for participants of which no primary outcome is 
available at follow-up. For incomplete assessments, multiple imputation on the outcome 
measure will be applied using both an optimistic and pessimistic scenario. 
Descriptive statistical methods and frequencies will be used to describe sample characteristics. 
A logistics regression analysis will be conducted to identify potential selective attrition of 
participants between baseline and follow-up with regard to demographics. The effect analyses 
will be conducted for the primary outcome measure which will consist of a combined index 
of individual behavior z-scores. Given the hierarchical structure of the data, multilevel linear 
regression analyses will be conducted. Besides the repeated measures structure, patients are 
nested within healthcare providers, and two types of healthcare providers will recruit the 
participants, i.e. practice nurses and diabetes nurses. Therefore, these levels will be included 
in the analyses as random factors. Both adjusted and un-adjusted analyses will be provided 
and analyses will be adjusted for potential confounders (i.e. baseline adherence, predictors of 
attrition, and demographics). All statistical analyses will be executed using SPSS version 24.0.
Discussion 
This paper presented the design, course and content, and proposed effect evaluation protocol 
for a newly developed web-based computer-tailored program named My Diabetes Profile. The 
program aims to improve patients’ adherence to core T2DM treatment recommendations and 
incorporates previously identified success factors to successfully influence patients’ adherence 
rates. Because patients’ adherence to treatment recommendations is frequently suboptimal, 
interventions are needed to support treatment adherence and to support the persistence of 
behavior over time. The Internet offers promising opportunities to intervene given a variety 
of advantages including the potential to reach out to the rapidly growing population of 
patients with T2DM, the potential (cost)-effectiveness of Internet based interventions, the 
application of computer-tailoring technology and the tempering of pressure on healthcare 
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systems. The MDP program combines various success factors such as using a theoretical 
framework, providing interactive tailored information, applying goal setting principles, using 
tracking tools, identifying risk behaviors, making use of visual support and brief text advice, 
and focussing on various phases of health behavior change. Hence, we hypothesize that the 
MDP program can effectively improve treatment recommendation adherence in patients 
with T2DM, which will be tested in a randomised trial.
Potential strengths of the study
Several potential strengths of the MDP program and the study are worth mentioning. First, 
the program’s design, course and content are based on extensive formative research including 
co-creation by a variety of key persons involved in diabetes care. Secondly, the MDP program 
incorporates previously identified success factors and uses salient personal beliefs in changing 
behavior, i.e. improving treatment recommendation adherence. Third, in order not to further 
burden health care professionals, the program is run completely independent of healthcare 
professionals in the trial. Fourth, the trial will be conducted nationwide, in both primary and 
secondary care, which increases generalization of the results obtained. Fifth, the program was 
comprehensively pilot tested among the target group which yielded useful input for pre-
implementation improvements. Last, randomization will occur on patient level which means 
that healthcare professionals include patients which will randomly be assigned to either the 
intervention or control group. Contrary to randomization on healthcare professional level, this 
procedure attempts to minimize the potential influence of healthcare professionals. 
Potential limitations of the study
The present study (design) and program is also subject to some limitations. A first potential 
limitation concerns high attrition rates of participants in online interventions (80, 170). Various 
factors might positively contribute to attrition rates, e.g. a high workload and limited usability 
of the intervention, and the ease of ending program and trial participation (170). In the 
program, workload was limited by creating fairly short sessions (20-30 minutes) and allowing 
participants to access and continue the program at any time where they left off. Moreover, 
we tried to minimize usability issues by comprehensively testing the intervention prior to the 
start of the effect evaluation in which participants indicated their satisfaction and by using 
prompts to pursue program revisits and continued use once a patient is registered. Although 
these measures are likely to limit the drop-out rate, we still expect considerable drop-put and 
adjusted our power calculation accordingly (i.e. 50% drop-out rate at the time of last follow-
up). A second potential limitation is the relatively short follow-up assessment of six months 
following intervention start. This way, it is not possible to assess if potential program effects 
sustain over time after program completion. Future studies should, if possible, apply study 
designs with extended follow-up periods to assess whether potential effects sustain over a 
longer period of time after intervention completion. Last, as our recruitment period will last for 
six months, and our intervention duration is six months, this might lead to seasonal variation 
in our outcome measures. Indeed, Ma and colleagues (171) showed that caloric intake was 
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higher in autumn compared to spring and that PA levels were lowest during winter whereas 
they were highest in springtime. However, seasonal differences in this particular study were 
considered generally small.
Lessons learned
As advocated in Havelock’s linkage approach (156), the involvement of relevant stakeholders 
was an essential element in the development of our computer-tailored program and the 
subsequent design of the trial. Based on our positive experiences we suggest that the 
program committee should be a representation of all relevant disciplines involved. Selecting 
one or two individuals, however, does not guarantee that all the relevant viewpoints that are 
current in a specific discipline are expressed. Therefore, we suggest that in future projects the 
representatives should, if possible, consult a larger group of colleagues, to seek input on the 
topics discussed and decisions made by the program committee. This requires not only the 
formation of a program committee, but also the formation of a number of stakeholder-specific 
panels. Moreover, our program committee met three times during the formative research and 
program development phase which lasted for eighteen months. However, it is unclear what 
the optimal frequency of such gatherings should be and which disciplines should always be 
involved. We suggest that future projects should properly investigate which disciplines to 
include and internally assess the necessity and frequency of gatherings.   
Conclusion
This paper offers detailed insight into the design and protocol for the effectiveness trial of 
the newly developed My Diabetes Profile program. The effectiveness trial’s data collection is 
expected to be available from the end of 2018. If the MDP program is effective in improving 
treatment adherence in patients with T2DM, adaptation of the intervention to other chronic 
diseases might have potential value for other patient groups. 
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The main aim of the studies displayed in this dissertation was to describe the development 
and the effectiveness of the eHealth program, My Diabetes Profile, which aimed to improve 
adherence of patients with T2DM to core treatment behaviors, i.e. improving physical activity 
levels, oral hypoglycemic agent adherence, insulin therapy adherence, and decreasing caloric 
intake from unhealthy snacks.
The first part of this dissertation included three chapters; two chapters on two studies 
conducted as part of the formative research process, and one chapter with a description of 
the development and content of the My Diabetes Profile program, as well as a blueprint of 
the randomized controlled trial that was conducted to examine the program’s effectiveness. 
The second part of this dissertation consisted of two chapters related to the evaluation of 
the My Diabetes Profile program. The first chapter described a study that examined factors 
influencing recruitment and its success of nurses who engaged in recruiting patients for our 
trial. The second chapter included a study that assessed the effectiveness of the My Diabetes 
Profile program on overall treatment behavior adherence and separate treatment behavior 
adherence in patients with T2DM. 
This final chapter summarizes the main study findings, outlines strengths and limitations of 
the studies described in this dissertation, and discusses research and practical implications. 
This general discussion ends with a general conclusion.
Formative research, program development, and trial protocol
Main findings
The studies included in the first part in this dissertation were described in chapters 2-4. First, 
a brief summary of the results is provided of each study, and subsequently the results are 
discussed by considering study strengths and limitations, and discussing implications for 
research and practice.
Chapter 2: Exploring beliefs on diabetes treatment adherence among patients and health 
professionals.
We explored the scope of patient (non)-adherence and associated beliefs and determinants 
among both patients themselves as well as health professionals directly involved in their 
T2DM management. Our results showed that treatment adherence to core T2DM strategies 
was suboptimal. Non-adherence was mainly reported in dietary patterns and medication 
taking behaviors. Patients indicated to adhere to physical activity (PA) guidelines, while health 
professionals held the opposite perspective. Unhealthy snack intake was reported by both 
groups as important contributor to unhealthy diets of patients with T2DM.
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Patients’ knowledge and risk perceptions regarding PA were considered sufficient by both 
health professionals and patients. With regard to healthy diets, health professionals indicated 
that these factors were insufficient, contrary to perceptions of patients themselves. Both 
groups reported that knowledge and risk perceptions related to medication taking could be 
improved. Health professionals and patients reported many advantages and no disadvantages 
of adherence to PA and healthy diets. Both advantages, e.g. feeling healthier, and disadvantages, 
e.g. a variety of potential adverse side effects were mentioned for medication taking. Patients’ 
self-efficacy to adhere to treatment behaviors seemed to be lower in out of daily routine 
situations, such as snacking when being on vacation. Across treatment behaviors, similar 
situations occurred in which self-efficacy to adhere to the particular behavior was lower. 
It seems that success factors for treatment adherence were insufficiently applied in 
consultations, i.e. patient preparation, collaboration between a health professional and patient 
in formulating treatment strategies, (clear) goal-setting, and self-management education, i.e. 
the process of informing, motivation, and equipping patients to manage T2DM and support 
treatment adherence outside the clinical setting. Health professionals reported that scarce, 
busy, and brief consultations may impede the application of such success factors. 
Chapter 3: Psychological predictors of adherence to oral hypoglycemic agents: An application of 
the ProMAS questionnaire.
A longitudinal study design was applied with surveys at baseline and six-months follow-
up. At baseline, oral hypoglycemic agent (OHA) adherence using the ProMAS and MARS-5, 
socio-cognitive determinants, and demographics were assessed. At follow-up, the ProMAS 
was applied as outcome measure, on which socio-cognitive determinants and demographics 
were regressed using linear regression analysis. When applying the currently advised 
and widely applied cut-off points of ≥15 for the ProMAS and ≥23 for the MARS-5, 47.7% 
and 89.5% adhered to their oral agents respectively. Data of the ProMAS were more in line 
with objectively collected data with regard to the percentage of patients that could be 
considered adherent. Consistent predictors of better adherence were a low education, lower 
severity perceptions, and higher self-efficacy and intention. After correcting for baseline 
adherence, a low education and higher self-efficacy remained significant predictors. The final 
model explained 48% of the variance in adherence behavior. 
Chapter 4: A web-based program to improve treatment adherence in patients with type 2 diabetes: 
Development and study protocol.
Findings from chapters two and three were complemented with knowledge accumulated 
from previously developed computer-tailored programs and input gathered from a program 
committee. Together these sources yielded input for the development of the eHealth program 
My Diabetes Profile. Consequently, the program addressed treatment non-adherence to 
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core T2DM treatment behaviors, and aligned with the needs of our target group and those 
involved in the committee. In addition, the program incorporated success factors for treatment 
adherence as identified from the literature, i.e. a solid theoretical base, interactive content and 
feedback tailored to relevant phases and determinants of behavior change, visual support, 
and the possibility to monitor adherence.
Discussion of findings and research implications
Treatment behavior adherence
Findings from the formative studies contributed to the understanding that treatment 
adherence was suboptimal and that non-adherence co-occurred across behaviors. Our results 
support the findings already described in earlier literature available on patient adherence to 
T2DM treatment behaviors: dietary and PA guideline targets are not met adequately, and 
many studies on adherence to pharmacological strategies report adherence prevalence 
percentages below 80%, which is generally considered suboptimal adherence (23-25, 29, 
30). The successful management of diabetes is complex and burdensome process for many 
patients as it frequently should include several healthy lifestyle interventions in combination 
with the use of multiple drugs – sometimes prescribed several times a day – and each of these 
medications can have side-effects. Below 5% of the patients with T2DM adheres to all treatment 
behaviors, while over 80% could improve at least two behaviors (25). Inadequate adherence 
could result in avoidable suffering of the patient, and is associated with considerable adverse 
personal, societal, and economic consequences (7, 17-22, 217). Moreover, if risk behaviors 
occur simultaneously, adverse effects on health and health outcomes may even be greater, 
while improving multiple behaviors may potentially result in greater health benefit (198). 
Therefore, it is recommended to apply a multi-behavior approach, covering both healthy 
lifestyle and medical behaviors, in attempts to improve adherence and ultimately glycemic 
control.
A discrepancy seems present in patients’ awareness with regard to their diet. Although 
patients in our study indicated to maintain a healthy diet, an in-depth review of their eating 
pattern revealed that unhealthy snack intake was highly prevalent in their diet and accounted 
for a substantial amount of caloric intake; this issue was also identified by health professionals. 
The intake of unhealthy snacks is an understudied issue in the dietary pattern of patients with 
T2DM. Largely, attention has been paid to macronutrients such as fat and carbohydrate intake 
and their relation to the prevention and management of diabetes (218). A transition towards 
an increased caloric intake such as from high-energy snacks is observed in many countries and 
this may have contributed to a current shift of focus from (isolated) macronutrients to food 
groups (218-220). As a decreased caloric intake is frequently part of the dietary management 
in overweight patients with T2DM, targeting unhealthy snack intake could contribute to a 
lower daily energy intake and might also improve glycemic control (1). 
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A discrepancy also exists regarding perceptions of health professionals and patients 
concerning patients’ PA adherence. While professionals reported that patients’ adherence 
to PA targets was poor, many patients indicated to be physically active, and mentioned a 
variety of activities accordingly. This discrepancy may lead health professionals to address 
the issue of non-adherence to PA targets, while patients may not perceive the necessity of 
improvements as they already are or assume to be adherent. Research points out that patients 
tend to overestimate their PA-levels and therefore may not be motivated to improve their 
PA or perceive PA promoting messages as not relevant (27). For example, adults at high risk 
for T2DM who either correctly or incorrectly estimated their PA-levels as sufficient, may not 
perceive improvements in PA-levels as a means to diminish their risk of T2DM (221). Another 
argument why patients may overestimate their PA-levels relates to the Dutch PA-guidelines. In 
our study we asked the participants if they perceived to adhere to the Dutch norm of healthy 
PA-levels of 150 minutes of weekly PA with a Metabolic Equivalent of Task value (MET) of ≥4 
(222, 223). A MET-value is a physiological measuring unit to quantify the energy expenditure 
needed for an activity, compared to the energy required in resting metabolism (190). Our 
patients reported considerable physical activities with a MET-value between three and four 
METs, e.g. normal speed walking (28). It may have been that participants included these 
activities in their total, resulting in an overestimation of their PA-levels. 
In sum, it seems that the discrepancy with regard to perceptions of health professionals 
and patients concerning patients’ adherence to PA-levels, may be explained by patients 
overestimating their actual PA-levels. Recently, however, Dutch PA guideline targets have 
been adapted to be more compatible and better connected to international guidelines (191). 
Main changes are that in the new guidelines the targeted 150 minutes of weekly PA requires 
not to be spread out over at least five days (PA divided over several days is still recommended), 
and that activities carried out less than 10 minutes consecutively are included in the total. In 
addition, activities with a MET-value of ≥3 may now be included in the total, compared to 
activities with a MET-value of ≥4 in prior guidelines (206, 222, 223). Taking into account the 
alteration with regard to MET-values in new guidelines compared to prior one’s, it may be that 
patients in fact adhere given they reported considerable engagement in three to four MET 
activities. Still patients could be stimulated to increase their PA, even if targets are already met 
as guidelines show that more PA leads to more health gain (206). The most viable target for 
intervention seems to be to increase patients’ awareness of either their overestimation of PA-
levels, or of the necessity of improvements despite already meeting targets. 
Results of both formative studies indicated that patients’ adherence to pharmacological 
strategies was suboptimal, and should therefore be targeted in interventions that aim to 
contribute to a more favorable management of T2DM. Perspectives of health professionals 
indicated that patients’ medication adherence was poor, and only half of the patients 
themselves reported to adhere to their diabetes medicines. A similar result was observed 
when adherence was quantified through application of the novel self-report ProMAS 
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questionnaire; 48% of the patients was considered adherent to their oral hypoglycemic agents. 
However, when applying the MARS-5, a patient adherence prevalence of 90% was observed. 
Divergent suboptimal results regarding the prevalence of adherence to diabetes medicines 
have also been reported across the literature, ranging from 39-93%, and are attributable to a 
wide variety of adherence measures applied (30). Existing self-report measures tend to yield 
skewed adherence distributions, and in general the adherence prevalence is estimated to be 
around 50% (124). Data collected through the novel ProMAS, which was developed to deal 
with flaws in existing instruments, show a similar percentage as to objectively collected data 
in terms of adherence percentages (125). Preferably, performance comparisons between self-
report measures to assess adherence such as the ProMAS are complemented with a more 
objective instrument, such as Medication Possession Ratio’s or Medication Event Monitoring 
Systems (122, 129). In order to obtain results from the exact same study population contrary to 
comparing results across studies and study populations, future research could simultaneously 
apply the ProMAS and a more objective measure, as a combination is considered to provide 
the most accurate estimation of adherence (129). 
In order to assess insulin therapy adherence, we applied an adapted version of the ProMAS 
questionnaire, including nine of the original eighteen items (124). Some items that are relevant 
to assess oral medication adherence, may be irrelevant regarding insulin therapy adherence. 
For instance, the item ‘I sometimes take fewer medicines than prescribed by my doctor’, does 
not distinguish between adherence and non-adherence for insulin therapy. Therefore, this 
item was removed from the original questionnaire as patients using insulin should adjust 
their dosage in case of hypoglycemia or illness. In line with cut-off points for the original 
ProMAS, we adapted the nine-item questionnaire for insulin therapy adherence accordingly. 
A systematic review on techniques to assess insulin therapy adherence in patients with T2DM, 
including self-report measures, concluded that these instruments entailed considerable 
measuring challenges, complex forms of data collection, and had no cut-off points for 
adherence or reliable associates of adherence outcomes. None of the identified instruments 
were appropriate for use as a quality measure for insulin therapy adherence (224). The original 
ProMAS showed to be a promising questionnaire to assess adherence to oral hypoglycemic 
agents as its data were less skewed towards adherence, similar to objectively collected data, 
and yielded insights in a broader spectrum of (non)-adherence behaviors, compared to the 
frequently applied MARS-5 (125). Therefore, we believe that the adapted ProMAS for insulin 
therapy may be as promising as the one applied for OHA adherence. However, future research 
should further assess its validity and applicability. 
Determinants of treatment adherence
Perceptions of patients and health professionals sometimes seemed to differ regarding 
whether patients had sufficient knowledge, were aware of risks of non-adherence, and were 
correctly aware of their own behavior. The I-Change Model postulates that knowledge, risk 
perceptions, and the level of cognizance are important precursors of motivation (43). A person's 
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cognizance level indicates if a person is (in)correctly aware of carrying out the recommended 
behavior. A discrepancy in perceptions could potentially lead health professionals to motivate 
patients to change their adherence behavior, while in fact they may not be aware of the 
necessity to change. Contrary, if patients indeed show sufficient awareness, the model posits 
that health professionals should rather intervene in a more proximate behavior change 
phase to provide patients with relevant feedback accordingly. It is known that both nurses 
and patients may lack knowledge on diabetes care, e.g. nurses on diet and physical activity, 
and patients on their insight in one’s own behavior (63, 225). To overcome discrepancies in 
perceptions of health professionals and patients, an implication could be to primarily assess 
the patient’s knowledge, risk perceptions, and cognizance levels. Subsequently, if it turns out 
that insufficient awareness of the necessity of behavior change is present, it is evident to 
tailor content to this behavior change phase to provide patients with relevant information. 
Contrary, if sufficient awareness is shown by the patient, the behavior change process could 
proceed to the motivational phase (43). 
Patients’ self-efficacy to adhere to distinct treatment behaviors seemed to be lower in certain 
out of routine situations. If daily routine is retained, individuals acquire self-knowledge by 
repeating a specific action; at a certain point no judgement of efficacy is required on such 
habitual occasions (226). Adherence across behaviors may therefore be more prone to failure 
when routine is compromised. A recent review also showed that self-efficacy beliefs were 
decreased in different risk situations across a wide variety of health behaviors, e.g. condom use 
in risky sexual practices (227). Therefore, it seems evident to increase patients’ self-efficacy in 
these out-of-routine occasions to enhance the chance of successful adherence despite being 
faced with a difficult situation. Potentially, an increase in self-efficacy could be facilitated by 
coping planning. For instance, individuals could first be prompted to identify their personally 
relevant risk situations in which adherence may be prone to failure, and anticipate these by 
forming a coping response on how to overcome failure if the situation would occur (43, 47). 
This way, the likelihood of behavior success is increased despite being faced with difficulty. 
Although we explored beliefs within the pre-motivation and motivation phase in changing 
behaviors, we did not manage to assess those for the post-motivation phase. It is not unlikely 
that patients who express a high willingness to pursue adherence, will fail to achieve their 
intentions, as this requires considerable self-regulatory capacities (56). We suggest that future 
studies should explore salient beliefs related to the post-motivation phase, e.g. on how to 
anticipate low self-efficacious situations, on what goals are feasible and realistic, and on how 
to prepare an intended behavior. Such factors – also referred to as action plans – are likely to 
facilitate enactment of intentions, and could yield information to be addressed in interventions 
(56), and have been shown to increase the chance of translating intentions into the desired 
goal behavior (46, 49, 50). Consequently, these factors were addressed in our intervention.
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Success factors for treatment adherence
We observed that success factors for treatment adherence are insufficiently applied in 
consultation; scarce, busy, and brief consultations may impede the application of such 
factors. In the Netherlands, consultation sessions between health professionals and patients 
occur every three to six months and last about 15-20 minutes (63). These consultations are 
highly protocolled, meaning that many topics such as glycemic control, cardio-vascular risk-
management, diabetic complications and therapy adherence should be addressed (14). 
Consultations should ideally serve as a setting where treatment strategies are formed, and 
where patients are informed, educated, motivated, and equipped with skills to optimally self-
manage and adhere to T2DM treatment strategies in everyday life (105). A collaborative care 
strategy should be a key part of diabetes consultations according to Dutch care guidelines and 
its application could result in improved execution of suggested treatment recommendations 
(14, 115). Not only passive patient preparation and involvement are at the basis of insufficient 
collaboration. Other contributors include scarce time, the difficulty health professionals 
experience to involve patients in decision making, and the misconceptions between 
professionals and patients about if treatment goals are actually set. Research posits that health 
professionals may lack the required knowledge, motivation, and confidence to involve patients 
in decision making, and to address the issue of non-adherence in consultations (63, 64, 228). 
It is advised that professionals should consider the motives and barriers of their patients to 
perform healthy lifestyles, as they also should with regard to medication taking, and that they 
tailor advice to the needs of their patients. The complexity of the behavior change process 
requires nurses to shift to a counseling-based approach. Such an approach of informing and 
motivating patients to improve on multiple behaviors, in a supportive, comprehensive and 
barrier-focused manner is a challenge in daily practice as a multitude of other factors need 
to be addressed (63, 229). Although it seemed that the lack of application of success factors 
for treatment adherence occurred at both the patient and health professional side, a main 
common barrier seemed to be the time constraints of scarce and relative short consultations; 
a common barrier to the conduct of healthy lifestyle counselling. Professionals do indicate 
the importance of addressing these factors and promoting healthy lifestyles, however, they 
simply do not have enough time to address them in consultations (62, 229, 230). To conclude, 
it seems that consultation sessions between health professionals and patients are not an 
ideal setting to thoroughly discuss the issue of non-adherence, to make efforts to assist in 
the ongoing and complex process of health behavior change, and to address success factors 
for treatment adherence. Avenues need to be explored that could alleviate pressure on the 
healthcare system, and still deliver patients the required ongoing support they need in order 
to optimize adherence to T2DM treatment strategies. 
Practical implications
The highly protocolled diabetes consultations in the Netherlands provide guidance and 
structure to those topics that need to be discussed (14). However, it seems that success factors 
for treatment adherence are insufficiently applied, and that the nature of consultations does 
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not allow for thoroughly discussing the issue of non-adherence or to make efforts to assist 
in the ongoing and complex process of health behavior change. A practical consideration 
could be to outsource the complex area of behavior change to a more feasible context, for 
example the context of Internet. The Internet has widely and successfully been applied for 
health services and health promotion activities such as the management of T2DM, and such 
activities delivered through the Internet are often referred to as eHealth (65, 69-71). An eHealth 
program could assess and identify risk behaviors, and assess relevant determinants and beliefs 
to intervene in for those behaviors subject to improvement, in order to aim for improvements. 
Given our findings from formative research studies, such an eHealth program could focus 
on assessing adherence to healthy lifestyles, i.e. PA-levels and unhealthy snack intake, and 
adherence to pharmacological strategies, i.e. adherence to OHAs and/or insulin therapy. 
An assessment of determinants and beliefs may yield information on relevant intervention 
targets, following the behavior change phases as suggested in integrative models such as the 
I-Change Model (43). 
Besides focusing on improvements in treatment non-adherence, an eHealth program could 
address treatment adherence success factors that are not sufficiently applied in consultations, 
such as patient preparation and active engagement. There may be no need to fully abandon 
discussing treatment adherence and the application of success factors in consultations 
between professionals and patients. A recent review on person-centered eHealth in patients 
with chronic illnesses, posits that eHealth integrated into usual care can help patients to 
manage their chronic illness better, and will provide better quality of care in long-term (231). An 
integration of eHealth with care as usual, referred to as ‘blended care’, provides opportunities 
to transfer information, and to facilitate communication between health professionals and 
their patients (231). A combination of face-to-face counseling with ongoing online support is 
suggested as a means to approach the etiological problem of diabetes. Thereby, a personalized 
approach to target lifestyle non-adherence may not only facilitate the management of T2DM 
but also contribute to the management of the disease and economic gain (232). To facilitate 
discussing treatment adherence in consultations efficiently in light of scarce, busy, and brief 
sessions, the program could transfer relevant information on patient activity in the program 
to their own nurse, for example, the goals a patient has set, and monitoring the treatment 
behavior a patient is currently working on. In addition, the program could prompt patients to 
consider topics or questions to discuss with their health professional as health professionals 
indicated to welcome a more prepared and active patient (233). 
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Recruitment and effectiveness evaluation
Main findings
The studies included in the second part in this dissertation, were described in chapters 5 and 
6. First, a brief summary of the results is provided of each study, and subsequently the results 
are discussed by considering study strengths and limitations, and discussing implications for 
research and practice.
Chapter 5: Exploring factors influencing recruitment success of nurses recruiting diabetes patients 
for a randomized controlled trial.
Ninety-six nurses participated in our trial and recruited on average seven patients (range 0-32). 
Fifteen nurses did not recruit any patient. Most patients were recruited close to recruitment 
onset. Nurses who did not recruit patient close to recruitment onset, ended up recruiting no 
patients. Data show a relative high early recruitment success that progressively declined over 
time; high-recruiters were generally successful recruiters throughout the entire recruitment 
period. Recruitment barriers and facilitators comprised of organizational, study, patient 
and especially recruiter characteristics. Contrary to non- and low-recruiters, medium- and 
high-recruiters reported more in-depth knowledge about the study and trial requirements, 
expressed more personal benefits of participation and fewer barriers, these nurses applied 
more recruitment activities, reminders, and barrier-focused coping strategies.
Chapter 6: The effectiveness of a web-based computer-tailored program to improve treatment 
adherence in patients with type 2 diabetes: A randomized controlled trial. 
After the follow-up assessment, 288/478 (60%) participants were retained from those who 
initially completed the baseline assessment. After controlling for relevant confounders, overall 
treatment adherence improved significantly in those patients allocated to the intervention, 
reflected by an overall significant small to medium effect size (d = .24). With regard to separate 
treatment behaviors, a significant decrease was observed in caloric intake from unhealthy 
snacks (d = .38). Small to medium positive intervention effects were observed for adherence 
to OHA (d = .18) and insulin therapy (d = .28), however, these effects were not statistically 
significant, probably due to a lack of power in these behaviors. 
Success factors for eHealth interventions identified across the literature and applied in our 
intervention, e.g. a theoretical base, tailored content and a multi-behavior approach, may 
have contributed to the success of the intervention. 
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Discussion of findings and research implications
Evaluation of nurses’ recruitment success
In trials, patient recruitment often occurs through efforts of health professionals, given their 
direct and relevant contact to the patient (89, 90). Therefore, in our trial, practice nurses and 
diabetes nurses were invited to aid in recruiting eight patients with T2DM to trial within a 
period of six months. We aimed to initially recruit approximately 700 patients, i.e. 150% of 
the required 464 patients with a completed baseline assessment, as not all patients were 
expected to participate after being recruited by their nurse. 
Ninety-six nurses recruited a total of 669 patients to our trial of which 478 completed the 
baseline assessment. In that light, it can be concluded that our recruitment was successful. 
Still, these results showed that approximately 30% of patients did not enact their expressed 
willingness towards their nurse to participate. To our knowledge, no studies have explored 
why patients with T2DM omit completing a first assessment, after being positive towards 
their nurse about participation, and the available literature focusses on drop-out after 
having entered the trial (234). Upon expressing willingness to participate towards their 
nurse, patients were registered, given time to rethink participation, and provided with more 
extended information before the online informed consent procedure would occur. It may be 
that patients experienced pressure to decline study participation as suggested by their nurse, 
or that they were in fact pushed by the nurse to commit to participation. Other reasons may 
be that patients actually forgot to follow-up their agreement, that the extended information 
withheld them from continuing, that the baseline assessment required too much effort to be 
completed, or that technological issues disabled them to continue. Cleary, further research is 
needed to explore and understand why participants who are initially recruited by their health 
professional to participate in a trial, fail to complete the first stage, i.e. the baseline assessment. 
In line with the before mentioned, this study only evaluated initial enrolment of patients 
by nurses rather their retention in the trial, which is primarily important when considering 
sufficient study power. Therefore, research could investigate the relation between initial 
recruitment success, and retention rates throughout the entire follow-up of the trial. 
If patient recruitment is regarded as a behaviour, its success seemed to be influenced by 
several facilitators and barriers identified in the area of organizational, study, patient and 
especially recruiter characteristics. Concerning recruiter characteristics, a similar pattern could 
be observed as to exploring treatment behaviour adherence according to the I-Change Model 
(43). For instance, medium- and high recruiters showed more knowledge about the study and 
trial requirements, and reported advantageous beliefs and fewer barriers towards recruiting 
patients, compared to non- and low-recruiters. Moreover, the prior group incorporated more 
recruitment activities, reminders, and barrier-focused coping strategies. Initially, all nurses 
expressed their willingness to contribute to recruiting patient to the trial, however, it is well-
known that not all professionals who intend to recruit patients, will actually succeed (89). 
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Awareness factors such as knowledge, and motivational factors such as attitudes and self-
efficacy are known to be precursors of an intention one has towards performing a behavior 
(45). It seemed that the intention to recruit patients of non- and low-recruiters was insufficiently 
grounded, as they showed poor study knowledge, few advantageous beliefs towards recruiting 
patients, and considerable recruitment barriers. For instance, time constraints and work 
pressure were often brought up, justifying their recruitment efforts and success; competing 
demands and time pressure are well known reported barriers to recruitment success, and 
impede the incorporation of research activities in daily practice (173, 180, 182, 183). Although 
as with health behaviors a multitude of factors may provide relevant intervention targets to 
improve successful recruitment, recruiter factors, such as their knowledge of and attitudes 
towards recruiting patients may be the most viable and changeable domain to intervene 
in (33). Explorative studies as the current inquiry may not result in conclusive evidence on 
what determines success, but yielded an in depth exploration of salient beliefs influencing 
recruitment success. Hence, findings observed should be tested through quantitative study 
designs, in which for instance also the contribution of organizational, study, and patient 
characteristics is examined in nurses’ recruitment success. As nurses in primary and secondary 
care participated in our trial, it may also be relevant to explore if beliefs and determinants 
of recruitment success differ between those nurses, in order to provide either group with 
relevant tailored advice on how to optimize recruitment efforts and success. 
Evaluation of program effectiveness
The My Diabetes Profile program is to the best of knowledge one of the few interventions 
to address both healthy lifestyle and medical behavior adherence, and the first to quantify 
the intervention effect in terms of an overall effect. Since most studies have focused on 
improving adherence to separate treatment behaviors, e.g. either physical activity or medical 
behavior adherence, there has been limited evidence on exploring overall change across 
risk behaviors (70, 71, 193). Programs that address multiple behaviors require methods to 
quantify change across those behaviors in order to evaluate their overall effect. In the current 
study we developed a standardized change score for each separate behavior. Subsequently 
a composite change score could be calculated for each individual. Such a composite score 
allows for comparison between distinct multi-behavior interventions, and examines overall 
impact on health behavior change, which is hampered when only focusing on changes in 
separate behaviors (193, 198). A small number of studies are available that quantified overall 
change in multiple behaviors through a composite change score as suggested by Prochaska 
and colleagues (165), however, these study populations differed from our participants. An 
intervention applying tailored mobile technology coaching in order to improve PA as well as 
fruit and vegetable consumption, and to decrease sedentary time and fat intake, reported a 
composite change score of around .80 (197). In a recalculation of two multi-behavior studies, 
Drake et al (193) demonstrated composite change scores of .82 and 1.05 of two interventions 
targeting cancer prevention through increases in PA, multivitamin intake, and fruit and 
vegetable consumption, and a decrease in red meat intake (235, 236). The number of targeted 
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behaviors in our intervention is equal to those addressed in the before mentioned studies, 
and a similar composite change score was observed in our study (.85; calculated based on the 
data reported in chapter 5). However, the different behaviors targeted across different study 
population, hampers clear comparisons. Moreover, although the application of a composite 
chance score has considerable advantages, it may be difficult to interpret. A possibility to 
increase interpretability is to transform, i.e. standardize, the composite change score by 
dividing the composite change scores for each individual by the pooled standard deviation 
of these composite change scores. Subsequently, a mean of the resulting ‘standardized 
composite change scores’ could be calculated per trial condition. The difference in these 
means gives information about the direction and the magnitude of the difference between 
groups, and can be interpreted as Cohen’s d (effect size) for the difference between treatment 
and control on the variable ‘change in treatment adherence as a whole’ (193, 194). Therefore, 
we recommend future studies to report results in terms of Cohen’s d in order to improve 
interpretability and allow comparisons across studies. As the management of T2DM generally 
consists of treatment strategies in the area of improving physical activity, dietary patterns, and 
medication taking, another possibility could be to combine the two medication adherence 
measures, i.e. merging OHA and insulin therapy adherence into a combined adherence score 
for medication taking (as the study power for these behaviors was relatively low). This was 
beyond the scope of the current dissertation, but potentially worthwhile exploring in future 
studies. 
Factors have been identified in the literature that seem to enhance the likelihood of an 
Internet interventions aimed at improving treatment behavior adherence being successful. 
Most eHealth interventions in the area of T2DM management have only to a small extent 
applied such ‘success’ factors, i.e. the application a solid theoretical framework, the possibility 
to identify behaviors at risk, the application of goal-setting and the possibility to self-monitor 
one’s behavior, the incorporation of interactive, tailored, and visual supported content, and 
aligning content on distinct behavior change phases, i.e. awareness, motivation, and self-
regulation (65, 70, 71, 79, 80). The positive effect observed in our study and the study of 
Glasgow et al (79) may be related to the incorporation of success factors in these interventions; 
both included a theoretical basis, interactive and tailored content, and addressed multiple-
behaviors involved in the treatment of T2DM. However, it is difficult to assign the success of 
these interventions directly to addressing these factors. Although our findings support the 
assumption that success may be enhanced through their application, more research is needed 
to assess what factors determine success of eHealth interventions targeting improvements in 
T2DM treatment adherence. 
Our intervention entailed some level of blended care as the My Diabetes Profile program 
enabled patients to transfer relevant program activity to their nurse, similar to the summary 
of activity that was transferred to the nurse in the It’s Life project (237). In addition to tailored 
behavioral modules, the program included several general modules, for example ‘My Care’ 
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and ‘My Values’. My Care facilitated patients in preparing their consultations and stimulated 
them to proactively formulate questions, provide a brief health update, and to learn how to 
be an active collaborator in consultations. My Values enabled patients to enter and visually 
keep track of their blood glucose levels, blood pressure, weight, and Body Mass Index. Data of 
these modules, together with relevant information from the tailored behavioral modules – the 
selected behavior to work on and the set goals by the patient – were automatically summarized 
and directly made available for the nurse to review. The approach where information can 
be transferred from the program to a health professional, and where patients can become 
more self-managed, may provide better care and results in more efficient consultations (231). 
Unfortunately, data on how exchange occurred between the patient and the nurse were not 
gathered and is recommended for future research. Similarly, we were not able to evaluate 
whether consultations were more efficiently organized. Moreover, it is unclear what the best 
level of integration of eHealth with care as usual will be. These topics should therefore be 
subject to future research, for example by exploring beliefs among nurses and patients on the 
blended care approach and its outcomes, and actual exchange of information about goals set 
and enacted upon.
Finally, two suggestions for future research include the assessment of cost-effectiveness of 
our eHealth intervention, and the application of longer follow-up periods. As the number 
of people living with T2DM as well as related costs of care are increasing, it is evident to 
explore interventions that can deliver relevant care that is not only effective, but also cost-
effective. Computer-tailored eHealth interventions have shown to be cost-effective, however, 
it is unclear if the current intervention, for example compared to care as usual, is a profitable 
alternative (75, 238). We therefore suggest to also evaluate the cost-effectiveness of the My 
Diabetes Profile program. We did not assess clinical outcomes, e.g. glycemic control, which 
is an important indicator of how well patients’ T2DM is controlled. No post-intervention 
follow-up period was included on top of our six-month intervention trial. It is acknowledged 
that adherence to both healthy lifestyle behaviors and medical behaviors are important 
in contributing to glycemic control. As the level of glycosylated hemoglobin (HbA
1c
) is an 
estimate of the average blood glucose levels over the past two to three months, it is unlikely to 
observe effects directly after the intervention. Patients could on average improve on multiple 
treatment behaviors. As behavior change was aimed for sequentially, it may have been that 
results on HbA
1c
-levels only occur after the program has fully been completed, i.e. at the point 
that multiple subjects to improvement are addressed. Prospective trials should therefore aim 
for adequate post-intervention follow-up periods. 
Practical implications
Based on the evaluation studies presented here, some practical implications can be 
considered. When nurses or other health professionals are asked to recruit patients for a 
trial, several measures can be taken in order to increase recruitment rates. It seems evident 
to assess the underlying reasons of nurses who express their willingness to recruit patients. 
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For instance, nurses’ knowledge about the background and conduct of the study could be 
assessed, in order to determine if their knowledge first needs to be improved, to process 
cognitive information on motivational determinants. Likewise, it requires exploration if 
expressed intentions are sufficiently grounded by motivational beliefs in order to provide 
nurses with relevant feedback if necessary. If the intention seems to be sufficiently grounded, 
researchers should warrant that nurses are facilitated to enact their intention. For instance, 
researchers could monitor the number of patients recruited per nurse, and assess personally 
relevant barriers of recruitment.
Of the initial 669 patients in our trial, 80% was recruited by the 74 nurses who were involved 
from the beginning of the recruitment period, while 20% by those 22 who became involved 
later. After the initial start of the study, researchers are thus advised to maintain involving new 
health professionals, if feasible, as they can still recruit a considerable number of patients. Last, 
our findings contribute to the cumulative evidence that early success seems to influence 
overall recruitment outcomes, and that longer time to enroll a first patients is associated with 
poor success (172). In that light, health professionals should be encouraged to recruit patients 
as soon as possible. In doing so, a personalized approach may aid recruiters to become 
and remain successful. For instance, researchers could provide health professionals with 
information to increase knowledge and motivational beliefs, or facilitate those who do not 
seem to be successful despite intending to do so with action planning and barrier-focused 
coping strategies. 
General conclusions
This dissertation described the development and evaluation of a web-based computer-
tailored program to improve adherence to core treatment behaviors in patients with T2DM. 
Our results showed the effectiveness the My Diabetes Profile on overall treatment adherence, 
and with regard to separate treatment behaviors on a decrease in caloric intake from unhealthy 
snacks. The My Diabetes Profile program was supported by thorough formative research 
which provided insight in the scope of non-adherence, and relevant determinants and 
beliefs that play a role in treatment behavior adherence. Scarce, busy, and brief consultations 
between health professionals and patients may not be ideal to discuss non-adherence and 
the complex process of behavior change adequately. An eHealth program could potentially 
offer the ongoing tailored support patients need in improving healthy lifestyle and medical 
treatment behavior adherence. Moreover, eHealth could address those treatment adherence 
success factors that are insufficiently applied in consultations, such as patient preparation, 
active involvement, and clear goal setting. To increase the likelihood of being a successful 
intervention, eHealth interventions should build on solid theoretical foundations, include 
tailored and visual supported content, and align with relevant phases of behavior change. 
Nevertheless, discussing treatment adherence as protocolled discussion topic by Dutch 
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guidelines should not be abandoned from consultations. An integration of eHealth and care 
as usual is proposed, however, this requires further research on its evaluation and optimal 
implementation format. Also the cost-effectiveness of the My Diabetes Profile requires 
additional research, as well as the long-term effects on treatment behavior adherence and 
related health outcomes. In order to be of impact, the reach of a successful intervention 
should be increased. Implementation challenges need to be explored, for example if the 
delivery format of the My Diabetes Profile program through nurses in consultations is in fact a 
feasible delivery strategy, and how information gathered through eHealth can be integrated 
in the multitude of information systems used in Dutch healthcare.
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Valorization
Addendum
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The main aim of this dissertation was to provide insight in the effectiveness of the newly 
developed web-based computer-tailoring program ‘My Diabetes Profile’ that aims to improve 
treatment adherence of patients with T2DM to core treatment behaviors, i.e. physical activity, 
healthy dietary patterns and medication taking. Formative research, conducted prior to the 
development and effectiveness study of the program, was directed at providing insight in 
the scope of treatment (non)-adherence and its determinants in Dutch patients with T2DM. 
The results of the studies presented in this dissertation show that treatment adherence 
in patients with T2DM is subject to improvement and that patients generally show non-
adherence in multiple treatment behaviors simultaneously. As non-adherence is associated 
with considerable adverse outcomes on personal, societal, and economical levels, it is highly 
relevant to pursue improvements in patients’ adherence. In chapter 6 we demonstrated that 
the newly developed eHealth program, My Diabetes Profile, has the potential to be an effective 
intervention to improve patients’ overall adherence to T2DM treatment recommendations. 
This chapter elaborates on the relevance and value of the findings from this dissertation and 
addresses valorization opportunities for the individual, the health professional, and research.
Relevance
Findings from our formative work are consistent with results from existing research regarding 
co-occurring treatment non-adherence in patients with T2DM. Results from our qualitative 
formative research study already suggested that non-adherence to treatment behaviors 
often co-occurs. Our baseline measurement from the conducted trial confirmed this 
finding and showed that, on average, patients could improve on three of the four treatment 
recommendations that were examined. Former research already showed an increasing 
negative trend towards co-occurring treatment non-adherence. Only 3.5% of the studied 
patients with T2DM adhered to all five key recommendations related to the treatment of 
T2DM, while this percentage was almost three times as high in prior observations (25). Results 
from former research demonstrated that almost 85% could improve adherence to two or 
more recommendations, while earlier research showed that this percentage was near 75%, 
also indicating a negative trend. With an increasing prevalence of T2DM, more patients are 
at risk for the multifaceted adverse consequences related to the disease and treatment non-
adherence. Moreover, the increasingly common co-occurrence of treatment non-adherence 
may result in greater adversity on health and related outcomes (198). In the first place for the 
patient, but also from a societal and economical perspective, it is therefore evident to target 
improvements in patients’ adherence and by doing so from a multi-behavior perspective.
Current Dutch guidelines with regard to diabetes care describe that discussing and promoting 
treatment adherence should be one of the standard discussion topics in encounters between 
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the patient and the health professional (14). Increasing care demands, time constraints, 
and scarce encounters between patient and professional may however impede addressing 
treatment adherence to a sufficient extent, as well as the adequate application of multiple 
factors which seem to determine successful treatment adherence. Findings reported in this 
dissertation, but also lessons learned from earlier work in which nurses reported to struggle 
providing effective lifestyle counselling, ask for new avenues to address and improve treatment 
adherence (63). Discussing treatment adherence in medical encounters could serve as a 
starting point for extended treatment adherence enhancing activities outside the healthcare 
setting. An example of such an activity could be to partly outsource the process of assessing 
and improving treatment adherence to the context of the Internet. The added value for the 
professional is that this could be useful given the presumed time and know-how shortage 
on how to promote health behavior change. In addition, the professional could be updated 
on the progress of the behavior change of the patient periodically, thereby integrating the 
online intervention into the healthcare context. For instance, like in the My Diabetes Profile 
program, the professional could get access to a summary of the activities a patient has done 
in the program and the progress in improving treatment adherence. Moreover, this way, 
professionals could devote more attention to other, more acute discussion topics such as 
the patient’s latest blood glucose levels. Especially as traditionally healthcare systems were 
developed to deal with acute conditions rather than chronic illnesses, it is not surprising 
that professionals experience difficulties and barriers in discussing and promoting treatment 
adherence amongst their chronic ill patients (105). For the patient, personalized advice as 
provided in the eHealth context, has the advantage that it can be accessed at any time and 
in a desired pace. 
The effectiveness study in the second part of this dissertation suggested that such an 
intervention delivered through the Internet, i.e. the newly developed My Diabetes Profile 
program, can be an effective way to improve patients’ overall adherence. Besides the 
general attributes of Internet interventions, such as its broad reach, constant accessibility, 
and potential to temper pressure on health care systems, the program also has its unique 
features. Compared to the vast majority of existing eHealth interventions targeting adherence 
improvements in patients with T2DM, the My Diabetes Profile program provided patients 
with personally relevant tailored content, applied a sound theoretical base, incorporated 
largely visual content, and was developed with input from patients and professionals. These 
attributes are well-known to enhance the likelihood of a program to be successful in improving 
treatment adherence, and it is likely that its application has resulted in the positive effects of 
My Diabetes Profile. However, future studies could investigate if indeed the application of the 
known success factors led to the positive results as observed in the effectiveness evaluation.  
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Innovation
The My Diabetes Profile shows some level of innovation in relation to existing computer-
tailored interventions, as well as in its strategy to improve patient adherence. Firstly, the field 
of computer tailoring technology and eHealth has evolved tremendously in recent decades. 
First generation tailored strategies applied print materials to bring about individualized health 
messages. In recent years, the Internet has increasingly emerged as mode for the delivery of 
tailored interventions to improve for instance adherence to treatment strategies, referred to 
as computer-tailoring technology (72, 81, 239). Most previous web-based computer-tailored 
interventions focusing on T2DM treatment adherence did not apply a solid theoretical 
framework, were generally mono-behavior oriented, included little interactive content, and 
were largely text-based (154). The My Diabetes Profile program not only builds on a solid 
theoretical framework, i.e. the I-Change Model, it also aims to improve patient adherence from 
a multi-behavior perspective, applying strategies towards both healthy lifestyle adaptations 
and medical intervention adherence. As disease and glycemic control are impacted by all 
these treatment behaviors, and as treatment non-adherence often co-occurs, it seems that a 
multi-behavior strategy is most relevant. The interactivity of the My Diabetes Profile program 
is reflected in the content that is assessment based, tailored to the behavior change phase 
an individual is in, and segmented to a high, medium, or low score on related determinant 
scales. In addition, at the level of beliefs, tailored advice is provided to e.g. persuade an 
individual of a certain advantage of carrying out a behavior, or to strengthen self-efficacy 
in a particular difficult situation. Advice is provided instantly and accessible at a preferred 
pace, contrary to e.g. the computer-tailored letters sent within weeks to months following 
the assessment in earlier work (239). Many of the interactive pathways applied in My Diabetes 
Profile are delivered through video-tailored advice. People with a low education level, which 
is common in people with T2DM, may be less text-oriented which in turn could inhibit 
the use and effectiveness of such programs (240). Video-tailoring is an innovative mode to 
bring about health promotion messages that can deliver content in a more interactive way 
compared to text-tailoring. Further, video-tailoring for example enables to demonstrate skills 
to patients, reduces cognitive processing of information, and can lead to better appreciation 
and attention, compared to text-tailored content (241). Moreover, it is suggested that the 
application of video-messages in order to deliver health promotion interventions, may 
particularly suit low-educated patients, given their generally low-literate skills and difficulty of 
translating abstract text into concrete actions (242-244). 
Secondly, rather than aiming to reach the recommended norms of those behaviors, as has 
been the case in previous similar work (52, 245), our program aimed for improvements in 
all of our targeted behaviors, i.e. physical activity, medication adherence, and a decrease in 
caloric intake from unhealthy snacks, from a continuous perspective. An increase from two 
to twenty-nine minutes of daily physical activity would not have counted as a successful 
behavior change in programs that aim for patients reaching the norm, while an increase from 
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twenty-nine minutes of daily physical activity to thirty minutes would actually have. Recent 
Dutch and international guideline targets on physical activity conclude that any increase, and 
especially an increase in activity levels from zero to any activity, can have an enormous impact 
on health and related outcomes (191). Moreover, if a certain norm was reached but an in- or 
decrease was still possible, our program aimed for these improvements as e.g. it is known that 
additional activity beyond the norm of 150 weekly minutes is desirable. Therefore, if feasible, 
future interventions should carefully consider whether aiming to reach the norm and only 
reaching the norm is sufficient to grasp behavioral improvements below or beyond those 
norms, and rather aim for continuous improvements instead. Moreover, by promoting small 
steps, it is also easier to provide reinforcing feedback in the challenging trajectory of behavior 
change among patients with T2DM (116). 
Target groups
Patients with type 2 diabetes mellitus
First and foremost, the results of this dissertation are of great value for the initial target group 
of the intervention, i.e. Dutch patients with T2DM. It is conceivable that patients with T2DM 
beyond the age restrictions applied in the trial could benefit from the intervention, as the 
presence of T2DM is increasingly common in those aged <40 and >70 (246). However, if the 
program would be made available for youngsters, young adults, or elderly above the age 
of 70 with T2DM, it is likely that the program requires some form of adaptation towards 
specific beliefs and target goals of those groups. Similar formative research as reported in 
the early chapters of this dissertation could yield information on if and how the program 
should be adapted to align with needs and salient beliefs present in those target groups 
(247). In addition, the program modules targeting improvements in healthy lifestyle behaviors 
could be of interest for people suffering from other lifestyle related diseases or for people 
at risk of developing T2DM. As the onset as well as the treatment of T2DM largely involves 
energy balance-related behaviors such as physical activity and dietary choices, those at risk 
could contribute to a decreased chance of developing T2DM by improving healthy lifestyle 
adherence. Internationally, the program could be of impact as T2DM is known to be a global 
epidemic, however, again the context and content should be fine-tuned to those countries or 
regions it is implemented to.
Health professionals
Another relevant target group to potentially benefit from current findings are health 
professionals, especially those directly involved in diabetes care of patients, i.e. nurses and 
physicians. First, a discrepancy seems to exist in perceptions of patients and their health 
professionals with regard to whether patients adhere to distinct treatment recommendations 
(28). Therefore, it is at least of relevance to raise awareness in professionals and patient that 
their views on patient adherence may deviate and that advice provided by health professionals 
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accordingly may be perceived as irrelevant by patients. Second, the My Diabetes Profile 
program includes a certain level of blended care as the program is proposed to patients in 
medical encounters, and as professionals get access to a summary of patients’ activity in the 
program. In blended care interventions, therapeutic guidance is complemented with online 
care. A combination is recommended, as stand-alone online interventions struggle with 
disappointing compliance rates (248, 249). However, it remains unclear what the best way and 
quantity is to integrate these two delivery modes. A trend is observable towards a declining 
share of the health professional in interventions that have been developed at our university in 
recent years that aimed for self-management support or improvements in healthy lifestyles. On 
the contrary, technology is more and more integrated in routine care to complement or partly 
replace the work conducted by nurses. In the work of Koelewijn and colleagues, primary care 
nurses were trained to deliver risk and motivational counseling to improve patients’ lifestyle 
related to cardiovascular risk management (250). It is concluded that nurses should support 
patients in their attempts to improve their lifestyle, but that only nurse-support does not 
seem to be sufficient (251). A project to improve the daily functioning of patients with T2DM 
by the implementation of a nurse-led intervention for integrated self-management support 
in routine care, showed limited effects. A process-evaluation showed that practice nurses 
felt restricted in time and expertise to adopt the intervention, and patients did not expect a 
discussion about psychosocial problems but rather saw their nurse as a specialist regarding 
the biomedical management of their T2DM (252). More recent work was pointed at assisting 
practice nurses on how to best deliver goal setting and action planning with regard to self-
management support in chronically ill patients. Nurses seemed to experience difficulties 
in setting goals and action plans with regard to self-management support. Their focus was 
merely on solving medical problems, and patients were characterized as rather passive 
collaborators in this process, as has been established earlier (28, 253). Furthermore, nurses 
indicated to struggle to integrate the approach in routine care and to apply it in a tailored way, 
and characterized the process as time consuming and complex (254). Verwey and colleagues 
aimed to improve physical activity levels in patients with T2DM and acknowledged that 
mere advice from a practice nurse would not result in significant improvements in activity 
levels. Patients visit their practice nurse a couple times a year, while behavior change may 
require day-to-day attention. Therefore, a technological support tool was developed for 
patients to complement the process of risk communication, motivational interviewing and 
goal setting by nurses (237). A summary of activity levels monitored by the tool was sent to 
the practice nurse automatically, similar as in the My Diabetes Profile program. The feedback 
tool, if embedded into a counseling protocol, was an effective instrument to improve physical 
activity levels of patients with T2DM, while mere counseling was not effective (255). In sum, it 
seems that efforts of nurses alone are often not enough to realize sufficient behavior change 
in patients, party through time constraints, the infrequent occurrence of medical encounters, 
know-how insufficiencies, and passive patient involvement. Especially in attempts to improve 
multiple behaviors, the integration of routine care with online interventions where patients 
can access advice on a daily basis seems evident. The counseling process, for example 
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risk communication, motivational messages and goal-setting and action planning, can be 
outsourced to the context of the Internet. Future studies need to explore how to best attune 
the face-to-face counseling process with tailored eHealth methods.
Researchers
Results from this dissertation also provide relevant knowledge and opportunities for 
researchers. An important step in developing health promotion programs is the phase 
of testing the program on its effectiveness and if results are positive, subsequently the 
dissemination of successful programs in order to increase its exposure and impact (256). In 
the trial that was conducted as part of the effectiveness study, patients were recruited by their 
health professional, i.e. practice nurses and diabetes nurses in the primary and secondary care 
setting. Beforehand, all nurses intended to recruit at least eight patients with T2DM to our trial. 
However, trial data showed a broad range of recruitment success of nurses, ranging from 0-32 
recruited patients. It is widely acknowledged that for instance for health promotion behaviors, 
a positive intention towards behavior change does not warrant subsequent success (56). 
It seems that recruitment behavior of nurses in our trial was subject to a similar intention-
behavior gap, and that nurses’ recruitment behavior in general follows similar pathways as 
how health behavior can be explained in the I-Change Model. Therefore, researchers need to 
be aware that not all nurses who intent to recruit patients will actually do so, and may drop-
out during the recruitment period. 
Researchers may, however, be able to influence the process of recruitment by health 
professionals. After conducting a qualitative exploration of factors influencing recruitment 
success among nurses it seems that there is a wide variety of factors that influences recruitment 
success including, and foremost, cognitions of recruiters themselves seem to have an impact 
on the outcome. A personalized approach seems to be the primary method once a nurse has 
expressed the willingness to participate. For instance, in some nurses the expressed intention 
is followed-up by clear action plans, coping strategies towards barriers, and goals regarding 
the intended number of recruited patients. Others seem to have expressed their willingness 
without actually having sufficient study and trial knowledge and sufficient motivation to recruit 
patients. It is yet to become clear how researchers can optimally support recruiters through a 
personalized approach to stimulate their recruitment efforts and related outcomes. For now, 
it is suggested that researchers could assess recruiters’ trial and study knowledge, motivation 
and willingness to recruit study subjects, and align their efforts in assisting recruiters towards 
their needs, in order to increase the likelihood of recruitment being successful. More research 
in this area, however, is required to substantiate the suggested initiatives. 
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Feasibility and dissemination of My Diabetes Profile
Program impact not merely depends on its effectiveness, but also on its reach and 
implementation by its users (257). In order to be of impact, the reach of the successful My 
Diabetes Program should be increased beyond the trial setting in which its effectiveness 
was examined. One needs to be aware that this is the first version of the My Diabetes Profile 
program, and although overall effectiveness has been shown, further refinement may 
be needed. First, largely the program was developed with input from local stakeholders, 
i.e. patients and professionals were interviewed as described in chapter 2, and a program 
committee was formed prior to program development to accumulate input. Although 
to some extent attention has been payed to co-creation, it is relevant to involve national 
stakeholders such as patient associations, health insurance companies and national diabetes 
federations to further attune the program and to create a supportive base for the program. 
As described earlier, further research should also be conducted on how to optimally integrate 
the program with face-to-face counseling. 
Subsequently, this information may help researchers to optimize the program and ultimately, 
a My Diabetes Profile program 2.0 version could be tested in a similar trial to examine if 
enhanced success is achieved, before widespread implementation is initiated. Subsequently, 
if researchers would aim for broad implementation of the My Diabetes Profile program, 
implementation challenges may need to be explored. For instance, researchers could explore 
if the delivery format of the My Diabetes Profile program through nurses in consultations is in 
fact a feasible delivery strategy, and if and how the eHealth program can be integrated in the 
multitude of information systems used in Dutch healthcare. Moreover, prolonged use as well 
as long-term effects and cost-effectiveness need to be researched to increase the marketing 
of the program. In sum, it can be concluded that the My Diabetes Profile program in its current 
version was an effective and feasible program to improve overall treatment adherence in 
patients with T2DM. However, the program may need further refinement before widespread 
implementation is initiated.
Lifestyle medicine and prevention 
The aims of My Diabetes Profile program are consistent with the vision of the Dutch ministry 
of Public Health, Welfare and Sports as stated in the recently published Dutch prevention 
agreement (258). Maintaining or improving healthy lifestyles are not only part of the 
prevention and treatment of T2DM, but are also urgent for Dutch society as in 2017 almost 
half of the people aged ≥20 was at least overweight. This number of overweight and obese 
people is increasing rapidly, which in turn are important risk factors for the onset of T2DM. 
Energy balance related behaviors, such as healthy dietary choices and sufficient physical 
activity, are key behaviors in the prevention of obesity and T2DM. Lifestyle medicine and 
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disease prevention have therefore gained ground in recent years, and are elaborated in the 
Dutch prevention agreement. However, few attention has been payed to eHealth as method 
to bring about improvements in healthy lifestyle behaviors. In addition, many initiatives 
stated in the agreement to target a complex problem of overweight and obesity, focus on 
the environment and to a smaller extent on cognitions, i.e. personal determinants such as 
the individual’s knowledge and motivation. The My Diabetes Profile program showed that 
eHealth as medium and intervening in the personal determinants was a successful strategy to 
decrease caloric intake from unhealthy snacks. Given the expectation that by 2040 over 60% 
of the Dutch population will at least be overweight as well as the expected increase of T2DM, 
My Diabetes Profile can be a valuable tool to support patients with T2DM and potentially 
those with overweight, in effective, personalized and broad reach healthy lifestyle changes.
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Summary
The main aim of this dissertation is to describe the development and effectiveness of the 
eHealth program, My Diabetes Profile, which aimed to improve adherence of patients with 
T2DM to core treatment behaviors, i.e. improving physical activity levels, oral hypoglycemic 
agent (OHA) adherence, insulin therapy adherence, and decreasing caloric intake from 
unhealthy snacks.
Chapter 1 provides a general introduction including background information on diabetes 
mellitus, its consequences, management strategies, and treatment adherence. Diabetes 
Mellitus is a progressive chronic disease characterized by hyperglycemia and the inability of 
the body to maintain a favorable glucose metabolism. By 2045, worldwide over 600 million 
people will be affected by diabetes, and nine in every ten people of those will have type 2 
diabetes mellitus. Treatment strategies consist of increasing physical activity levels, improving 
dietary patterns, and if applicable adherence to medical behaviors such as OHA taking and 
insulin therapy. Patient adherence poses a serious challenge, non-adherence co-occurs across 
treatment behaviors, and non-adherence is associated with considerable individual, societal, 
and economic consequences. In that light, it is evident to improve adherence and to explore 
avenues on how to achieve improvements in patients’ treatment adherence. In addition, the 
introduction provides insight in the theoretical framework applied in this dissertation, and 
discusses computer-tailoring technology as medium to improve treatment adherence in 
patients with diabetes. 
Chapter 2 describes a qualitative inquiry among patients with type 2 diabetes and relevant 
health professionals involved in the management of diabetes. The study aimed to explore 
the scope of non-adherence, to explore salient personal beliefs associated with treatment 
adherence, and to explore if and how success factors for treatment adherence are applied 
in diabetes consultations. Results demonstrated that treatment adherence to healthy 
lifestyle and medical behaviors was suboptimal. It seems that for some treatment behaviors, 
patients had more knowledge and were more aware of risks compared to other behaviors. 
Health professionals and patients reported many advantages and no disadvantages of 
adherence to healthy lifestyle behaviors. Both advantages and disadvantages were reported 
for medical behavior adherence. Self-efficacy of patients to adhere to treatment behaviors 
seemed to be lower in situations when routine was compromised; similar situations were 
identified for distinct treatment behaviors. Last, success factors for treatment adherence were 
insufficiently applied in consultations. Health professionals reported that scarce, busy, and 
brief consultations may impede the application of such success factors. In conclusion, patient 
adherence is suboptimal, non-adherence co-occurs across behaviors, beliefs have been 
identified to target in interventions, and new avenues need to be explored to address success 
factors for treatment adherence. 
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Chapter 3 describes a longitudinal study that aimed to identify psychological predictors of 
adherence to OHAs and to compare the prevalence of adherence between two self-report 
adherence instruments. At baseline, we assessed OHA adherence using the ProMAS and 
MARS-5, socio-cognitive determinants, and demographics. At follow-up, the ProMAS was 
used as outcome measure, on which socio-cognitive determinants and demographics were 
regressed using multiple linear regression analysis. With currently advised and widely applied 
cut-off points of ≥15 for the ProMAS and ≥23 for the MARS-5, 47% and 90% adhered to their 
OHAs respectively. Data of the ProMAS were more in line with objectively collected data with 
regard to the percentage of patients that could be considered adherent. Consistent predictors 
of better adherence were a low education, lower severity perceptions, and higher self-
efficacy and intention. After correcting for baseline adherence, a low education and higher 
self-efficacy remained significant predictors. In sum, the ProMAS seems better equipped to 
deal with pitfalls present in available self-report measures. Suboptimal adherence stresses the 
need for effective adherence improving interventions. Interventions should particularly target 
higher-educated patients and patients with low self-efficacy in situations out of daily routine.
Chapter 4 describes the development of the My Diabetes Profile program as well as a protocol 
for the conduct of a randomized controlled trial to examine its effectiveness. Results from 
chapters two and three were complemented with knowledge accumulated from previously 
developed computer-tailored programs and input gathered from a program committee. 
Together these sources yielded input for the development of the eHealth program My 
Diabetes Profile. Consequently, the program addressed treatment non-adherence to healthy 
lifestyle and medical behaviors, and aligned with the needs and desires of our target group 
and others involved in the committee. In addition, the program incorporated success factors 
for treatment adherence as identified from the literature, i.e. a solid theoretical base, interactive 
content and feedback tailored to relevant phases and determinants of behavior change, visual 
support, and the possibility to monitor adherence.
Chapter 5 discussed the evaluation that was conducted regarding the recruitment of patients 
with type 2 diabetes by nurses to our randomized controlled trial. The aim of this study was 
to map the number of patients recruited per nurse and how this total came about during the 
recruitment period, and to explore factors that influenced nurses’ their recruitment success. 
Nurses’ recruitment success and the course of recruitment success were derived from trial 
data (NTR6840). Based on the standardized total number of recruited patients, nurses were 
categorized either as non-, low-, medium-, or high-recruiter. Ninety-six nurses participated in 
our trial and recruited a mean of seven patients (range 0-32), which was slightly lower than 
the minimum of eight patients we aimed for. Fifteen nurses did not recruit any patient. Most 
patients were recruited close to recruitment onset. Nurses who did not recruit patients close 
to recruitment onset, ultimately showed no recruitment success. Data showed a relative high 
early recruitment success that progressively declined over time; high-recruiters were generally 
successful throughout the entire recruitment period, while low-recruiters mostly in the early 
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months. Telephone interviews among a subset of nurses per group revealed that recruitment 
barriers and facilitators emerged in the area of organizational, study, patient and especially 
recruiter characteristics. Contrary to non- and low-recruiters, medium- and high-recruiters 
reported more in-depth knowledge about the study and trial requirements, expressed more 
personal participation benefits and fewer barriers, and applied more recruitment activities, 
reminders, and barrier-focused coping strategies. To conclude, early recruitment success 
should be encouraged, and a personalized approach may facilitate recruiters to become and 
remain successful. 
Chapter 6 describes the results of the randomized controlled trial that was conducted to 
examine the effectiveness of the My Diabetes Profile program in comparison to a waiting list 
control arm. Intervention effects were examined on overall and separate treatment behaviour 
adherence. Sixty percent of those patients who completed the baseline assessment were 
retained after follow-up, which was a promising result for eHealth interventions. Overall 
treatment adherence improved significantly in those patients allocated to the intervention, 
reflected by an overall small to medium effect size (d = .24). With regard to separate treatment 
behaviors, a significant decrease was observed in caloric intake from unhealthy snacks (d =.38). 
Small to medium positive intervention effects were observed for adherence to OHA (d = .18) 
and insulin therapy (d = .28), however, these effects were not statistically significant, potentially 
due to a lack of power in these medical behaviors. As the My Diabetes Profile program 
applied several success factors for eHealth interventions identified from the literature, i.e. a 
theoretical base, tailored content and a multi-behavior approach, this may have contributed 
to the success of the intervention. eHealth has shown to be an effective avenue to improve 
treatment adherence in patients with T2DM. Future research should investigate how wide-
scale implementation could best be shaped and if and how the integration of eHealth in usual 
care could be of additional value. 
Finally, chapter 7 provides a general discussion and conclusion based on the studies 
presented throughout the dissertation. The My Diabetes Profile program was effective in 
improving treatment adherence of patients with T2DM. However, several research areas have 
been touched upon which require further research. For instance, the long-term effects of 
the program on treatment behavior adherence and related outcomes remain unknown. 
Furthermore, the cost-effectiveness evaluation, process-evaluation, and optimal delivery 
format for wide-spread implementation should be explored in order to provide entries 
to market the program, refine the program, and increase the program’s impact. Last, the 
integration of eHealth interventions in usual care, i.e. blended care, has shown to be beneficial, 
but requires further investigation for the My Diabetes Profile program.
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Samenvatting
Het belangrijkste doel van dit proefschrift is om de ontwikkeling en de effectiviteit 
van het eHealth-programma, Mijn Diabetes Profiel, te beschrijven. Het doel van het 
programma was om therapietrouw van type-2 diabetes patiënten te verbeteren aan kern 
behandelingsgedragingen, dat wil zeggen het verhogen van lichamelijke activiteit, het 
verbeteren van therapietrouw aan orale medicatie en insuline voorschriften, en het verlagen 
van de calorie-inname uit ongezonde snacks.
Hoofdstuk 1 bevat een algemene inleiding over diabetes mellitus, de gevolgen hiervan, 
managementstrategieën en het opvolgen van de behandeling. Diabetes Mellitus is 
een progressieve chronische ziekte die wordt gekenmerkt door hyperglykemie en het 
onvermogen van het lichaam om een optimale glucosestofwisseling te onderhouden. In 
2045 zullen wereldwijd meer dan 600 miljoen mensen diabetes hebben, waarvan negen van 
de tien de type-2 diabetes variant. Behandelingsstrategieën bestaan uit het verhogen van 
de lichamelijke activiteit, het verbeteren van voedingspatronen en, indien van toepassing, 
het naleven van medische behandelingen, zoals het nemen van orale bloedsuikerverlagende 
medicatie en behandeling met insuline. Naleving door patiënten is een serieuze uitdaging. 
Therapieontrouw vindt plaats over verschillende behandelingsgedragingen heen en wordt 
gekoppeld aan aanzienlijke individuele, maatschappelijke en economische gevolgen. Het is 
daarom duidelijk dat therapietrouw moet worden verbeterd en nieuwe manieren moeten 
worden ontdekt waarmee patiënten hun behandeling beter kunnen naleven. De inleiding 
biedt verder een inzage in het theoretische kader dat is toegepast binnen dit proefschrift. Ook 
wordt er gesproken over computer-tailoring technologie als middel om ervoor te zorgen dat 
patiënten met diabetes hun behandeling beter naleven.
Hoofdstuk twee beschrijft een kwalitatief onderzoek dat heeft plaatsgevonden onder 
patiënten met diabetes type-2 en gezondheidsprofessionals die zijn betrokken bij het onder 
controle houden van diabetes. Het onderzoek richt zich op de omvang van therapieontrouw 
aan behandelingsgedragingen onder patiënten, belangrijke persoonlijke overtuigingen met 
betrekking tot het opvolgen van behandelingsgedragingen en of en hoe succesfactoren 
voor het opvolgen van de behandeling zijn toegepast in diabetesconsulten. De resultaten 
lieten zien dat het opvolgen van de behandeling met betrekking tot een gezonde 
levensstijl en medisch gedrag suboptimaal was.  Het lijkt erop dat patiënten voor sommige 
behandelingsgedragingen meer kennis hebben en meer op de hoogte zijn van risico’s dan 
voor andere gedragingen. Professionals en patiënten benoemden veel voordelen en geen 
nadelen van het naleven van gedrag dat hoort bij een gezonde levensstijl. Zowel voor- als 
nadelen werden gerapporteerd voor het naleven van medisch gedrag.
De eigen-effectiviteit van patiënten met betrekking tot het naleven van behandelingsgedrag 
leek lager te zijn in situaties waar routine werd doorbroken. Eenzelfde situaties werden 
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geïdentificeerd voor afzonderlijke behandelingsgedragingen. Ten slotte, succesfactoren 
voor het opvolgen van behandeling werden onvoldoende toegepast in consulten. 
Gezondheidsprofessionals melden dat geringe, drukke en korte consulten de toepassing 
van dergelijke succesfactoren belemmerd kunnen hebben. Onze conclusie luidt dus dat 
de naleving van behandelingsgedragingen door patiënten suboptimaal is, niet-naleving 
plaatsvindt over verschillende vormen van gedrag, overtuigingen voor toepassing in 
interventies kenbaar zijn gemaakt, en nieuwe manieren onderzocht moeten worden om 
succesfactoren toe te passen. 
Hoofdstuk drie beschrijft een longitudinaal onderzoek dat tot doel had psychologische 
voorspellende factoren van therapietrouw aan orale bloedsuikerverlagende medicatie 
te identificeren. Ook is binnen dit onderzoek een vergelijking gemaakt in therapietrouw 
prevalenties tussen twee zelf-rapportage instrumenten. In de eerste vragenlijst is 
therapietrouw in kaart gebracht middels de ProMAS en MARS-5 vragenlijsten, evenals 
sociaal-cognitieve variabelen en demografische factoren. Binnen de tweede vragenlijst 
is de ProMAS gebruikt als een uitkomstmaat en zijn de sociaal-cognitieve variabelen als 
gemeten in de eerste vragenlijst gebruikt om de therapietrouw te voorspellen middels een 
meervoudige lineaire regressieanalyse. Met de afkappunten van >15 voor de ProMAS en >23 
voor de MARS-5, was respectievelijk 47% en 90% van deelnemers therapietrouw aan hun 
orale bloedsuikerverlagende medicatie. Gegevens van de ProMAS kwamen meer overeen 
met objectief verzamelde gegevens als men kijkt naar het percentage van patiënten dat als 
therapietrouw kan worden beschouwd. Terugkerende voorspellers van betere therapietrouw 
waren een laag opleidingsniveau, lagere ernstinschatting van risico’s, en een hogere eigen-
effectiviteit en bereidheid om de medicatie te gebruiken. Na correctie voor therapietrouw 
als gemeten in de eerste vragenlijst, bleven een laag opleidingsniveau en een hogere eigen-
effectiviteit over als significante voorspellers. Kortom, de ProMAS lijkt beter om te kunnen gaan 
met valkuilen die aanwezig zijn in beschikbare zelf-rapportage instrumenten. Suboptimale 
therapietrouw benadrukt de behoefte aan effectieve interventies die therapietrouw kunnen 
bevorderen. Interventies moeten met name hoger opgeleide patiënten en patiënten met 
een lage eigen-effectiviteit in situaties die niet in de dagelijkse gang van zaken voorkomen, 
als doelgroep hebben.
Hoofdstuk vier beschrijft de ontwikkeling van het Mijn Diabetes Profiel programma en 
een protocol voor het uitvoeren van een gerandomiseerd gecontroleerde studie om de 
effectiviteit daarvan te onderzoeken. De resultaten van hoofdstukken twee en drie zijn 
aangevuld met kennis die is opgedaan uit eerder ontwikkelde programma’s waarbij computer-
tailoring technologie gebruikt wordt, evenals input die vergaard is vanuit een stuurgroep. 
Samen boden deze bronnen input voor de ontwikkeling van het eHealth-programma Mijn 
Diabetes Profiel. Als gevolg hiervan besteedt het programma aandacht aan therapieontrouw 
aan gezonde leefstijl gedragingen en medisch gedrag, en wordt het programma afgestemd 
op de wensen en behoeften van onze doelgroep en anderen die deel uit maakten van de 
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commissie. Verder bevat het programma ook succesfactoren voor therapietrouw die naar 
voren zijn gekomen uit literatuuronderzoek. Bijvoorbeeld, het gebruik van een theoretische 
onderbouwing, interactieve inhoud en feedback die is afgestemd op relevante fases en 
determinanten van gedragsverandering, visuele ondersteuning en de mogelijkheid om 
therapietrouw te monitoren.
In hoofdstuk vijf wordt gesproken over de evaluatie die werd uitgevoerd inzake de werving 
van patiënten met diabetes type-2 door verpleegkundigen om deel te nemen aan ons 
gerandomiseerd gecontroleerde studie. Het doel van deze studie was om het aantal 
patiënten dat per verpleegkundige werd geworven in kaart te brengen, hoe dit totaal 
tot stand kwam tijdens de wervingsperiode, en om te onderzoeken welke factoren het 
uiteindelijke wervingstotaal van de verpleegkundigen hebben beïnvloed. Gegevens over het 
wervingstotaal en het verloop van het wervingssucces werden gehaald uit studiegegevens 
(NTR6840). Op basis van het gestandaardiseerde totale aantal geworven patiënten werden 
verpleegkundigen gecategoriseerd als verpleegkundigen zonder wervingsresultaat, 
verpleegkundigen met lage werving, verpleegkundigen met gemiddelde werving of 
verpleegkundigen met hoge werving. 96 verpleegkundigen namen deel aan onze studie 
en wierven gemiddeld zeven patiënten (spreiding 0-32), wat enigszins lager lag dan het 
minimumaantal van acht patiënten dat beoogd was. Vijfteen verpleegkundigen wierven 
geen enkele patiënt. De meeste patiënten werden geworven vlak nadat de wervingsperiode 
van start ging. Verpleegkundigen die geen patiënten wisten te werven vlak na aanvang van 
de werving bleken uiteindelijk geen tot weinig patiënten te werven. De gegevens laten een 
relatief hoog succes zien bij het begin van de werving dat op den duur geleidelijk minder 
wordt. Verpleegkundigen met een hoog wervingstotaal hadden over het algemeen meer 
succes tijdens de volledige wervingsperiode terwijl verpleegkundigen met een lage werving 
meestal (alleen) tijdens de eerste maanden. Telefooninterviews afgenomen onder een 
subset van verpleegkundigen per groep laten zien dat wervingsbarrières en facilitators zich 
voordeden op organisatorisch, studie- en patiëntgebied, maar voornamelijk bij kenmerken 
van de verpleegkundigen zelf. In tegenstelling tot verpleegkundigen zonder wervingssucces 
of verpleegkundigen met laag wervingsresultaat, lieten verpleegkundigen met een middel en 
hoog wervingsresultaat meer diepgaande kennis zien over de studie en de studievereisten. 
Ook lieten zij de persoonlijke voordelen voor deelname meer naar voren komen, spraken zij 
minder over belemmeringen en pasten zij meer wervingsactiviteiten, herinneringen en coping 
strategieën toe om het hoofd te bieden aan belemmeringen. De conclusie is dat vroegtijdig 
wervingssucces moet worden aangemoedigd en een persoonlijke aanpak verpleegkundigen 
kan helpen om succesvol te worden en te blijven. 
In hoofdstuk zes zijn de resultaten weeggegeven van de gerandomiseerd gecontroleerde 
studie die werd uitgevoerd om de effectiviteit te onderzoeken van het Mijn Diabetes 
Profiel programma ten opzichte van een wachtlijst principe voor controle patiënten. 
De effecten van de interventie werden onderzocht op algehele therapietrouw aan 
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behandelingsgedragingen en op afzonderlijke therapietrouw aan behandelingsgedragingen. 
Zestig procent van de patiënten die de eerste meting voltooiden werden behouden na de 
nameting, wat een belovend resultaat is voor eHealth-interventies. Algehele therapietrouw 
aan behandelingsgedragingen verbeterde aanzienlijk bij patiënten die werden toegewezen 
aan de interventie, wat weergegeven werd door een kleine tot gemiddelde effectgrootte 
(d = .24). Wat betreft afzonderlijke therapietrouw aan behandelingsgedragingen konden wij 
een aanzienlijke verlaging zien van de calorie-inname uit ongezonde snacks (d = .38). Kleine 
tot gemiddelde positieve interventie-effecten werden waargenomen voor therapietrouw 
aan orale bloedsuikerverlagende medicatie (d = .18) en behandeling met insuline (d 
= .28). Deze effecten waren echter niet significant, wat mogelijk te maken heeft met een 
gebrek aan studie-power van deze medische gedragingen. Aangezien het Mijn Diabetes 
Profiel programma meerdere succesfactoren heeft toegepast voor eHealth-interventies die 
naar voren zijn gekomen uit literatuuronderzoek, zoals een theoretische onderbouwing, 
gepersonaliseerde content en een aanpak van meerdere behandelingsgedragingen, is het 
mogelijk dat deze bijgedragen hebben aan het succes van de interventie. eHealth heeft 
laten zien een effectieve manier te zijn om therapietrouw van type-2 diabetes patiënten 
te verbeteren. Toekomstig onderzoek is nodig om na te gaan hoe implementatie op brede 
schaal het beste vorm kan worden gegeven en of en hoe de integratie van eHealth in de 
algemene zorg van toevoegende waarde kan zijn.
Tot slot wordt in hoofdstuk zeven een algemene discussie en conclusie beschreven die gebaseerd 
zijn op de studies die aan bod zijn gekomen in het proefschrift. Het Mijn Diabetes Profiel 
programma was effectief in het verbeteren van therapietrouw aan behandelingsgedragingen 
bij patiënten met diabetes type 2. Er zijn echter onderzoeksgebieden waarvoor verder 
onderzoek vereist is. Op dit moment zijn langer termijn gevolgen van het programma met 
betrekking tot verbeterde therapietrouw aan behandelingsgedragingen en gerelateerde 
secundaire uitkomstmaten onbekend. Bovendien moeten een kostenbatenanalyse en 
een procesevaluatie worden uitgevoerd en moet de optimale manier van levering voor 
implementatie op grote schaal worden onderzocht om het programma op de markt te 
brengen, het programma te finetunen en de impact ervan te vergroten. Ten slotte heeft de 
integratie van eHealth-interventies in algemene zorg, blendend care, laten zien gunstig te zijn, 
maar is er verder onderzoek nodig met betrekking tot het Mijn Diabetes Profiel programma. 

Dankwoord
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Dankwoord
Na ruim 4 jaar is mijn proefschrift af en is het tijd om een hele rits aan mensen te bedanken. En 
hoewel ik niet hou van clichés is het hier zeker op zijn plaats om te zeggen dat dit proefschrift 
zonder jullie niet tot stand was gekomen. 
Mijn promotieteam
Hein, jij belde mij eind 2014 op om mij welkom aan boord te heten. Ik kende je natuurlijk als 
docent en hoogleraar van mijn tijd in de Health Education and Promotion master, uiteraard 
als fouding father van het alom bekende I-Change Model en als pionier op het gebied van 
computer-tailoring technologie. Twee dagen na mijn start viel je bij mij binnen en zei: “wil je 
mee naar Cyprus, dan doe maar even dit bestand analyseren, een abstract schrijven en dien 
hem maar in bij de EHPS.” EHPS? Zo geschiede het. De toon was gezet: even dit, even dat, 
maar alles diende het doel van het project en het opbouwen van een netwerk. In overleggen 
probeerde je mij vooral bij de hoofdzaken te houden als ik weer eens honderdduizend ideeën 
had terwijl ik de 80 namen opschreef waarmee ik volgens jou contact moest leggen. Ook 
was het vaak een toets-uurtje of ik de theorie wel diepgaand genoeg bestuurd had. Dennis 
omschreef je, zoals je zo vaak zelf zegt, als de ‘advocaat van de duivel’ al zou rechterhand 
ook niet misstaan J. Het is maar goed dat we enige ‘darlings’ aan studies gekilld hebben, 
anders was ik nu nog aan het schrijven of video’s aan het maken in Vyond en dat zou het 
budget niet ten goede komen. Excuses dat mijn Word bestanden bij jou significant vaker 
crashten dan bij andere aio’s en dat je vaak 8 keer opnieuw moest beginnen met feedback 
geven, uiteraard volgens het Molenaars principe. Soms vraag ik me af hoe je dat doet; 30 aio’s, 
10 masterstudenten, aanvragen schrijven, en heel vaak ‘reloading batteries’, zeilen, zingen, 
dansen, tennissen, en choreograferen. Chapeau. Dank voor het vertrouwen, en om in jouw 
stijl af te sluiten vriendelijke groeten en best wishes.
Nicolaas, ik zag je in 2014 wel eens rondlopen bij de Maastricht Studie en dacht: zo zien 
professoren er dus uit: lange witte jassen, een wijze snor en altijd druk. Niet wetende dat jij 
een tijd later mijn promotor zou worden. Ik ging op onderzoek uit bij mijn collega Julianne 
van der Berg die jou omschreef als een hartelijke en warme man, en achteraf kan ik het alleen 
maar met haar eens zijn. Jouw klinische toevoegingen binnen het project evenals jouw brede 
kennis op het gebied van diabetes en de zorg daaromheen waren zeer welkom. En hoewel 
je, volgens jezelf, vaak in een toestand van alzheimer-light verkeerde en ik weleens geduldig 
moest wachten op feedback, nam je op de geplande overlegmomenten altijd rustig de tijd 
om zaken te bespreken en uit te pluizen. Zo mocht ik ook af en toe bij jou thuis langskomen 
om voorstellen of vragenlijsten tot in detail door te spreken. Van het spaarzame uurtje dat 
er stond voor het overleg, werd in het eerste kwartier rustig een kopje koffie gezet, melk 
opgeschuimd en over andere dingen dan onderzoek gepraat. Je hebt me veel geleerd over 
diabetes, onderzoek doen, en de politiek en keuzes maken binnen een promotie-traject, en ik 
wil je hier graag voor bedanken.
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Ciska, als dagelijks begeleider hadden wij het meeste contact. Vaak was het een gestructureerd 
wekelijks overleg waarin ik een stijgende lijn zag in jouw verwachtingen van mij als onderzoeker. 
Hoewel ik soms tot in de diepste diepte mijn keuzes moest beargumenteren, denk ik wel dat 
je op deze manier mij hebt gestimuleerd om het beste uit mezelf te halen. Zo merk ik dat ik 
in mijn conceptueel vermogen en schrijfstijl flinke stappen heb gemaakt en vooral niet de 
functionaliteit van dingen uit het oog probeer te verliezen. Ook is door jou mijn vocabulaire 
aan (spreek)woorden flink uitgebreid. Naast de Engelstalige wetenschappelijke termen, viel er 
altijd wel een (spreek)woord te ontleden als ‘bot vangen’, ‘het moet wel hout snijden’ of ‘boude 
uitspraak’ (gewaagd). Ik heb veelal het idee dat wij samen het project gedragen hebben; tot 
in de diepte dingen voorbereiden, of het nu artikelen of interventiecomponenten waren, 
en deze ter goed- (of af-) keuring voorleggen aan de rest van het team. Dankjewel voor je 
uitdagende begeleiding en fijne samenwerking.
Deelnemers aan studies
Zonder deelnemers geen studies. De vele mensen en zorgverleners (praktijkondersteuners, 
diabetesverpleegkundigen, artsen, diëtisten en eHealth experts) wil ik dan ook bedanken voor 
hun bereidheid mee te doen met de vele studies die we verricht hebben. Het werven van 
voldoende deelnemers blijft altijd een lastig punt in het doen van onderzoek. Ik vond het dan 
ook fijn en interessant om een van mijn studies hieraan gewijd te hebben. In het bijzonder wil 
ik dhr. van Rooijen bedanken voor zijn nauwe betrokkenheid bij de studies, het vormgeven 
en pilot testen van mijn interventie, en het verzorgen van een patiëntendemonstratie bij mijn 
colleges. 
Verpleegkundigen MUMC+
De verpleegkundigen van de diabetespoli MUMC+ wil ik bedanken voor hun gastvrijheid, 
vriendelijkheid en bereidheid te willen helpen bij welke studie dan ook. In het bijzonder wil 
ik Yvonne Koolen en Jean-Gilles Ruyters bedanken. Yvonne, je was vanaf het begin betrokken 
bij het opzetten van mijn studies en interventie, evenals bij DIEP. Ik denk dat je erg trost mag 
zijn op de manier hoe je die rol hebt ingevuld. Daarnaast ben je ook nog eens een heel fijn 
persoon om mee te praten en samen te werken, én ben je niet te beroerd om ook je duidelijke 
mening te uiten als je iets vanuit verpleegkundig perspectief gevraagd werd. Dankjewel, en 
moge je nog vele mooie jaren bij het MUMC en op de fiets hebben. 
De leescommissie
Experts op het gebied van computer-tailoring, eHealth, gezondheidspsychologie, diabetes en 
therapietrouw die jouw stuk gaan lezen en beoordelen. Dank, Nanne, Stef, Hilde, Catherine en 
Trudy voor jullie oordeel en tijd die jullie in het lezen van mijn proefschrift hebben gestoken. 
Nanne, je hebt mij ooit tijdens een kerstlunch overtuigd dat het écht mogelijk is dat een witte 
wijn lekkerder kan zijn dan een rode, maar dan moest het wel een hele goede witte zijn. Ik 
wacht in alle rust je advies af. 
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Stuurgroep
Vanaf het begin van het project hebben wij een stuurgroep opgericht met daarin 
afvaardiging vanuit eHealth, de doelgroep, onderzoek, diëtetiek, eerste- en tweedelijnszorg, 
en praktijkgericht onderzoek. Het op deze manier co-creëren van onze interventie is zeker 
van meerwaarde geweest en heeft ons vanuit verschillende invalshoeken de interventie laten 
aanvliegen en opbouwen. Naast mijn team wil ik daarom Silvia, Sonja, Anna, Yvonne, Erwin, 
Ronald, Esther, Rik, Dirk, en Pie bedanken.
Het secretariaat
Kim, Patricia, Denise, Daisy, Helga, Joyce en Yvonne, dank voor jullie ondersteuning in de 
afgelopen jaren. Patricia en Kim, mijn excuses dat ik vaak niet tijdig mijn afwas deed en 
daardoor kopjes, bordjes, bestek etc. veel te laat terugbracht naar de vergaderkamer, dat ik 
vaak mijn sleutel kwijt was en er weer een nieuwe besteld moest worden, of dat mijn auto 
weer eens verkeerd geparkeerd stond en er een boze mail naar GVO volgde. Het ga jullie 
goed, en moge de schilderijen nog lang in de gang hangen.
Ouders
Dank voor jullie steun in de afgelopen jaren, hopelijk begrijpen jullie na het lekenpraatje 
eindelijk wat ik nou echt voor onderzoek doe, want dat is en blijft toch altijd lastig om uit te 
leggen. Ik ben blij dat het nu zo gaat zoals het gaat met jullie en laat dat niet meer los.
Oma
Ja, waarom niet. Helaas moesten we gedurende mijn promotietraject afscheid van je nemen. 
Ik denk echter, en jij zelf ook, dat veel mensen zouden tekenen voor de ruim 96 jaar die je hebt 
mogen worden. Ik heb nog ooit nagedacht om je aan te stellen als mijn paranimf, dan had je 
daar met 98 misschien nog een stelling mogen voorlezen, maar jammer genoeg is ons dat 
niet gegeven. Dankjewel voor de wijze levenslessen die je me hebt meegegeven, en ik weet 
zeker dat je op de dag van mijn verdediging een oogje in het zeil houdt. 
Assistentie
Door de jaren heen heb ik heel wat assistentie gehad bij mijn projecten, zowel van 
medewerkers als student-assistenten. Jullie zijn van onschatbare waarde geweest voor mijn 
project en graag wil ik jullie dan ook bedanken voor jullie werk en toewijding. 
Claire, dank voor je fijne samenwerking. Jij was de expert op het gebied van tailoring en ik ben 
heel blij dat jij mij daarin geassisteerd hebt. Ook deelden we de frustraties als het opeens toch 
weer allemaal anders moest, maar gelukkig hebben we dat overleefd. 
Kenny, jij was in het begin bij mijn project betrokken, eveneens bij het vormgeven van mijn 
programma en het uitwerken van interviews. De nauwkeurigheid en rust waarmee jij te werk 
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ging is bewonderenswaardig te noemen. Ik hoop dat je nu je plekje hebt gevonden waar je 
collega’s ook mogen genieten van deze capaciteiten.
Merel en Marion, jullie waren eventjes betrokken bij mijn project maar daarom niet het noemen 
minder waard. Ik ben blij voor jullie dat jullie een eigen PhD-project hebben binnengesleept 
en ik weet zeker dat jullie dit met succes gaan afronden.
Raesita, sinds de middelbare school mijn klasgenoot en opeens werkten we samen op 
hetzelfde project. Beiden oes Kirchroa, en dan samenwerken in Maastricht, hoe is het zo ver 
gekomen. Je bent écht oprecht een heel fijne collega en je levert kwalitatief heel goed werk. 
Dat zijn mijn collega phd-studenten waarvoor je gewerkt hebt, denk ik volledig met mij eens. 
Niet alleen de snelheid waarmee jij tailor-builder hebt geleerd, maar ook de manier hoe je 
dingen kunt uitleggen en werk verzet, tekenen volgens mij de persoon die je bent. Ik vind het 
nog steeds bijzonder dat ze mensen als jij niet langer vastleggen, maar helaas ga ik daar niet 
over. Ik wens je veel plezier bij de Maastricht Studie en  we komen elkaar vast nog wel tegen.
Yil, toen ik in mijn eerste jaar van mijn promotietraject lesgaf, vroeg ik de toenmalige eerstejaars 
wie er bij mijn project wilde helpen. Zo kwam je bij mijn project terecht en ging vrijwillig aan 
de slag met interviews uitwerken (erwtjes) en data-invoer. Niet het leukste werk om vrijwillig 
te doen, maar je klaagde nooit, gapen wel overigens. In de loop van de jaren bleef je bij 
mijn project betrokken en hoewel ik mijn best deed om vrijwillige assistentie betaald te laten 
worden, hield de projectbaas de vinger meestal op de knip. Nu heb je je eigen PhD project, 
gaapt nog veel meer dan eerst, maar staat wel altijd klaar voor een lunch of wandeling. Je 
bent een heel fijne en optimistische collega en dat siert je. Dank voor al je vrijwillige uurtjes in 
het MDP project en je gezelligheid en succes met het vervolg van je eigen project.
Lieve, eigenlijk hoor je niet in het rijtje assistentie of collega’s thuis, maar ik heb je toch maar 
ergens bijgezet. Je interesse om bij een project betrokken te raken eindigde in een artikel 
dat we grotendeels samen geschreven hebben, en waar we menig uur of dagdeel samen 
aan gewerkt hebben. Niet alleen leverde dit een mooi artikel op, maar ook fijne gesprekken. 
Ik denk dat je trots op jezelf mag zijn met het werk dat je geleverd hebt, dat heb je toch 
maar even gedaan als 2e/3e jaars student. Ik denk dan ook dat een PhD project goed bij je 
zou passen, maar dat moet je natuurlijk maar helemaal zelf uitvogelen of je dat wil. Stiekem 
merk ik dat je er meer en meer open voor gaat staan en ik zou je bij iedereen zonder twijfel 
aanbevelen. In ieder geval veel succes bij het afronden van je master en alles wat daarna op 
je pad komt.
Paranimfen 
Carolin, a.k.a. dr. Muschalik, wat ben jij een fijne collega en fijn mens. Auch an dir herzlichen 
glückwunsch zu deiner promovierung. Vanaf de eerste tot de laatste dag zaten we op dezelfde 
plek, aan elkaars overkant van de gang. En als de deuren open waren dan was één blik of 
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e-mail vaak genoeg om te begrijpen wat we bedoelden. Er bestond dan ook geen twijfel 
dat ik jou wilde vragen om mijn paranimf te zijn. Ik bewonder je rust, relativeringsvermogen, 
mindfulness en de manier waarop je 45 minuten kunt doen over het eten van een pizzapunt. 
We hebben heel veel gelachen om de meest onzinnige dingen of uitspraken, en ik kon het 
niet laten om ze nog een keer hier te benoemen: Beheeeeeevior, appreciaaaation, kijk eens 
kijk twee, wat is de STAVAZA, to know is to know that you know nothing, IKEA: international 
kidney essembly associeeeeetion, @Zuyderland, working elsewhere, the day the duck got saved, 
you knoooow, beheeevior change wheeeel, kaput day, HALT STOP, chai-latte, wat zijn jullie aan 
het doeeeen, awaiting reeeeviewer selection, coping plants, self-EFFcacy, When I want to smoke, 
I make a plan not to smoke, and then I will not smoke, Prögram, gehirm amputiert, jullie hebben 
mij 10000 euro gekost, greetings of the day, ‘dear prof. dr. Muschalik, we are pleased to inform you 
we have a special issue on cheese consumption adherence in Korean nurses, and would like you to 
contribute. You have time till tomorrow’, adHIERENCE, WAAR IS DE PRULLENBAK?!, the journal of no 
impact, pills give me chills, I won’t travel for a poster, affenkopf, fameeeeuze, genereeeuze, theetje 
Stanislas? Ik ga deze momenten echt heel erg missen. Thanks for all your support and great 
collegiality. 
Guido, ouwe Madlipz koninig. Niet alleen ben je een goeie kerel, maar ook in veel opzichten 
hetzelfde als ik. Zo hou je ook graag van een feestje, dingen organiseren, weer eens een 
veadige vriendenweekend of Finland trip, een vuurtje stoken, frustratie als de rest van de 
vrienden niet hetzelfde enthousiasme hebben als wij, en uiteraard het maken van Madlipz 
filmpjes of satire nieuws. Eigenlijk zou je misschien zelf eens moeten denken aan een PhD 
project: een uitgebreide literatuurstudie naar de opwarming van de aarde heb jij immers 
al gedaan. Bedankt dat je mijn paranimf wil zijn en laten we samen met de rest van de 
vriendengroep nog veel mooie feesten mogen beleven.
Vrienden en collega’s
De Veadige – East Holz Massive en TCK’54 vrienden, bedankt voor jullie steun en toeverlaat. 
De vele feesten, Ardenne weekenden en Finland trips waren een welkome afwisseling in de 
afgelopen jaren. 
Kai, ik zou mijn boekje zonder enige twijfel zo inleveren om je weer erbij te hebben vriend. 
In mei 2017 hielp je me nog met het vouwen van enveloppen voor mijn studie en maakten 
we de nodige filmpjes voor onze Facebook pagina. Het is niet te bevatten dat je er een paar 
maanden later niet meer was. Het is een groot gemis voor iedereen en onze vriendengroep. 
En hoewel het er niet minder erg door wordt, hoop ik, en weet ik eigenlijk zeker, dat jij je rust 
gevonden hebt. 
Esther en Karlijn, onlosmakelijk van elkaar verbonden zijn jullie twee. Bedankt voor de 
gezellige momenten en voor het eten dat ik altijd bij jullie kwam stelen (ondanks alle vliegen 
en muizen) als mijn eigen eten weer eens op was. Ook jullie gaan zonder twijfel je project 
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goed afronden. Het bord met achievements wordt voller en voller. Veel succes met jullie 
bedrijf dat jullie gaan starten daarna waar ik nog steeds ENORM benieuwd naar ben, want 
als ik jullie mag geloven zal het geld binnenstromen. Moge jullie lach, en met name die van 
Esther, nog zolang jullie projecten duren, luid klinken op de GVO gangen. 
Marika, het laatste half jaar was jij mijn kamergenoot en dat was een gezellige tijd. Heden, 
bliksem, Frjentsjer. Enkele van de Friese woorden die je me geleerd hebt. Dat taaltje kun je 
beter niet al te lang aanhoren, maar goed, dat zal wel wederzijds zijn voor het Kerkraads 
dialect. Hopelijk vind je genoeg deelnemers voor je studie en krijg je een ooit een mooi PhD 
project. En als dat (voorlopig) niet lukt, kun je nog altijd terug naar je favo-job bij de Mac. 
Dennis en Latifa, ik wil jullie bedanken voor jullie fijne collegialiteit en hulp als ik vragen had 
over mijn project of bepaalde studies. Als twee PhD’ers die ‘kort’ voor mij begonnen waren, 
waren jullie voor mij in de ideale positie om mij op weg te helpen. Dank voor de tijd die jullie 
daarvoor hebben genomen en veel succes verder bij jullie wetenschappelijke carrières. 
Niki, we leerden elkaar kennen bij de Maastricht Studie in 2013 en niet lang nadat ik naar 
GVO ging voor mijn promotieonderzoek volgde jij datzelfde pad. Hoe gezellig was het dat 
jij bij mij op de kamer kwam: ‘Ja maar JOS? Doe mij eens 5 euro’s geven voor Toro Picine’, of 
het schrijven van het GVO-ALL NEWS. Ik denk dat je je plekje zometeen wel gevonden hebt 
in het leefstijl en coaching gebeuren. Misschien kom je nog wel ooit bij je droombaan uit bij 
de Efteling, het land van ooit, of bij onze vriend Chiel van Adaptics. Ik blijf je gewoon taggen 
op LinkedIn bij hun vacatures totdat ze je smeken om naar Nijmegen terug te verhuizen 
om directeur van SGM te worden. Hoewel ik ook denk dat je zeker je PhD project succesvol 
afgerond had. Dank je voor de leuke momenten en leuke collega die je was bij DMS en GVO. 
De kurk met handtekeningen van eind 2014 zal ik zoals beloofd meenemen op de dag van 
mijn verdediging. 
Anke, je werkt nu ook al heel wat jaartjes bij GVO en hebt mijn traject ook redelijk vanaf het 
begin meegemaakt. Zo weet je als geen ander de momenten waarop het goed en minder 
goed ging en stond je altijd klaar om daarnaar te luisteren, over te praten/beppen, of je advies 
over te geven. Ik kan je daar niet genoeg voor bedanken. Ook denk ik aan de vele mooie en 
gezellige momenten. De Wednesday afternoon challenge, de plantenasiel battles, de tien 
kilometer, het organiseren van wie is de mol en de serieuze leedvermaak-blik waarmee je de 
kandidaten trakteerde op een rood scherm... Verder ben je gewoon een topper, een goed 
mens, een echte sfeermaker voor de afdeling, en wissel je de Brabantse taal af met native 
Engels alsof je er geboren bent. Het is dan ook een kwestie van tijd voor je je eigen PhD 
project binnensleept en nog jarenlang jokers verstopt op onvindbare plekken. Ik vind het 
heel jammer dat je er niet bij bent, maar ik weet zeker dat je aan de andere kant van de wereld 
geniet van je welverdiende vakantie. 
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Steffi, we zijn ongeveer tegelijk begonnen maar je bent al een tijdje klaar met je onderzoek. 
Das hast du gut gemacht. Ik wil je bedanken voor de gezellige momenten en onze vele 
bezoekjes, met name in het begin, aan Banditos en wens je al het beste toe.
Dirk-Jan, ongelooflijk dat je nog voor mij promoveert, maar alleen maar iets om trots op te zijn. 
Gelukkig kan ik mezelf tot twee dagen van tevoren voorhouden dat er nog altijd iemand vóór 
mij is. Congratz, alvast, en veel succes bij het vervolg van je carrière. 
Rik, dankjewel voor de fijne collegialiteit en samenwerking. Je bent denk ik een voorbeeld 
voor velen, niet alleen in het werk dat je verricht, maar ook op sociaal gebied. Je hebt altijd tijd 
voor een praatje, tijd om je advies te geven over een stuk tekst of idee, of tijd om te informeren 
hoe het gaat. Als ik zelf al vergeten was dat ik 3 weken geleden een presentatie had gegeven, 
dan vroeg jij nog hoe het was gegaan. Hopelijk kunnen we in de toekomst voor het een of 
ander nog samenwerken.
Caroline, ik bewonder je doorzettingsvermogen, harde werken en zorgzaamheid. Ik wil je 
ontzettend bedanken voor je support, met name in het laatste deel van het traject. Op naar 
meer rust, en tijd voor dingen die er echt toe doen!
Iedereen die niet genoemd is of die ik vergeten ben te noemen, ook aan jullie een welgemeend 
dankjewel!
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secondary school (VWO) at College Rolduc in Kerkrade in 2007, he started studying Health 
Sciences at the Maastricht University. After one year, he moved to Nijmegen to study Sports, 
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